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ABSTRACT 
 
New Green Technologies for Organocatalytic Asymmetric 
Epoxidation Applications in Synthesis 
Noor Armylisas Binti Abu Hassan 
 
This thesis describes the application of asymmetric epoxidation reactions on chromene 
substrates mediated by Page’s iminium salt catalysts. Organocatalytic asymmetric 
epoxidation is an efficient tool to access enantiomerically rich epoxides. This study is 
divided into three main parts which are discussed in each chapter. The first part of this 
research is the preparation of iminium salt catalysts followed by synthesis of several 
chromene substrates. The final part is the application of the asymmetric epoxidation of the 
readily prepared iminium salts on chromene substrates. 
 
The first chapter reviews brief introduction and historical background of organocatalysis, 
chromene substrates and asymmetric epoxidation reactions. Towards the end of the 
chapter, several examples are described of past and current development of asymmetric 
epoxidation by organocatalysts. In the last part of Chapter 1, the discussion focuses on 
asymmetric epoxidation on chromene substrates. Chapter 2 discusses the preparation of 
Page’s iminium salts and improvement of previous methods followed by several 
approaches to synthesis of chromene substrates. The final part is discussing application of 
asymmetric epoxidation using synthesized iminium salts on the chromene substrates. 
Excellent enantioselectivities were observed in nonaqueous condition using TPPP as 
oxidant for 6-cyano-2,2’-dimethylchromene giving ee >99% while reactions under aqueous 
conditions afforded the corresponding diol giving ees as high as 71%. 
 
In Chapter 3, experimental procedures and data for all the compounds synthesized are 
included. Appendices contain HPLC trace data, NMR and IR data of several compounds. 
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1 INTRODUCTION 
1.1 Green Technologies and Green Chemistry 
 
The field of “green technology” encompasses a continuously evolving group of methods 
and materials, to monitor, model and conserve the natural environment and resources, and 
to control the negative impacts of human involvement. Examples of green technology 
subject areas include energy, green building, environmentally preferred purchasing, green 
chemistry and green nanotechnology.1 
 
As for this thesis, we are focusing on the green chemistry scope for the invention, design 
and application of chemical products and processes to reduce or to eliminate the use and 
generation of hazardous substances. We are investigating the development of a green and 
highly efficient asymmetric epoxidation system mediated by metal-free organocatalyst, and 
less hazardous oxidant such as Oxone® and TPPP. 
 
1.2 Organocatalysis 
 
In the modern world of chemistry, the field of organocatalysis has attracted a lot of 
attention. The term organocatalyst comes from concatenation of two general words in 
chemistry, “organic” and “catalyst”. It is a small organic molecule where an inorganic 
element or transition metal is not involved in the active principle.2 Organocatalysis provides 
a means of accelerating chemical reactions with a substoichiometric amount of organic 
molecules, which do not contain a metal element.3 Generally the term catalysis is 
synonymous with transition metal-mediated reactions or enzyme-aided biocatalysis. 
However, since the field of organocatalysis developed, it has become topical in the 
chemistry world, with at least 1,500 manuscripts describing the use of organocatalysts in 
more than 130 discrete reaction types published between 1998 and 2000.4 Over 4,000 
publications have been reported in the area of organocatalysis up until 2011. In year 2010 
alone, there were over 1,000 articles published compared to just over 800 in 2009. 
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Considering the word organocatalyst was coined only 10 years ago – even though 
organocatalyst reactions have been around longer – this is considered as an impressive 
achievement in organic chemistry.5 
 
Since then, organocatalysis has become an additional efficient tool that can achieve 
remarkably selective and efficient transformations – as intense research efforts in this 
emerging area are proving, complementing the current methods rather than competing. 
Organocatalysts offer several advantages. They are usually robust, inexpensive and readily 
available, non-toxic and they are often available as both enantiomers. No harsh reaction 
conditions, such as inert atmosphere, extremely low temperature, dry solvents, etc., in 
many instances, are required due to their inertness toward moisture and oxygen.6 
Organocatalytic methods seem to be especially attractive for the preparation of 
compounds that do not tolerate any metal contamination, for instance, pharmaceutical 
products, because of the absence of transition metal. A selection of typical organocatalysts 
is shown in Figure 1.1.  
 
Figure 1.1 - Some typical organocatalysts 
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Some organocatalytic reactions have evolved from the ligand chemistry of organometallic 
reactions. Large arrays of ligands were developed for metal-mediated enantioselective 
catalytic reactions and are still among the most effective organocatalysts. It is thus not 
surprising that there are metal catalysed reactions in which the metal-free ligand is known 
to be active by itself, even in the same enantioselective transformation. One example is the 
use of ʟ-proline 1 for the Michael addition reaction. Yamaguchi reported the asymmetric 
Michael addition catalysed by ʟ-proline rubidium.7–9 In 2001, List reported efficient proline-
catalysed Michael additions of unmodified ketones to nitro olefins with moderate ee 
values.10  
 
Compared to organometallic processes, organocatalytic reactions can be more closely 
related to enzyme- or antibody-catalysed reactions. Indeed, these small organic molecules, 
which are sometimes also described as artificial enzymes11 or as enzyme mimetics, show 
some characteristic features of bioorganic reactions which often follow saturation or 
Michaelis-Menten kinetics reminiscent of a mechanism that involves the reversible 
formation of an enzyme-substrate complex.12 
 
Table 1-1 - Examples of simple well-established metal-based catalysis process and biocatalysis reactions 
Metal-based Catalysis Biocatalysis 
 
(1) Iron in the Haber process13 
     
 
 
(2) Nickel in the hydrogenation of 
C=C bonds 
    
 
 
(3) Vanadium(V) oxide in the 
Contact Process14 
 
(1) Enantioselective reduction of ketone by 
yeast 
 
 
(2) Lyases – addition-elimination on C=C, C=N, 
C=O bonds 
 
 
(3) Hydrolases – formation/breakdown of 
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esters, amides, lactones, etc. 
 
 
 
1.2.1 Asymmetric Organocatalysis 
 
Asymmetric organocatalysis, in which a chiral organic molecule catalyses an 
enantioselective transformation, is a rapidly growing field.3 A collection of chiral 
organocatalysts have been involved in asymmetric synthesis, such as the typical examples 
of proline, cinchona alkaloids, such as quinine 2 and various sugar-, amino acid-, or peptide-
derived compounds. Although the first examples were reported many decades ago,15,16 the 
area of asymmetric organocatalysis became a main focus of research only recently while 
the last decade has seen an exponential growth in the field. 
 
1.2.1.1 Historical Background of Asymmetric Organocatalysis 
 
Until a few years ago, it was generally accepted that transition-metal complexes and 
enzymes were the two main classes of very efficient asymmetric catalysts. Throughout the 
last century, small organic molecules were rarely used as catalysts despite the fact that 
some of the very first asymmetric catalysts were purely organic.6 In 1871, the first “pure” 
organocatalytic reaction was discovered accidentally, with the transformation of dicyan 7 
to oxamide 8 in the presence of an aqueous solution of acetaldehyde by J. von Liebig 
(Scheme 1-1). This role of acetaldehyde was identified to be similar to “ferment” which was 
the term used for enzymes. This efficient reaction forms the basis of the Degussa oxamide 
synthesis that is applicable on an industrial scale.3 
 
Scheme 1-1 - von Liebig's oxamide synthesis 
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1.2.1.1.1 Cinchona Alkaloids 
 
 
Figure 1.2 - Structure of (–)-quinine 2 and (+)-quinidine 11 
 
In the beginning of the 20th century, the use of small organic molecules as catalysts in 
chemical transformations was reported by G. Bredig.17 This finding was the first example of 
an organocatalytic enantioselective reaction ever reported. He reported a modestly 
enantioselective cinchona-catalysed cyanohydrin synthesis. The cinchona alkaloids 
represent a class of natural products that possess several important features rendering 
them useful as asymmetric organocatalysts. They are readily available, inexpensive, and as 
in the case of diastereomeric pairs such as quinine 2 and quinidine 11 (Figure 1.2), allow 
access to either enantiomeric product. The enantioselectivities were less than 10%, 
however this work was conceptually important (Scheme 1-2). 
 
Scheme 1-2- Bredig's decarboxylation of camphorcarboxylic acid 
 
Later, after a century of transition from achiral to asymmetric organocatalytic reactions, in 
1960, by using O-acetylquinine 13 as catalyst, (R)-phenyl methylpropionate 14 was 
generated from methylphenyl ketene 12 with up to 74% ee (Scheme 1-3),18 reported by 
Pracejus. This process showed that organocatalysts could give significant 
enantioselectivities. 
CHAPTER 1 - INTRODUCTION 
 
 
6 
 
 
Scheme 1-3 - Reagents and conditions: (i) Catalyst 13 (1 mol%), MeOH (1.1 equiv), toluene, –111 
o
C, 93% 
yield, 74% ee 
 
1.2.1.1.2 Proline 
 
In 1970s, the development of the Hajos-Parrish-Eder-Sauer-Wiechert reaction, i.e. the 
proline 1-catalysed intramolecular asymmetric aldol cyclodehydration of the achiral 
triketone by Hajos et al. and Eder et al. has become a major contributor in this 
organocatalysis field. Eder, Sauer and Wiechert isolated the cyclized aldol condensation 
product in one step using 1 and an acid co-catalyst (Scheme 1-4a).15 This finding brought a 
milestone in the area of asymmetric organocatalysis as they published the first highly 
enantioselective catalytic aldol reactions using a small amount of simple amino acid 1 as 
the catalyst. Excellent yield and ee was reported for the asymmetric Robinson annulations 
of achiral triketones 17 where in the second step acid catalysed dehydration furnished the 
condensation products 19 reported by Hajos and Parrish in excellent yields and ees for both 
steps (Scheme 1-4b).19  
 
 
Scheme 1-4 - The Hajos-Parrish-Eder-Sauer-Wiechert reaction; (a) acid co-catalysed isolation of the cyclized 
aldol condensation product by Eder, Sauer and Wiechert in 1971
19
 and (b) intramolecular aldol reaction of 
achiral triketones by Hajos and Parrish in 1974.
15
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Hajos suggested the role of H bonding in the asymmetric cyclization reaction and that the 
use of aprotic solvent should interfere less with a H-bonded transition state.15 Subsequent 
investigation by Agami et al. led to the proposed mechanism involving formation of 
enamine intermediate 20 (Figure 1.3)20 which then has been confirmed by mechanistic 
study as reported by Barbas.21 ʟ-Proline 1 contains both a nucleophilic secondary amino 
group and a carboxylic acid moiety functioning as a Brønsted acid. This facilitates a highly 
pre-organized transition state during the reaction pathway, which results in exceptionally 
high enantioselectivities. 
 
Figure 1.3 - Enamine intermediate 20 
 
The transformation of the side-chain carbonyl into an enamine by proline was possible due 
to secondary amine function of proline, and is followed by nucleophilic attack of the 
enamine at a ring carbonyl group that gives rise to the cyclization. Less-substituted tertiary 
enamine is known for its greater reactivity which led to the selective activation of the side-
chain carbonyl group.22  
 
List, Lerner and Barbas have reported a direct intermolecular aldol reaction between 
unmodified acetone and a variety of aldehydes (Scheme 1-5).23 They proposed in the aldol 
reaction, enamine attack occurs on the re-face of the aldehyde (21, Figure 1.4). This high 
enantiofacial selectivity is controlled by minimising steric interactions of the aldehyde 
substituent. Thus attack of the enamine on the si-face of the aldehyde leads to the 
unfavourable transition state 22 (Figure 1.4). The hydrogen transfer between the 
carboxylate on proline and the oxygen of the aldehyde also plays an important role in the 
enantioselectivity by limiting which face of the enamine attacks the aldehyde.24 
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Scheme 1-5 - Reagents & conditions: (i) Acetone (20 vol%), proline 1 (30 mol%), DMSO, rt, 4 h, 68% yield, 76% 
ee
23
 
 
 
Figure 1.4 - Proposed transition state of enamine intermediate
24
 
 
The work of List, Lerner and Barbas was significant because it showed that the underlying 
mechanism of the Hajos-Parrish reaction could be extended and applied to transformations 
that have broader applicability (specifically, the intermolecular aldol reaction). Moreover 
this work showed that small organic molecules (such as proline) could catalyse the same 
chemical reactions as much as larger organic molecules (enzymes) by using similar 
mechanisms. 
 
The quinidine alkaloids 11 and ʟ-proline 1 were the best known organocatalysts for some 
time. The revival of this chemistry is continuously growing with an increasing number of 
research groups all over the world focusing on a wide range of new organocatalysis 
systems with a variety of chemical reactions. Examples of research groups involved in 
developing a new system for asymmetric organocatalysis include hydrogenation by Wills,25–
27 aziridination using bifunctional organocatalysis by Dixon,28 alcoholysis by Schreiner29 and 
many more. This rapid growth is due to the advantages offered by this field.  
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1.2.2 Advantages of Organocatalytic Research 
 
Organocatalysis has now become one of the main branches of enantioselective synthesis 
alongside the other, previously accepted branches, enzymatic catalysis and organometallic 
catalysis. The sudden and rapid growth of the field of organocatalysis is contributed by 
three factors as suggested by MacMillan: first, the conceptualization of the field; second, 
the advantages of organocatalytic research; and the third, the advent of generic modes of 
catalyst activation.4 
 
The field of organocatalysis grew quickly, once it had been defined. Such rapid adoption is 
possible only when a field offers real advantages to those who exploit the resulting 
technologies. In this case, the fundamental advantages of organocatalysis were quickly 
recognised by the chemical synthesis community, namely the ease and low cost of carrying 
out such reactions in the laboratory and the potential for new lines of academic thought 
and investigation. 
 
Before 1998, the state of the art in asymmetric catalysis involved metal-based chiral 
catalysts almost exclusively, and these catalysts allowed a wealth of oxidations, reductions, 
σ-bond insertions, π-bond activations and Lewis-acid catalysed reactions. Although the 
impact of metal-based catalysts on chemical synthesis cannot be understated, some (but 
certainly not all) organometallic systems can be expensive, toxic and/or sensitive to air and 
moisture. 
 
The growth of organocatalysis brought prospects of a complementary mode of catalysis, 
with the potential for savings in cost, time and energy, an easier experimental procedure, 
and reductions in chemical waste. These benefits arise from three factors. First, organic 
molecules are generally insensitive to oxygen and moisture in the atmosphere. Because of 
their inertness towards water and oxygen, demanding reaction conditions, e.g. inert 
atmosphere, low temperature, absolute solvents, etc., are in many instances not needed, 
so there is no need for special vessel, storage containers and experimental technique, or 
for ultra-dry reagents and solvents. Second, a wide variety of organic reagents – such as 
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amino acids, carbohydrates, and hydroxy acids – are naturally available from biologically 
sources as single enantiomers. Simple organocatalysts are therefore usually cheap to 
prepare and readily accessible in a range of quantities, suitable for small-scale reactions. 
Third, small organic molecules are typically non-toxic and environmentally friendly, 
increasing the safety of catalysis in both biological research and chemical research across 
all research settings, including industry and academic institutions. 
 
The combinations of these factors substantially lowered the entry costs for researchers 
who were interested in developing enantioselective catalysis. With no need for glove 
boxes, inert gases, ultra-dry solvents or even a high level of experimental expertise, it is not 
surprising that the field quickly become flooded with research groups from around the 
globe. Indeed, the increase in competition helped to accelerate the pace of innovation and 
discovery, albeit perhaps at the expense of ‘elbow room’ for those in this popular field. 
 
Some critics suggest that low turnover numbers might limit the potential uses of 
organocatalysis for industrial applications, but this view is simplistic and dogmatic for any 
larger quantities than metal-based ones for the same price. Moreover, it is widely 
recognised in manufacturing that the removal of toxic catalyst-related impurities from the 
waste stream can often have a larger financial impact than the turnover number of the 
catalyst. Organocatalysts are typically less toxic than metal-based catalysts. Because of the 
absence of transition metals, organocatalytic methods seem to be especially attractive for 
preparation of compounds in which metal contamination is not tolerated, such as 
pharmaceutical and agrochemical products, in which the presence of hazardous metallic 
traces is inadmissible in the final product. Consequently, this methodology will be 
important in industry, due to its versatility and its favourable environmental impact. 
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1.2.3 Iminium Salts as Organocatalysts in Asymmetric Epoxidation 
1.2.3.1 Introduction to Iminium Catalysis 
 
Iminium salts are more electrophilic than the corresponding aldehydes or ketones. For this 
reason, the reversible formation of the iminium salt activates the carbonyl component 
towards nucleophilic attack. This type of activation is thus related to that induced by Lewis 
or Brønsted acids. It should be emphasized that the activation provided by iminium ion 
formation is very general, and many types of nucleophile – electrophile interactions can be 
envisaged. 
 
The iminium-activated reaction will be catalytic only if the amine catalyst is released in a 
final hydrolysis or elimination step. As an example, nucleophilic addition of hydride ion to 
the C=N double bond is the basis of reductive amination processes. These reactions 
proceed via iminium intermediates and are properly called iminium-activated reactions. 
However, they are not iminium-catalysed, since the amine becomes trapped in the 
reduction step. 
 
1.2.3.2 Historical Development of Iminium Catalysis 
 
Iminium salt catalysts are Lewis base catalysts, which is one of the most powerful and 
general strategies of organocatalysis.2 The historical development of the introduction of 
the concept of iminium catalysis is quite unclear. Knoevenagel condensation is probably the 
earliest recorded example of an iminium-catalysed process mediated by primary or 
secondary amines. The idea that the Knoevenagel reaction might proceed using iminium 
catalysis emerged slowly. Knoevenagel himself suggested a possible role for the aldehyde-
derived imines or aminals in this reaction.30 After more than 40 years, in 1931, Blanchard et 
al. suggested that positive ions are involved in the catalysis of the Knoevenagel reaction 
with secondary amines,31 and twenty years later, kinetic evidence for imine/iminium 
intermediates in Knoevenagel-type condensations was presented by Crowell and Peck.32 
Today, the contribution of iminium catalysis to the Knoevenagel reaction is generally 
recognised. 
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The decarboxylation of -ketocarboxylic acids was the first reaction where iminium ions 
were postulated as active intermediates. In 1907, Pollak reported different proteins and 
extracts as well as different amino acids and ammonium salts catalyzed the 
decarboxylation of acetoacetic acid and suggested that imines are likely intermediates in 
these reactions.33 In 1933, Pederson also suggested the iminium ion as intermediate in the 
decarboxylation reaction.34  
 
Table 1-2 – Summary of iminium catalysis development history
35
 
Year  
1894 
– 
1898  
Knoevenagel discovers a family of iminium-catalysed condensation reactions: 
 
 
 
 
 
1907 β-decarboxylation reactions discovered by Pollak and he suggested imine as 
intermediate 
 
 
 
 
1931 Blanchard suggested positive ion catalysis in Knoevenagel reaction31 
 
 
1934 Pederson proposes the intermediacy of iminium ions as intermediates in the 
decarboxylation reaction34 
 
 
1937 Langenback discovers the first iminium-catalysed conjugate addition 
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1953 Crowell and Peck showed kinetic evidence for a Schiff base intermediate in the 
Knoevenagel condensation32 
 
1962 Jencks discovers aniline catalysis of semicarbazone formation 
 
 
 
 
1976 Lusinchi and Hanquet first reported an oxaziridinium salt as a reactive 
intermediate, which is able to transfer oxygen to alkene substrates with 
regeneration of the iminium salts. 
 
1976 The role of iminium activation in cycloadditions recognised by Viehe and Baum 
 
 
 
1981 Woodward and co-workers use asymmetric proline catalysis to effect an 
iminium-catalysed deracemization and intramolecular aldol reaction in the 
total synthesis of erythromycin 
 
 
1991 The first catalytic asymmetric iminium-catalysed conjugate addition reactions 
discovered by Yamaguchi 
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2000 MacMillan reports the first asymmetric iminium-catalysed cycloaddition 
reaction 
 
 
 
 
 
1.2.3.3 Chiral Iminium Salt-Catalysed Epoxidation 
 
Oxaziridines are organic molecules that feature a three-membered ring containing a carbon 
atom and two heteroatoms, nitrogen and oxygen, and are generally prepared from imines 
by oxidation with peroxy compounds such as m-CPBA and Oxone® (Scheme 1-6). 
Oxaziridines are nitrogen analogues of dioxiranes, and constitute an important class of 
organic oxidants under non-aqueous conditions. N-H oxaziridines, first reported in the early 
1960s, induce amination of nitrogen, oxygen, sulphur and carbon nucleophiles, including 
aziridination of alkenes and amination of enolates.36 Indeed, Davis and co-workers 
developed very successful systems of asymmetric oxidation of sulphides to sulfoxides by 
oxaziridines, but the systems are less successful for alkenes. 
 
 
Scheme 1-6 - Preparation of oxaziridine using m-CPBA
37
 
 
Oxaziridines were first discovered in 1956 by Emmons.38 Since the first discovery of this 
structure, it has received an enormous attention from researchers39 – principally for two 
reasons. Due to the presence of the highly strained three-membered ring and the relatively 
weak N-O bond, oxaziridines allow for electrophilic transfer, despite the nucleophilic 
property of nitrogen and oxygen, which also results in low basicity of the oxaziridine 
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nitrogen compared to amines. When the substituent of nitrogen atom of the oxaziridine is 
small, it is the preferred site of nucleophilic attack, and when the nitrogen substituent has 
greater steric bulk, nucleophiles tend to attack on oxygen.40 Another remarkable property 
is that this system possesses the structural elements that seem to be required to observe 
stereochemical isomerism at nitrogen: ring strain and an atom with unshared electron pairs 
attached to nitrogen. 
 
Chiral oxaziridine reagents were also developed later, which allow for stereospecific 
transfer of heteroatoms. Oxaziridines are unique in their exceptionally high inversion 
barrier for nitrogen to retain its stereochemical configuration. Chiral 
(camphorsulfonyl)oxaziridines 24, first synthesized in 1988 by Davis have become a 
cornerstone in asymmetric synthesis (Scheme 1-7)41 which were reported to oxidize non-
functionalized sulfides giving up to 91% ee,42 and to epoxidize olefins (up to 65% ee).43 He 
first reported the epoxidation of olefins by oxaziridines back in 1981.44 
 
 
Scheme 1-7 - First chiral (camphorsulfonyl)oxaziridine by Davis
41
 
 
In 1995, Page reported high enantioselectivity for asymmetric sulfoxidation of dialkyl 
sulfides using [(3,3-dimethoxycamphoryl)sulfonyl]oxaziridine giving excellent ee up to 98% 
(Scheme 1-8).45 
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Scheme 1-8 - Page oxaziridine system for oxidation of sulfide
45
 
 
Application of oxygen transfer using oxaziridine system in total synthesis has been proved 
to be a success following a report by Papeo in 2009. Papeo et al. reported high selectivity of 
oxygen transfer by oxaziridine in the total synthesis of (–)-chaetominine 28. Oxidation of 
the double bond on the pyrrole ring of the tetracyclic intermediate 25 was achieved using 
oxaziridine 26 (Scheme 1-9) giving only one cis-diastereoisomer 27.46  
 
 
Scheme 1-9 - Reagents and conditions: (i) 26 (1.1 equiv), CH2Cl2/MeOH 2:1, rt, 50%; (ii) Et3SiH, CH2Cl2, TFA, rt, 
65% 
 
Oxaziridinium ions are the derivative of the oxaziridine with positively charged nitrogen. 
Oxaziridinium salts, a related electrophilic oxygen source were first reported in 1976 by 
Lusinchi and Hanquet as reactive intermediates for oxygen transfer to nucleophilic 
substrates, including sulphides and alkenes. The oxaziridinium species is able to transfer 
oxygen to alkene substrates with regeneration of the iminium salts under the reaction 
conditions, giving overall a catalytic process. Moreover, the propensity of iminium ions to 
react with the Oxone® triple salt to generate the oxaziridinium species renders the 
development of catalytic processes possible.47 Oxaziridinium salts have also been obtained 
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by either methylation of the corresponding oxaziridine with FSO3Me or oxidation of the 
corresponding iminium salt with peracid (Scheme 1-10).48,49 The steroidal pyrrolinic 
immonium salt plays a vital role in oxidation of peracid. 
 
 
Scheme 1-10 - Initial approach by Hanquet 
 
It was, however, not until some eleven years later that a second, racemic, oxaziridinium salt 
29 (Figure 1.5) was derived from dihydroisoquinolinium reported by Hanquet and his co-
workers. This second oxaziridinium salt was prepared by alkylation of an oxaziridine and by 
oxidation of the iminium salt.50,51 In 1988, Hanquet and co-workers reported that this 
oxaziridinium salt can efficiently epoxidize various olefins.47,51 They further reported that 
the epoxidation can be carried out with in situ generated oxaziridinium salt 29 using a 
catalytic amount of its corresponding iminium salt with Oxone®-NaHCO3 in CH3CN-H2O or 
m-CPBA- NaHCO3 in CH2Cl2 as oxidant. 
 
Figure 1.5 - Compound 29, second oxaziridinium salt by Hanquet in 1987;
50
 compound 30, first 
enantiomerically pure chiral oxaziridinium salt by Lusinchi in 1993
52
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A reaction pathway for iminium salt-catalysed epoxidation is shown in Scheme 1-11. The 
iminium salt catalyst is regenerated upon epoxidation of olefin.  
 
 
Scheme 1-11 - Catalytic cycle for iminium salt-catalysed epoxidation by using Oxone® as oxidant
53
 
 
Asymmetric epoxidation using chiral oxaziridinium salts has also been investigated. The first 
enantiomerically pure chiral oxaziridinium salt 30 (Figure 1.5) was reported by Lusinchi and 
co-workers in 1993. This enantiomercially pure chiral oxaziridinium salt was derived from 
(1S, 2R)-(+)-norephedrine 34 by methylation with Meerwein’s salt and oxidation with m-
CPBA from dihydroisoquinoline. Alternatively the salt could also be produced by switching 
the reaction order (Scheme 1-12). Epoxidations were carried out with either stoichiometric 
amounts of recrystallized salt or a catalytic amount of in situ generated salt using Oxone® 
as the oxidant giving 89% conversion and 61% ee. Lusinchi also showed that the transition 
states of such reaction have strong ionic character since the reaction rate increased in polar 
aprotic solvents such as nitrobenzene and nitromethane as compared to reaction in DCM.52 
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Scheme 1-12 - Synthesis of oxaziridinium salt 30 by Lusinchi’s group
52
 
 
Since then, iminium salt catalysis has become a significant interest to be developed for 
epoxidation for olefins.54 Epoxidation is a very important reaction in organic synthesis, and 
the catalytic oxaziridinium-mediated epoxidation of olefins is a promising method in this 
field. This can be seen by contributions made into this area by a number of research groups 
including ours.53–55 
 
In 1996, Aggarwal developed binaphthyl-derived oxaziridinium system for asymmetric 
epoxidation giving ee as high as 71% using 1-phenylcyclohexene as substrate.56 Armstrong 
et al. reported intramolecular epoxidation using unsaturated oxaziridines, presumably via 
oxaziridinium salts57 and previously reported iminium salts derived from pyrrolidine for 
alkene epoxidation.58 
 
Our group has also extensively investigated the oxaziridinium system for asymmetric 
epoxidation since 1998. We have successfully developed several iminium salt catalysts 
(Figure 1.6), which are further discussed in Chapter 1.3. A range of dihydroisoquinolinium 
salts was developed for initial study.59,60 We then included biphenyl-derived61 and 
binaphthyl-derived62 iminium salt to investigate the system further. 
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Figure 1.6 - Iminium salts developed in Page's group 
 
In 2000, Rozwadowska and co-workers reported the synthesis of the single enantiomer of 
iminium salt 41, derived from thiomicamine 42 (Figure 1.7).63 
 
 
Figure 1.7 - Rozwadowska iminium salt derived from thiomicamine 42 
 
Naturally, any improvement in the global efficiency of the catalytic system may contribute 
to the development of this new methodology as an attractive and convenient alternative to 
the known and widely used epoxidation methods. 
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1.3 Chromene Substrates 
 
Natural products play important roles in both drug discovery and chemical biology. In fact, 
many approved therapeutics as well as drug candidates are derived from natural sources. 
The chromene ring system has a central position in various classes of naturally occurring 
products.64 Chromene, as it is named in IUPAC nomenclature also known as benzopyran, 
has a naphthopyran cyclic skeleton as can be seen in Figure 1.8 – a benzene ring fused to 
heterocyclic pyran ring. Generally there are two isomers of chromene, 1-benzopyran 
(chromene) and 2-benzopyran (isochromene) – depending on the orientation of the fusion 
of the two rings. 
 
 
 
Figure 1.8 - (a) Structural isomers of chromene, left: 2H-chromene and right: 4H-chromene; (b) structural 
isomers of isochromene, left: 1H-isochromene and right: 3H-isochromene 
  
1.3.1 2H-Chromenes (2H-1-Benzopyrans) 
 
In this thesis, the research is focused on the synthesis of 2H-chromenes for the application 
of Page group’s iminium salt catalyst for asymmetric epoxidation specifically of the C3-C4 
double bond.  
 
 
 
Figure 1.9 - Structures of chromenes isolated from (a) Piper gaudichaudianum and (b, 43 - 46) P. Aduncum 
(a) (b) 
R1 R2 R3 
43 OH H CH3 
44 OCH3 H CH3 
45 OCH3 OH CH3 
46 OCH3  CH3 
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There are many 2H-chromenes isolated as natural products. For example, there are several 
natural chromenes isolated from Piper gaudichaudianum and Piper aduncum (Figure 1.9), 
along with a series of semisynthetic derivatives, have been shown to exhibit potential 
trypanocidal activities against the flagellate protozoan Trypanosoma cruzi,65 the etiological 
agent of Chagas disease, which is responsible for the deaths of approximately 400,000 per 
year and affects more than 18 million people in Latin America.66 These biologically active 
chromenes have also been shown to exhibit anti-fungal67,68 and anti-tumour69 properties. 
This core structure is also found in a number of flavonoids isolated from green tea extracts 
such as epigallocatechin-3-gallate 47 (EGCG) and catechin 48 (Figure 1.10). 
 
 
Figure 1.10 – Flavonoids extracted from green tea  
 
 
1.3.2 Properties of 2H-Chromene Compounds and Their Derivatives 
1.3.2.1 Biological Activities 
 
One of well-known biological activities of chromenes is as an airways selective potassium 
channel activator for the treatment of asthma, which include levcromakalim 49, and BRL 
55834, 50 (Figure 1.11).70 All the structures shown are biologically active 2, 2-
dimethylchromenes, in which the pyran olefin has been modified in order to improve the 
properties of a particular lead structure or to increase library diversity.64 Such pyran olefins 
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are readily modified by hydrogenation, epoxidation, dihydroxylation, and amino 
hydroxylation giving rise to a large number of biologically active structures. A search of 
Chemical Abstracts for 2, 2-dimethylchromene alone revealed approximately 4,000 
structures,71 suggesting the importance of 2H-chromenes in natural product synthesis. 
 
 
Figure 1.11 - Examples of potassium channel activator with chromane structure 
 
Isoflav-3-enes bearing containing chromene units are featured in well-known oestrogens – 
morpholino- 53 and piperidinylisoflav-3-enes 54 (Figure 1.12).72 The oestrogenic properties 
of these compounds are very important in the treatment of various oestrogen dependent 
diseases such as breast cancer, osteoporosis, Alzheimer’s disease, and coronary heart 
disease.73 Another remarkable property is as an anti-juvenile hormone in insects shown by 
compounds like precocene I 55 and precocene II 56 (Figure 1.12) that have been isolated 
from plants.74–76 
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Figure 1.12 - Several chromene examples from natural product 
 
The chromane ring can also be found in vitamin E constituents, tocopherols and 
tocotrienols. The basic chemical structure of tocopherol has a long phytyl chain attached at 
the 2-position of the chromane ring, while tocotrienols differ from tocopherols by the 
presence of three E double bonds in the phytyl tail. Moreover, the tocopherols and 
tocotrienols have , , , and  forms, named on the basis of the number and position of 
the methyl groups on the chromane ring (Figure 1.13). 
 
 
 
Figure 1.13 - Vitamin E constituents 
 
 R1 R2 R3 
α CH3 CH3 CH3 
β CH3 H CH3 
δ H H CH3 
γ H CH3 CH3 
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Vitamin E exerts important functions in anti-oxidative defence in mammalian cells.77 
Extensive investigations have been carried out on -tocopherol and its model compound 
2,2,5,7,8-pentamethylchroman-6-ol due to the chemical oxidant activity shown by the 
former.78 One of the vitamin E derivatives developed, -tocopherol ether-linked acetic acid 
(-TEA), exhibits potent anticancer activity in a wide variety of epithelial cancer cell types79 
in combination with the cyclooxygenase-2 inhibitor celecoxib and the chemotherapeutic 
drug 9-nitro-camptothecin.80 
  
In order to produce new derivatives, chemical modifications of vitamin E can occur at the 
following distinct regions of the molecule (Figure 1.14):79 (1) side chain length and 
saturation, (2) the position and geometry (E or Z) of the double bonds, (3) the heteroatom 
member of the saturated ring, (4) numbers of methyl substitutions on the benzene ring, 
and (5) esterification and amidation of the hydroxyl on the benzene ring. The water 
solubility and potency of the molecule can be enhanced by esterification of the hydroxyl 
group on the benzene ring81–83 while amides derived from - and -tocopheramines have 
been reported to have improved anticancer activity.81,84,85 
 
 
Figure 1.14 – Possible modification positions of vitamin E
79
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, Δ 
1.3.2.2 Photochromism86,87  
 
 
 
Scheme 1-13 - Photochromic activity
86
 
 
Photochromism is one of the properties of 2H-chromene that has drawn attention among 
scientists. The reversible action of rapid colour changing of a compound when irradiated 
with light containing ultraviolet rays such as sunlight or light of a fluorescent lamp, and 
resumption of the initial colour when placed in dark place is called photochromism 
(Scheme 1-13). It is the result of the ability of this compound to undergo a reversible 
cleavage of the alkylic C-O bond, leading to a quasi-planar ‘open form’ with a distinct 
absorption spectrum, i.e. different colours. These colour change phenomena are classified 
and named after the stimulus that causes the change. Accordingly, photochromism is a 
change in colour, usually colourless to coloured, brought about normally by UV light, 
electrochromism is a reversible colour change upon oxidation or reduction brought by an 
electrical current or potential, thermochromism is a colour change brought about by heat, 
solvatochromism by solvents and ionochromism by ions, etc. 
 
1.3.3 Syntheses of 2H-Chromenes 
 
Due to these interesting properties of 2H-chromenes, many synthetic methods for their 
preparation have been introduced from various starting materials. These methods include 
rearrangement of propargyl phenol ethers by high temperature Claisen rearrangement 
(Scheme 1-14)88–93 or recent reports of  metal-catalysed cycloisomerization (Scheme 1-
15),94 phenylboronic acid-mediated reaction of a phenol with an unsaturated aldehyde 
(Scheme 1-16),95 base-catalysed condensation of phenols with , -unsaturated aldehyde 
(Scheme 1-17)96–99 or their acetal  equivalents,100–102 Lewis acid-catalysed condensation 
(Scheme 1-18).103–106 
colourless closed form coloured s-trans open 
form 
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Scheme 1-14 - Thermal Claisen rearrangement of propargyl ether
93
 
 
 
Scheme 1-15 - Reagents and conditions: (i) (Ph3P)AuNTf2 (0.1 m0l%), toluene, 85 
o
C, 2 h, HPLC ratio of a/b/c: 
94.0/2.3/0.9
94
 
  
 
Scheme 1-16 - Reagents and conditions: (i) PhB(OH)2: HOAc (1:88), toluene, reflux
95
 
 
 
Scheme 1-17 - Reagents and conditions: (i) Pyridine, 140 
o
C, 2 h
96
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Scheme 1-18 - Reagents and conditions: (i) BF3(OEt)2 (50 mol%), geraniol (2 equiv), anhydrous benzene, 
reflux, 3 h
103
 
 
Barton used a pyridine-catalysed condensation reaction to afford a good yield of 2, 2-
dimethylchromene 62 from ortho-hydroxyacetophenone 61 and 1,1-dimethoxy-3-
methylbutan-3-ol 64 in a total synthesis of isorobustin 59 in four steps using 5-
methoxyresorcinol 60 as precursor (Scheme 1-19).100 
 
 
Scheme 1-19 - (i) CH3CN, HCl, 73%; (ii) 64, pyridine, 170 
o
C, 10 h, 68%; (iii) NaH, (EtO)2CO, reflux, 20 min, 81%; 
(iv) 65, anhydrous pyridine, anhydrous chloroform, 60 
o
C, 12 h, 84%
100
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Several metal-based methods have also been reported for the synthesis of chromene 
compounds such as palladium-catalysis (Scheme 1-20),107 and metal-phenoxide (Scheme 1-
21),108 as a few examples. 
 
 
Scheme 1-20 - 2-methyl-3-buten-2-ol (1.5 eq), NaHCO3 (2.5 equiv), Pd(OAc)2 (0.02 equiv), DMF, 120 
o
C, 3 h, 
95%
107
 
 
 
Scheme 1-21 - 3-Methyl-2-butenal (1.5 equiv), reflux, 8 h, 81%
98
 
 
Described in this thesis, the following synthetic approaches are used in this research to 
obtain chromene substrates 66 – 69 (Figure 1.15), and are discussed further in Chapter 2.2: 
thermal cyclization of aryl propargyl ethers, phenylboronic acid-mediated reaction of a 
phenol with an unsaturated aldehyde, pressure-induced condensation of phenol, methyl 
methacrylate and formaldehyde, and base-catalysed condensation of phenol with diethyl 
acetal. 
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Figure 1.15 - Chromene substrates synthesized in this research 
 
1.3.4 Asymmetric Epoxidation of Chromene 
 
The functionalization of the double bond on the pyran ring of the chromene had been 
reported previously using both chemical and bio-transformations.75,76,109 Such pyran olefins 
are readily modified by hydrogenation,110 epoxidation,76,111,112 and dihydroxylation,76 giving 
rise to a large number of biologically active compounds, well-known examples of which 
include the ATP-dependent potassium channel activator levcromakalim (49, Figure 1.11), 
the anti-HIV agent suksdorfin 57,113 and the breast cancer cell inhibitor natural product -
lapachone (58, Figure 1.12).114 
 
Chiral epoxychromanes can be intermediates in the synthesis of natural or synthetic 
compounds with biological activities. The initial chromene structure of modified 
compounds 47 and 50, 6-cyano-2, 2-dimethylchromene 69, had also previously modified by 
Patel et al. using stereoselective microbial epoxidation using culture Mortierella 
ramanniana SC 13840 to give a mixture of epoxide 70 and (+)-trans-diol 71 (Scheme 1-
22).109 
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Scheme 1-22 - Microbial epoxidation of 69 
 
Another example is asymmetric dihydroxylation of chromene 72 by using the soil bacterium 
Pseudomonas putida to give enantiopure cis-diol 73 in as high as 98% ee (Scheme 1-23). 
This enzyme-catalysed method of asymmetric dihydroxylation may be regarded as 
complementary to the developed chemical methods of asymmetric dihydroxylation. This 
group demonstrated earlier the chemical transformation of the chromene to cis- and trans-
diol enantiomers, even though the chemical oxidation method appears to be less 
stereoselective as compared to the enzyme-catalysed transformation. 
 
 
Scheme 1-23 - Asymmetric dihydroxylation of 72 
 
In our group we have also demonstrated the asymmetric epoxidation reaction on several 
chromenes plus recent investigations of kinetic resolution in 2-monosubstituted 
chromenes.115 Page has reported several synthesis of natural products containing a 
chromene ring, including levcromakalim 49,116 (–)-(3’S)-lomatin 75,117 (+)-(3’S, 4’R)-trans-
khellactone 76, and (+)-scuteflorin A 80.118 
 
The synthesis of levcromakalim 49 was achieved via its epoxide 70 using our iminium salt 
catalysts to afford ee as high as 98% (Table 1-3).112,116 The corresponding (S, S)-epoxide 70 
was then treated with pyrrolidin-2-one using the conditions described by Evans to afford 
the (–)-(3S, 4R) enantiomer of 49 in 52% yield (Scheme 1-24).92 
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Scheme 1-24 - Reagents and condition: (i) pyrrolidin-2-one, NaH, DMSO, rt, 4 h, 52% 
 
Table 1-3 - Asymmetric epoxidation of chromene 69
a 
Iminium Salt Catalyst Conversion/
%b 
Reaction 
time/h 
Yield/
% 
ee/%c Configurationd 
36116 – 24e 59 97 (–)-1S, 2S 
 
37112 90 20 – 97 (–)-1S, 2S 
 
 
74112 
100 48 – 98 (–)-1S, 2S 
aEpoxidation conditions: iminium salt catalyst (10 mol%), TPPP (2 equiv), CHCl3, 0 
oC. 
bConversions were evaluated from the 1H NMR spectra by integration of the alkene and 
epoxide signals. cee was determined using chiral HPLC using a Chiracel OD-H column. 
dAbsolute configurations of the major enantiomers were determined by comparison of 
optical rotation with those reported in the literature. eTemperature: –40 oC. 
 
Compounds 74 and 75 were obtained by asymmetric epoxidation of seselin 81 followed by 
ring opening of the epoxide. The precursor seselin was synthesized according to the 
method of North102 and could also be achieved using microwave irradiation in neat 3-
picoline, affording 94% yield.119 Asymmetric epoxidation was carried out under standard 
non-aqueous conditions used in our laboratory using iminium salt 36 to afford the epoxide 
in 65% yield with excellent ee, 97%. Conversion of the epoxide into (–)-(3’S)-lomatin 74 was 
achieved by reductive cleavage with NaBH3CN at 0 
oC in 92% yield and 97% ee. Acid-
catalysed ring opening of the chiral epoxide yielded (+)-(3’S, 4’R)-trans-khellactone 75 in 
95% yield (Scheme 1-25).117 
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Scheme 1-25 - Reagents and conditions: (i) TPPP (2 equiv), catalyst 36 (10 mol%), CHCl3, 24 h, –30 
o
C, 65%; (ii) 
1 M H2SO4 (5.5 equiv), acetone (1:2 ratio), rt, 1 h, 95%; (iii) NaBH3CN (1 equiv), BF3OEt2, THF, 0 
o
C, 0.5 h, 
92%
117
 
 
In 2012, Page reported the first enantioselective total synthesis of (+)-scuteflorin A 80 in 
very high ee, 97%, via (+)-trans-decursinol 78.118 The seven step synthesis of 80 started with 
the synthesis of xanthyletin 76 from 7-hydroxycoumarin using a method outlined by 
Ahluwalia,90 giving 29% yield. Enantioselective epoxidation of xanthyletin gave chiral 
epoxide 77 in excellent ee, 99% using catalyst 37 under non-aqueous conditions (Scheme 
1-26).118 
 
 
Scheme 1-26 - Reagents and conditions: (i) TPPP (2 equiv), catalyst 37 (10 mol%), CHCl3, 30 h, –30 
o
C, 97%; (ii) 
acetone/1 M H2SO4 (2:1), rt, 10 min, 60%; (iii) DMP (1 equiv), CHCl3, rt, 95%; (iv) 3, 3-dimethyl acrolyl chloride 
(5 equiv), NaHCO3 (1.1 equiv), THF, rt
118
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1.4 Asymmetric Epoxidation 
 
Asymmetric epoxidation of olefins is an effective approach for the synthesis of 
enantiomerically enriched epoxides. A variety of efficient methods have been developed, 
including Sharpless epoxidation of allylic alcohols, metal-catalysed epoxidation of 
unfunctionalized olefins, and nucleophilic epoxidation of electron-deficient olefins. 
 
1.4.1 Some Definitions in Asymmetric Synthesis 
 
The spatial arrangements of the substituents of chiral molecules can have a significant 
impact on reactivity and interaction towards other molecules. Many chiral drugs must be 
made with high enantiomeric purity because the other enantiomer may be inactive or have 
side effects. Thus, there is need to develop methods to synthesize organic compounds as 
one pure enantiomer and the use of these techniques is referred to as asymmetric 
synthesis.  
 
Research in the field of asymmetric synthesis has witnessed an explosive growth in the last 
10 – 20 years as documented by several books and review articles.120 The aim of 
asymmetric synthesis is to produce chiral product (as a single enantiomer as the ultimate 
goal) starting from a prochiral or achiral substrate, by exploiting the presence of a chiral 
auxiliary or catalyst.  
 
1.4.1.1 Enantioselectivity, Chirality and Stereochemistry 
 
The enantioselective production of compounds is one of the major themes of organic 
chemistry. The agrochemical and pharmaceutical industries are fields in which chirality and 
stereochemical control are of special relevance. Drug chirality is now a major theme in the 
design, discovery and development, launching and marketing of new drugs and, therefore, 
stereochemistry is an essential dimension to be taken into account. The thalidomide case in 
the 1960s is a paradigmatic example of this behaviour. This drug was prescribed in Europe 
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in a racemic form to pregnant women to alleviate sickness, but, while one of the 
enantiomers had sedative and antiemetic activities, the opposite enantiomer had 
teratogenic effects. This tragedy led to a new awareness of the importance of 
stereoselective pharmacodynamics and pharmacokinetics, enabling the differentiation of 
the relative contributions of enantiomers to overall drug action. There are two main 
methods for the preparation of enantiopure compounds: chiral resolution and asymmetric 
synthesis. Asymmetric synthesis is the method that is discussed in this thesis. This method 
introduces a mixture of isomers with an excess of one desired enantiomer. Enantiomeric 
excess (ee) is a measure of extent to which a particular enantiomer dominates the mixture 
and is readily calculated. 
 
1.4.1.2 Stereochemistry 
 
Isomers are different compounds which have the same molecular formula and are divided 
into two groups: stereoisomers and constitutional isomers. Stereoisomers are isomeric 
molecules that have the same molecular formula and sequence of bonded atoms 
(constitution), but that differ only in the three-dimensional position of the atoms in space. 
Stereochemistry is chemistry that studies the properties of stereoisomers. This contrasts 
with constitutional isomers, which share the same molecular formula, but the bond 
connections are different.121 Stereochemistry involves diastereomers and enantiomers. 
Therefore stereoselectivity encompasses diastereoselectivity (product diastereomer 
discrimination) and enantioselectivity (product enantiomer discrimination).  
 
1.4.1.3 Chirality 
 
Chirality (from the Greek meaning hand) is a concept well known to organic chemists and, 
indeed to all chemists concerned in any way with structure. It has numerous applications 
ranging from those affecting physical properties of matter to those related to biological 
mechanisms. These implications extend far beyond the borders of pure chemistry. Chiral 
molecules may exist as a pair of stereoisomers (enantiomers). If plane polarized light is 
passed through a sample of each enantiomer, one will rotate the light to the left (a 
levorotatory or (–)-enantiomer or l-form), and the other will rotate the light to the right 
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(dextrorotatory or (+)-enantiomer or d-form). Rotation of light will not be observed if the 
light is passed through an equimolar mixture also known as a racemic mixture. Racemic 
mixture is the definition of compound having same amount of left- and right-handed 
enantiomers of a chiral molecule.122 
 
1.4.1.4 Enantiomeric Excess (ee) 
 
The enantiomeric excess of a substance is an indicator of the purity of a chiral chemical 
compound. The impurity is the undesired enantiomer that occurs frequently as by-product 
in asymmetric syntheses. ee is determined by the following equation: 
Enantiomeric excess (ee) =  
        
        
       
R and S stand for the individual optical isomer in the mixture where R is the major 
enantiomer and S is the minor enantiomer. 
 
ee determinations are important in the pharmaceutical industry because undesired optical 
isomers of a drug can potentially alter pharmaceutical efficacy or result in toxicity, as 
mentioned above regarding the case of thalidomide. 
 
1.4.2 Asymmetric epoxidation 
 
The optically active epoxides are versatile intermediates in organic chemistry that can be 
converted into a wide variety of enantiomerically enriched molecules.123 The inherent 
polarity and strain of their three-membered ring makes them readily undergo 
stereospecific ring-opening reactions with a large number of reagents – electrophiles, 
nucleophiles, acids, bases, reducing agents, and some oxidizing agents – to form 1, 2-
difunctional compounds.124,125 In addition, many biologically active compounds and natural 
products contain epoxide functionalities.125,126 The chiral epoxides can be used either as key 
intermediates in the preparation of more complex optically bioactive compounds such as 
leukotriene 81 (SK&F 104353),127 GABOB 82 (γ-amino-β-hydroxybutyric acid),128 
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erythromycin 83,129 or as end products which also have biological activities, such as 
triptolide 84, epothilones 85 & 86 (Figure 1.16), and the gipsy moth pheromone: (+)-
disparlure 87 (Scheme 1-29).130  
 
 
Figure 1.16 - Biologically active compounds with chiral epoxides as key intermediate 
 
1.4.3 Catalytic Asymmetric Epoxidation 
 
The first attempts to prepare optically active epoxides were reported in 1965 by Henbest. 
He used a chiral peracid reagent, (+)-monoperoxycamphoric acid, and epoxidation 
reactions were carried out with various terminal olefins to give up to 10% ee.131 Since then 
considerable attention has been paid to asymmetric epoxidation of olefins. Particularly, the 
use of chiral transition-metal complexes as epoxidation catalysts has received increased 
attention over the past three decades. The asymmetric epoxidation of allylic alcohols, 
discovered by Sharpless and Katsuki in 1980, which utilizes alkyl hydroperoxide together 
with titanium (IV)-dialkyltartrate catalyst, is a noteworthy example of catalytic methods. 
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The highly effective system has been widely used in organic synthesis and has been the 
subject of several review articles.123 
 
One of the recent challenges in asymmetric catalysis has been the achievement of high 
enantioselectivity in the epoxidation of unfunctionalized alkenes. While the Sharpless 
epoxidation works efficiently with substrates capable of precoordinating with the catalyst, 
it is not suitable for the asymmetric epoxidation of unfunctionalized alkenes. The greatest 
difficulty in the selective epoxidation of alkenes bearing only hydrocarbon substituents is 
control of olefin approach to the active oxidant, since selectivity is determined only 
through low-energy, non-bonded interactions between the catalyst and the substrates. 
 
Over recent years, a number of research groups around the world have worked towards 
the development of methodologies to access chiral epoxides with high enantioselectivities. 
The greatest impact in the construction of chiral epoxides has been made with the 
introduction of catalytic systems. Undoubtedly the best-known catalytic process is that of 
Sharpless for the epoxidation of allylic alcohols, usually with greater than 90% ee.132,133 
Shown below are several examples of well-known catalytic asymmetric epoxidation 
systems grouped into two categories: metal-catalysed and organocatalysed asymmetric 
epoxidation. 
 
1.4.4 Metal-Catalysed Asymmetric Epoxidation 
 
Metal-catalysed asymmetric epoxidation was first reported in 1979 by Otsuka. However, 
the ee was quite low (1 – 7%, in most cases) for unfunctionalized alkenes with t-BuOOH in 
the presence of Mo(IV) and optically active dialkyl tartrate esters, (+)-DIPT at 20 – 25 oC. 
This system was applied to the asymmetric synthesis of (3S)-2, 3-oxidosqualene (Scheme 1-
27) giving mixture of epoxides – 31% of 2, 3-epoxide, 47% of a mixture of the 6, 7- and 10, 
11-epoxide and 23% of a mixture of the diepoxides.134 
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Scheme 1-27 - Reagents and conditions: (i) MoO2(acac)2, t-BuOOH, (+)-DIPT, 31%, 14% ee
134
 
 
1.4.4.1 Sharpless Epoxidation 
 
In 1980, a highly enantioselective epoxidation of allylic alcohols was reported by Katsuki 
and Sharpless. They successfully converted allylic alcohols into asymmetric epoxides in high 
chemical yields with more than 90% ee, under the catalysis of a transition metal catalyst 
titanium tetra(isopropoxide), Ti(OPri)4 by using t-BuOOH as the oxidant with a chiral 
additive diethyl tartrate (DET) or diisopropyl tartrate (DIPT)(Scheme 1-28).132,135,136  
 
 
Scheme 1-28 - Sharpless epoxidation
136
 
 
The original Sharpless asymmetric epoxidation reaction requires large amount of Ti(OPri)4, 
as high as 50 mol%. The main reason for this is the presence of water that destroys the 
catalyst, and a large amount of titanium-tartrate species and isopropyl alcohol ring-opens 
the epoxide. Further investigation by Sharpless showed that addition of 3Å or 4Å molecular 
sieve dramatically reduced the requirement of Ti catalyst to a catalytic amount.136 Since the 
discovery, the system has undergone rapid development.  
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Epoxidation of a vinyl silanol under Sharpless condition with t-butyl hydroperoxide (t-
BuOOH), Ti(O-i-Pr)4 and (+)-diisopropyl tartrate (DIPT) in CH2Cl2 was applied to the 
enantioselective synthesis of (+)-disparlure 87 (Scheme 1-29), giving up to 52% ee.130  
 
 
Scheme 1-29 - Reagents and conditions: (i) CuI, P(OMe)3; (ii) 1-iodo-5-methylhexane, 56%; (iii) NiBr, THF, 81%; 
(iv) t-BuOOH, Ti(O-i-Pr)4, (+)-diisopropyl tartrate (DIPT), CH2Cl2, –20 
o
C, 13 h, 67%; (v) F
-
, 67%
130
 
 
1.4.4.2 Jacobsen-Katsuki Epoxidation 
 
Jacobsen epoxidation was the first metal-catalysed epoxidation to result in high ee values 
for alkenes without an allylic OH group.111 This system uses a Mn-salen catalyst based on 
Kochi’s achiral salen catalyst,137 and allows a broader scope of substrate than the Sharpless 
system. 
 
 
Scheme 1-30 - Jacobsen-Katsuki asymmetric epoxidation system 
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The influence of additives on the reaction rate, yield, and enantioselectivity of Jacobsen-
Katsuki epoxidation was first proposed by Kochi138 and was then further investigated.139,140 
Amine N-oxides such as Py-N-oxide proved to be the best axial co-ligands, because they 
also stabilize the manganese(v)-oxo complex.139,141,142 
 
Figure 1.8 - Py-N-oxide 
 
The application of the catalyst has also been investigated on dimethylchromene derivatives 
using catalyst 88, affording >90% ee (Table 1-4). As can be seen in Table 1-4, Jacobsen 
showed that the catalyst system is applicable to chromene substrates with various 
substituents at the 6-position as well as at the reaction site 3- and 4-positions of chromene. 
Epoxidations were carried out using commercial bleach, NaOCl as oxidant at 0 oC or room 
temperature with catalyst 88.111 
 
Table 1-4 - Asymmetric epoxidation of chromene by Jacobsen
111
 
Olefin Major product ee(%) Isolated 
yield (%) 
Absolute 
configuration 
69 70 97 96 (+)-(3R, 4R) 
72 
 
98 87 (+)-(3R, 4R) 
  
94 76 (+)-(3R, 4R) 
  
98 75 (+)-(3R, 4R) 
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97 51 (+)-(3R, 4R) 
  
>98 82 (+)-(3R, 4R) 
 
1.4.5 Organocatalysed Asymmetric Epoxidation 
1.4.5.1 Dioxirane-Catalysed Epoxidations 
 
Chiral dioxiranes are also promising reagents for asymmetric epoxidation reactions.143 The 
first attempts to effect asymmetric epoxidation using chiral dioxiranes were reported by 
Curci et al. in 1984, giving ees between 9 – 12.5%.144 It was more than ten years later, that 
chiral ketones, the precursors of the corresponding dioxiranes, were developed that allow 
the epoxidation of a wide range of alkenes with good enantioselectivities.145–147 Steric and 
electronic factors need to be considered to design efficient ketone catalysts as highlighted 
by Yang146 to achieve good selectivity and reactivity.143 
 
1.4.5.1.1 Shi Epoxidation 
 
This catalyst was derived from ᴅ-fructose and is one of the most notable ketone catalysts. 
In 1996, Shi provided the first general enantioselective dioxirane epoxidation of trans-
olefins (Scheme 1-31).145  
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Scheme 1-31 - Shi epoxidation 
 
Due to rapid decomposition of the ketone at pH 7 – 8 involving Baeyer-Villiger reaction, the 
initial epoxidation procedure required excess catalyst (3 equiv). Shi subsequently showed 
that the catalytic efficiency of the ketone catalyst is highly pH dependent.148 At pH 10, the 
conversion to epoxide increased dramatically as he suggested that the Baeyer-Villiger 
reaction might be suppressed at higher pH. One concern when the reaction was carried out 
at higher pH was the decomposition of the oxidant, Oxone®. However, by increasing the 
pH, the amount of ketone used can be reduced to a catalytic amount and the amount of 
Oxone® can be reduced to a near-stoichiometric amount (1.5 equiv), suggesting at this pH 
the ketone is sufficiently reactive to compete with Oxone® decomposition. The catalytic 
cycle of Shi’s asymmetric epoxidation system can be seen in Scheme 1-32.143,148 
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Scheme 1-32 - Shi epoxidation catalytic cycle
143
 
 
1.4.5.1.2 Yang Epoxidation 
 
In 1996, Yang et al. successfully reported good enantioselectivity for epoxidation of trans-
olefins and trisubstituted olefins by a C2 symmetric chiral ketone 97 (10 mol%) using 
Oxone® as oxidant giving as high as 87% ee.146,147,149 She showed that ketones with 
electron-withdrawing groups at  positions give higher activity, which then led to her 
design of the catalyst. On the other hand, the reactivity of ketone catalysts decreased in 
the presence of steric hindrance at the -positions. The optimized chiral ketone was 
derived from 1, 1’-binaphthyl-2, 2’-dicarboxylic acid.146  
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1.4.5.2 Juliá-Colonna Epoxidation 
 
In 1980, Juliá et al. reported the poly-ʟ-alanine catalysed asymmetric epoxidation of 
chalcone, giving ees as high as 93%.150 The Juliá reaction conditions were triphasic, 
consisting of the insoluble polyamino acid catalyst, an aqueous solution of NaOH and H2O2, 
and a solution of chalcone in an organic solvent. 
 
 
 
1.4.5.3 Chiral Oxaziridinium-Catalysed Asymmetric Epoxidation 
 
Early reports on asymmetric epoxidation using oxaziridines by Davis41 are discussed above 
in Chapter 1.1.3.3. Since the discovery of the efficiency of oxaziridinium salts as powerful 
electrophilic oxidants by Lusinchi,52 the number of research groups investigating this 
system has grown rapidly, this includes Aggarwal,56 Yang,151 Komatsu,152 Armstrong,153 and 
our group59 (Figure 1.16). Asymmetric epoxidation by chiral iminium salts is normally 
carried out using Oxone® as the primary oxidant. 
 
CHAPTER 1 - INTRODUCTION 
 
 
46 
 
 
Figure 1.16 - Chiral iminium salts developed by several research groups
151
 
 
Lusinchi subsequently demonstrated that iminium salts could be converted by Oxone® into 
the corresponding oxaziridinium species, which could then effect alkene epoxidation in a 
catalytic cycle (Scheme 1-11, page 18).154 
 
1.4.5.3.1 Davis Oxaziridines-mediated Epoxidation 
 
Davis reported the first chiral oxaziridine 101 in 1983 derived from condensation of 
optically active bromocamphor sulfonamide (R*SO2NH2) with the diethyl acetal of an 
aromatic aldehyde at 150 – 180 oC (Scheme 1-33).155 
 
Scheme 1-33 - Synthesis of chiral oxaziridine by Davis
155
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However, the highest ee observed was only 40% for epoxidation of 1-phenylcyclohexene 
(Scheme 1-34).156 
 
Scheme 1-34 - Davis's first chiral oxaziridine for asymmetric epoxidation
156
 
 
Further investigation by Davis using chiral sulfamyloxaziridines 102 then improved the 
enantioselectivity, giving up to 65% ee for asymmetric epoxidation of unfunctionalized 
alkenes (Scheme 1-35).43 
 
 
Scheme 1-35 - Asymmetric epoxidation of unfunctionalised alkene using sulfamyloxaziridine
43
 
 
1.4.5.3.2 Aggarwal’s Epoxidation 
 
Aggarwal designed a chiral iminium salt combined with binaphthyl based system due to its 
emergence as one of the best general ligand motifs in asymmetric synthesis.120,157 This 
system was reported to provide enantioselectivity as high as 71% for 1-phenylcyclohexene 
using catalyst (S)-(+)-104, derived from oxidation of (S)-(+)-binaphthylamine 103 followed 
by methylation using Meerwein’s reagent (Scheme 1-36).56 
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Scheme 1-36 - Reagents and conditions: (i) KMnO4, THF, 80%; (ii) Me3O
+
BF4
-
, CH2Cl2, 96%
56
 
 
Aggarwal later reported that asymmetric epoxidation of alkenes by simple chiral secondary 
amines can also be achieved, for example by catalyst 106, on 1-phenylcyclohexene, giving 
up to 57% ee. He suggested that the reaction occurred via radical cations. The 
regioselectivity of the catalyst is shown by reaction with triene 105, which gave a single 
mono-epoxide, uncontaminated by other regioisomers (Scheme 1-37).158 
 
 
Scheme 1-37 - Chiral amine 106 (10 mol%), Oxone® (2 equiv), pyridine (0.5 equiv), NaHCO3 (10 equiv), 
MeCN/H2O (95:5), rt, 2 h, 61% 
 
1.4.5.3.3 Armstrong’s Acyclic Iminium Salt-mediated Epoxidation 
 
In 1997, Armstrong reported asymmetric epoxidation using several acyclic iminium salts 
(Scheme 1-38), synthesized by intermolecular condensation, suggesting such an approach 
would allow greater range in the preparation of chiral iminium salts. The catalyst was 
prepared by condensation of commercially available N-trimethylsilylpyrrolidine (1 equiv) 
and an aromatic aldehyde (1 equiv) with trimethylsilyl triflate (1 equiv) in ether.159 Amongst 
all the catalysts, iminium salts with ortho-withdrawing group, i.e. catalysts 110 and 111, 
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gave 100% conversion at low catalyst loading, 25 and 10 mol% respectively.58 In this acyclic 
iminium salt-mediated system, catalyst 100 (Figure 1.16) was found to give the best result 
for asymmetric epoxidation of 1-phenylcyclohexene (100% conversion, 22% ee).153 
 
 
Scheme 1-38 - Reagents and conditions: (i) ArCHO (1 equiv), TMSOTf (1 equiv), ether
58
 
 
He also showed that intramolecular epoxidation can occur by treatment of unsaturated 
oxaziridines with MeOTf, presumably via oxaziridinium salts. This method has been applied 
for regioselective epoxidation of a nonconjugated diene (Scheme 1-39).57 
 
 
Scheme 1-39 - Reagents and conditions: (i) BnNH2, 4Å mol. sieves, CH2Cl2; (ii) Oxone®, NaHCO3, CH3CN/H2O, 
47%; (iii) MeOTf, CH2Cl2; (iv) Aq. NaHCO3, 48%
57
 
 
Aldehyde 113 was first converted into the imine, which was then selectively oxidized by 
Oxone® to give the corresponding oxaziridine. This was treated with MeOTf in CH2Cl2 
followed by brief exposure to aqueous NaHCO3, giving epoxide 114 in 48% yield (Scheme 1-
39). Komatsu (catalyst 100, figure 1.16)152 and Yang151 also reported asymmetric 
epoxidations employing acyclic iminium salts generated in situ (Scheme 1-40), giving ee up 
to 39% and 65% respectively. 
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Scheme 1-40 - Acyclic iminium salts prepared in situ by Yang
151
 
 
1.4.5.3.4 Page Epoxidation 
 
Our group has also continuously contributed to the development of iminium salt-mediated 
asymmetric epoxidation. Page has previously designed chiral iminium salts that contain 
asymmetric centres in the exocyclic nitrogen substituent. Several series of catalysts that 
contain a number of chiral moieties have been reported, with the catalysts bearing (4S, 5S)-
5-amino-2, 2-dimethyl-4-phenyl-1, 3-dioxane (acetonamine) moiety reported to be among 
of the most reactive. Inspired by work of Hanquet and Lusinchi, Page designed the chiral 
iminium salts derived from dihydroisoquinoline and a primary amine, but chiral at the 
exocyclic nitrogen substituent. The advantages of the chiral iminium salts used are the 
preparation can be done on any scale and large structural variation is available as the 
chirality is resident in the amine component (Figure 1.17). 10 mol% of catalyst 98d gave the 
best ee of 73% for asymmetric epoxidation of trans-stilbene59 and gave 40% ee with 
catalyst loading as low as 0.5 mol%.60 
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Figure 1.17 – Example of catalyst 98 derived from various chiral primary amine
59
 
 
Later, iminium salts with additional functionality at the nitrogen atom prepared from 
amino alcohols, aminoethers, and aminoacetals were studied. Page reasoned that the 
presence of polar units within the chiral exocyclic substituent might help to control the 
diastereofacial selectivity of attack of the iminium unit by persulfate and/or the 
diastereofacial selectivity of approach by the alkene substrate to the reactive oxidizing 
intermediate and hence improve epoxide ee.  
 
Figure 1.18 – Chiral primary amine 115 and new iminium catalyst 116 by Page 
 
The study revealed that catalyst 35 (Figure 1.6) derived from an amino acetal precursor, 
(1S, 2S)-2-amino-1-phenylpropane-1, 3-dioxane, 115 (Figure 1.18), induces much higher 
enantioselectivities in the asymmetric epoxidation than the previously synthesized 
catalysts. The comparison of the results with those obtained using catalyst 98d is presented 
in Table 1-5.160 
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Table 1-5 - Asymmetric epoxidation results comparison
61,160
 
 
Entry 
 
Catalyst/  
Alkene 
 
98d 
 
35 
 
37 
 
116 
Yield/%; ee/%; configuration 
1 
 
68; 8;  
(+)-(R) 
64; 20;  
(+)-(R) 
100; 24; 
(+)-(R) 
90; 3; 
(+)-(R) 
 
2 
 
72; 15;  
(+)-(1R, 2R) 
52; 52;  
(–)-(1S, 2S) 
95; 37;  
(–)-(1S, 2S) 
93; 14; 
(+)-(1R, 2R) 
 
3 
 
43; 5;  
(+)-(S) 
54; 59;  
(+)-(S) 
90; 59; 
(+)-(S) 
100; 17;  
(+)-(S) 
 
4 
 
68; 40;  
(+)-(1R, 2R) 
55; 41;  
(–)-(1S, 2S) 
100; 60; 
(–)-(1S, 2S) 
100; 29; 
(+)-(1R, 2R) 
5 
 
34; 3;  
(+)-(1S, 2R) 
52; 17;  
(+)-(1S, 2R) 
100; 10; 
(+)-(1S, 2R) 
95; 8; 
(+)-(1S, 2R) 
 
6 
 
73; 20;  
(–)-(1S, 2R) 
64;49;  
(–)-(1S, 2R) 
90; 41;  
(–)-(1S, 2R) 
95; 38; 
(–)-(1S, 2R) 
 
Following this finding, in 2002, Page developed new iminium salt catalysts replacing the 
dihydroisoquinoline moiety of catalyst 98 with a biphenyl structure fused to a seven-
membered azepinium salt, with the chirality retained in the exocyclic nitrogen substituent. 
Two new iminium salt catalysts, 37 (Figure 1.6) and 116 (Figure 1.18) were prepared from 
the (–)-isophenylcamphenyl (IPC) 98d and amino acetal precursor 115, respectively.61 These 
two chiral primary amines were later used to synthesize azepinium salt catalysts, fused to 
(R)- or (S)-binaphthalene units.55 The binaphthyl-derived catalyst 39 (Figure 1.6) appeared 
to be the most enantioselective iminium salt catalyst known in our group at that time, as 
95% ee was recorded for asymmetric epoxidation of 1, 2-dihydro-1-phenylnaphthalene. 
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Page has also developed non-aqueous conditions for iminium salt-catalysed epoxidation, 
which eliminates the use of both water and base. This new system uses 
tetraphenylphosphonium monoperoxysulfate, which is soluble in organic solvents, as 
oxidant. This study also revealed the use of chloroform (CHCl3) to be the best solvent for 
this system.54 
 
1.5 Conclusion 
 
This chapter has covered brief introduction and historical background of topics discussed in 
this research; organocatalysis, chromene substrates and asymmetric epoxidation. The 
discovery of oxaziridinium salt as an effective electrophilic oxygen transfer reagent leads to 
its development.  
 
A number of biological properties such as potassium channel activator, anti-oxidant, anti-
HIV and the oestrogenic property exhibit by natural compound containing chromene as 
core structure show the importance of synthetic approach of this class of compounds. 
Further modification of double bond on pyran ring gave rise to a large number of 
biologically active compounds such as levcromakalim 49, suksdorfin 57 and β-lapachone 58. 
 
Application of our asymmetric epoxidation systems to the synthesis of natural products and 
biological active compounds containing chromene core structures had been investigated 
previously, giving excellent enantioselectivities, such as synthesis of levcromakalim 49, (–)-
(3’S)-lomatin 74, (+)-(3’S, 4’R)-trans-khellactone 75 and (+)-scuteflorin A 80, giving >97% ee 
for each reaction. 
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2 RESULTS AND DISCUSSION 
2.1 Synthesis of Oxaziridinium Salts 
2.1.1 Catalysts Selection and Preparation 
  
As mentioned earlier in Chapter 1.1, Lusinchi and co-workers reported the first 
oxaziridinium salt as effective electrophilic oxygen-transfer reagent for epoxidation of 
sulfides and alkenes.1–4 Addition of Oxone® as the oxidant to an iminium ion species 
produces a highly reactive oxidative intermediate, an oxaziridinium species. The oxygen 
transfer from electrophilic oxaziridinium ion to nucleophilic sulfide or alkene substrate 
regenerates the iminium species, giving overall a catalytic cycle. Lusinchi also showed that 
the oxygen transfer reactions can be done either by a separately prepared oxaziridinium 
salt 1 or by one prepared in situ (Figure 2.1). They then successfully developed related 
enantiomerically pure oxaziridinium salt 2 (Figure 2.1), giving up to 33% ee for asymmetric 
epoxidation of trans-stilbene.5  
 
 
Figure 2.1 - Compound 1, second oxaziridinium salt by Hanquet in 1987; compound 2, first enantiomerically 
pure chiral oxaziridinium salt by Bohé, Lusinchi and Hanquet 
 
In Page’s group, the catalysts for asymmetric epoxidation were first designed with the 
dihydroisoquinolinium nucleus generated from variety of chiral amines as a basis for study  
(Figure 2.2).6  
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Figure 2.2 - Several dihydroisoquinolinium-based catalysts developed by Page 
 
Later in 2002, new catalysts were designed by replacing the dihydroisoquinolinium moiety 
with a biphenyl structure fused to a seven-membered ring azepinium salt (Figure 2.3) and 
these new catalysts were shown to be more reactive than the six-membered ring catalysts, 
although with a somewhat different pattern of selectivity.7 
 
 
Figure 2.3 - The most reactive biphenyl-derived catalysts from the Page group 
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The biphenyl-derived catalysts induced better ees for asymmetric epoxidation of 1-
phenylcyclohexene than their six-membered ring dihydroisoquinolinium counterparts. 
However, reactions with trans-α-methylstilbene and triphenylethylene showed poorer or 
same ees were obtained for the biphenyl-derived catalysts 7 as compared to the 
corresponding dihydroisoquinolinium catalyst 3 (Table 2-1). These seven-membered ring 
catalysts, however, provide dramatically faster reactions, providing complete consumption 
of alkene substrates in ten minutes or even less, as opposed to around one hour for the six-
membered ring systems under the same conditions.8 
 
 
Table 2-1 - Comparison of catalytic asymmetric epoxidation of unfunctionalized alkenes using 
dihydroisoquinolinium salts and dibenzazepinium salts
a
 
Alkene 
 
  
Entry Catalyst In each case: eeb(%)/Conv.(%)/Configurationc 
1 
 
41/55/ 
(–)-(1S, 2S) 
52/52/ 
(–)-(1S, 2R) 
59/54/ 
(+)-(S) 
2 
 
60/100/ 
(–)-(1S, 2S) 
37/95/ 
(–)-(1S, 2S) 
59/90/ 
(+)-(S) 
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3 
 
39/100/ 
(–)-(1S, 2S) 
32/100/ 
(–)-(1S, 2R) 
50/100/ 
(+)-(S) 
4 
 
47/56/ 
(–)-(1S, 2S) 
21/100/ 
(–)-(1S, 2S) 
10/55/ 
(+)-(S) 
5 
 
45/54/ 
(+)-(1R,2R) 
60/55/ 
(+)-(1R,2S) 
71/60/ 
(–)-(R) 
6 
 
63/50/ 
(+)-(1R,2R) 
50/61/ 
(+)-(1R,2R) 
26/63/ 
(–)-(R) 
a
Reagents and conditions: Iminium salt (10 mol%), Oxone® (2 equiv), Na2CO3 (4 equiv), MeCN/H2O (1:1), 0 
o
C, 
2 h; 
b
Enantiomeric excesses were determined by 
1
H NMR spectroscopy in the presence of (+)-Eu(hfc)3 or by 
chiral HPLC on Chiracel OD column; 
c
The absolute configuration of the major enantiomers were determined 
by comparison of optical rotations with those reported in the literature 
 
In 2004, Page reported several new binaphthyl-derived catalysts, of which catalyst 9 (Figure 
2.4) was reported to give the highest ee, as high as 91% for iminium salt-catalysed 
asymmetric epoxidation of 1-phenylcyclohexene under aqueous conditions.9 
 
It is common for the epoxidation catalysts to have the iminium bond as part of a ring, and is 
therefore effectively derived from intramolecular condensation of a carbonyl compound 
and an amine. An initial concern was that simple acyclic iminium salts might prove too 
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sensitive to hydrolysis to be useful as epoxidation catalysts. It has been previously proved 
by preliminary experiments in our group that acyclic iminium salts derived from carbonyl 
compounds do not promote the desired reaction to any reasonable extent6 which is in 
accord with the work of Armstrong et al. (Scheme 1-38, page 49) and Yang et al., reporting 
high catalyst loading is required (as high as 100 mol%) for better conversion to epoxides 
due to the hydrolysis of the catalysts. Moderate enantiomeric excesses were observed 
utilizing acyclic chiral iminium salts generated in situ from chiral amines and aldehydes.10–12 
Page therefore chose cyclic iminium salts for investigation and the dihydroisoquinolinium 
nucleus was selected as the basis for initial study. 
 
 
Figure 2.4 - Binaphthyl-derived iminium salts synthesized for this research 
 
The first attempt to design new cyclic chiral iminium salts in our group derived from 
dihydroisoquinoline was based on the idea to have the controlling asymmetric centres 
close to the iminium nitrogen atom, in an exocyclic group, on the basis that this might lead 
to higher ees by bringing the asymmetric centre near to site of oxygen transfer.6 Our group 
was the first to report enantioselective iminium salt catalysts bearing an exocyclic chiral 
stereocontrolling groups as substituents on the nitrogen atom13 such as 
dihydroisoquinolinium salts 3 – 6 (Figure 2.2),8 biphenylazepinium salts 7 & 8 (Figure 2.3),7 
and binaphthazepinium salts 9 & 10 (Figure 2.4).14 
 
Counter-anion exchange is used to overcome the difficulties encountered on attempts to 
purify the salts by conventional methods, which takes place readily simply by addition of 
appropriate inorganic salts to the cyclocondensation reaction mixture before work up. 
Fluoroborate, hexafluorophosphate, perchlorate, and periodate salts did not prove ideal, 
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but the tetraphenylborate salts, produced using sodium tetraphenylborate, are the most 
suitable: they are all solids, with the degree of crystallinities varying with the alkyl group of 
the parent amines.15 Tetraphenylborate salts gave the best ee (40%) when all the salts were 
tested in the asymmetric catalytic epoxidation of 1-phenylcyclohex-1-ene under aqueous 
conditions.6 
 
For this research, all three backbone moieties that had been established in our lab – 
dihydroisoquinoline, biphenyl and binaphthyl moieties – are used in the synthesis of the 
iminium salts as backbone for the investigation. The catalysts were prepared through 
condensation of the backbone moiety precursors – 2-(2-bromoethyl)benzaldehyde 26, 2, 
2’-bis(bromomethyl) biphenyl 29, and (R)-2,2’-bis(bromomethyl)[1,1’]-binaphthalene 33 
(Figure 2.5) – with enantiomerically pure chiral primary amines 11 & 12 (Figure 2.6), to 
obtain the corresponding dihydroisoquinoline-derived catalysts 3 and 4, biphenyl-derived 
catalysts 7 and 8, and binaphthyl-derived catalysts 9 and 10 respectively.  
 
This approach has the great advantage that asymmetric catalysts may be derived rapidly 
from a wide variety of readily available chiral primary amines. 
 
 
Figure 2.5 - Backbone moieties used to synthesize the iminium catalysts 
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2.1.2 Synthesis of Chiral Primary Amines 
 
The syntheses of iminium salts were started with the preparation of the chiral amine 
moieties 11 and 12. The primary amines 11 and 12 (Figure 2.6) are required for the 
preparation of all selected iminium salt catalysts 3, 4 (Figure 2.2), 7, 8 (Figure 2.3), 9 and 10 
(Figure 2.4).  
 
 
Figure 2.6 - Chiral amine motifs for iminium salt catalysts 
 
These two amine precursors, having aminoacetal functionalities, were selected as they are 
more effective amine parents for the catalysts as reported in our group,7 some of which are 
extremely active and selective, giving ee of up to 97% with catalyst loading as low as 0.1 
mol% in epoxidation reactions.14  
 
The catalysts derived from (S,S)-acetonamine 11 have been demonstrated to be one of the 
most reactive chiral amine motifs for iminium salt-mediated asymmetric epoxidation 
reactions and also display the highest levels of enantiocontrol.7  
 
(S,S)-Acetonamine 11 was synthesized from the commercially available diol (1S,2S)-(+)-2-
amino-1-phenyl-1,3-propanediol 13 in a good yield, using a method similar to that 
developed by Nordin and Thomas (Scheme 2-1).16 This method can be conducted in one 
pot, the product is suitably pure for most purposes without distillation, and the reaction is 
easily scaled up. 
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Scheme 2-1 - Reagents and conditions: (i) MeOH, methyl formate (1.1 equiv), NaOMe (0.1 equiv), rt, 
overnight; (ii) Acetone, (±)-CSA (0.1 equiv), 2, 2-dimethoxypropane (10.0 equiv), 95%; (iii) Hydrazine hydrate 
(98%), reflux, 3 h, 96% 
 
The preparation of (S,S)-acetonamine 11 was started by formyl protection of the primary 
amine followed by ketalization of 1,3-diol 13 to obtain (4S,5S)-5-(formylamino)-2,2-
dimethyl-4-phenyl-1,3-dioxane 14. The formyl protection of the amine was achieved by 
dissolving the amino diol 13 in methanol in the presence of methyl formate as the source of 
formyl group and sodium methoxide as the catalyst. The mixture was then stirred overnight 
at ambient temperature. Dimethoxypropane was then added under acidic conditions using 
catalytic amount of camphorsulfonic acid (CSA) for the ketalization reaction (Scheme 2-1). 
These two steps afforded 14 in excellent yield as a yellow foam. 
 
According to Nordin, a catalytic amount of HBr was used as the acid catalyst in the 
ketalization step, giving 71% overall yield16 but the use of CSA was found to give a better 
yield of 14 as a yellow foam, up to 95%. This is the general procedure for both the 
protection of primary amine and ketalization of diol which can also be applied to (S,S)-
thiomicamine 15, afforded 16 as yellow oil (Scheme 2-2) in 87% yield. The amine must first 
be protected as its formamide prior to ketalization due to the greater nucleophilicity of the 
primary amine as compared to diol. 
 
The deprotection of the amines completed the preparation of the chiral amine motifs by 
heating under reflux the formate-protected acetonide in hydrazine hydrate (98%) for 3 
hours, giving compound 11 as yellow oil in 96% yield (Scheme 2-1). Previously, hydrazine 
hydrate was diluted to 85% aqueous solution for this deprotection step14 but the 
commercially available 98% solution of hydrazine hydrate gave a better yield. 
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For the preparation of (S,S)-acetonamine 12, there is one extra step prior to the 
deprotection of formyl group. The sulfide must first be oxidized to sulfone, which was 
accomplished in 98% yield at the formate-protected stage using 3.1 equivalent of m-CPBA 
in dichloromethane at 0 oC to obtain colourless crystalline solid methylsulfonyl moiety 17, 
crystallized from chloroform/diethyl ether (1:3) (Scheme 2-2). The methyl group of the 
sulfone 17 shifted slightly downfield compared to sulfide 16 from δ 2.46 ppm to δ 3.05 ppm 
in the 1H NMR spectrum. In the IR spectrum, two strong peaks at 1383 and 1149 cm-1 show 
the presence of S=O bonds in the compound. 
 
 
Scheme 2-2 – Reagents and conditions: (i) MeOH, methyl formate (1.1 equiv), NaOMe (0.1 equiv), rt; (ii) 
Acetone, (±)-CSA (0.1 equiv), 2, 2-dimethoxypropane (10.0 equiv), 87%; (iii) m-CPBA (3.1 equiv) in CHCl3, 
DCM, 0 
o
C, 2 h, 98%; (iv) Hydrazine hydrate (98%), reflux, 3 h, 73% 
 
The oxidation of sulfide to sulfone is important due to the susceptibility of the thiomethyl 
group to undergo oxidation to sulfone during the epoxidation reaction, and so consuming 
the oxidant; it is well known that Oxone® can oxidize sulfides to sulfoxides or sulfones.17–19 
Catalysts bearing a sulfide group on the para position of the phenyl substituent gave similar 
ee values to the sulfone-based catalysts but gave poorer epoxide conversion.8 After the 
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oxidation step of 16 to 17, the deprotection of the formyl group gave crude 12 as a 
colourless oil, which was then recrystallized from diethyl ether/ethyl acetate (1:1), 
affording yellowish crystaline 12 in a good yield of 73%. 
 
The presence of the dioxane core in (S,S)-(+)-acetonamine has proven to provide catalysts 
generating excellent yields and induction of enantioselectivities in epoxidation reactions. 
For example, biphenylazepinium salts 18 and 7 induced 29% and 60% ees respectively using 
1-phenylcyclohexene as substrate under typical aqueous reaction conditions using Oxone® 
as oxidant.  
 
 
Figure 2.7 - Biphenylazepinium salts without and with dioxane core, catalysts 18 and 7 respectively 
 
The aromatic substituents in the acetal moieties of the catalysts are important for 
asymmetric induction during the epoxidation reactions. According to the previous studies 
in our group, catalysts 19 and 20 containing alkyl group substituents in the acetal moieties, 
gave less than 5% ee in the epoxidation of 1-phenyl-cyclohexene. These results suggest that 
the aromatic nature of the C4 substituent of the catalysts is vital for catalyst 
enantioselectivities, perhaps due to interactions of the aryl substituents with the biaryl 
moieties and/or with the substrates.8 
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Figure 2.8 - Catalysts 19 and 20 bearing methyl group and isopropyl group at C4 respectively 
 
The feature of the acetal-containing iminium salts which may contribute to the 
enantioselectivities is the syn relationship between the nitrogen heterocycle and the 
phenyl group. It has been shown in a previous study by Page that the 1,3-dioxane ring 
retains a chair conformation consistent with both 1H NMR and 13C NMR spectrum,20 in 
accord with previous reports of substituted 2,2-dimethyl-1,3-dioxane rings (Figure 2.9).21 
 
 
Figure 2.9 - Chair conformation of acetal-containing iminium salts
20
 
 
Page proposed that there may be a stabilizing interaction between the electron cloud 
associated with the oxygen lone pairs and the electron-depleted carbon atom of the 
iminium unit as can be seen in Figure 2.9. This stereoelectronic effect may contribute to 
high conformational rigidity leading to relative success of the dioxane-derived catalysts. 
Such a conformation has a strong preference in the related system 23 and has been 
documented both experimentally and theoretically.20 
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After successfully synthesizing the chiral amine motifs 11 and 12, we next prepared the 
backbone moieties for the iminium catalysts – the dihydroisoquinoline motif 26 and the 
biaryl motifs, 2,2’-bis (bromomethyl) [1,1’] biphenyl 29 and (R)-2,2’-bis(bromomethyl) 
[1,1’]-binaphthalene 33 – were then synthesized followed by cyclization to obtain the 
corresponding azepinium iminium salts 3, 4 and 7 – 10. 
 
2.1.3 Synthesis of Catalysts based on the Dihydroisoquinoline Motif 
 
The precursor 2-(2-bromoethyl)benzaldehyde 26 was prepared according to the procedure 
of Rieche and Schmitz.22 Bromination of isochromane 24 afforded the expected 1-
bromoisochromane 25, which may be isolated by distillation if required. Treatment of 
product 25 with concentrated aqueous HBr (48%) furnished the desired bromoaldehyde 26 
in a good yield of 85% (Scheme 2-3). Compound 26 may also be purified by distillation, but 
the crude product can be used with equal success in most cases.  
 
 
Scheme 2-3 – Reagents and conditions: (i) Br2, CCl4, 1.5 h; (ii) HBr (48%), reflux, 10 – 15 min, 85%; (iii) Primary 
amine 11 or 12, EtOH/MeCN, NaBPh4 
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Cyclocondensation of chiral primary amines 11 and 12 proceeded smoothly and rapidly 
with 2-(2-bromoethyl) benzaldehyde, affording the corresponding dihydroisoquinolinium 
bromide salts. The crude hydrobromide salts are then reliably converted into easily 
handled crystalline material by counter-ion exchange with sodium tetraphenylborate 
(Scheme 2-3). The salts can be purified by crystallization from ethanol, giving iminium salts 
3 and 4 as bright yellow solids in 58% and 80% yields respectively.  
 
Bohé has showed that incorporating a gem-dimethyl group alpha to the iminium unit as in 
27 (Scheme 2-4) can increase the catalyst’s reactivity and extend the lifetime of the 
catalysts.  
 
 
Scheme 2-4 - Active iminium salt reported by Bohé. Reagents and conditions: (i) (a) KCN, AcOH.H2SO4, rt; (b) 
Oxalyl chloride, CH2Cl2,; (c) FeCl3; (d) MeOH, H2SO4, 73%; (ii) KNO3.H2SO4, rt, 2 h, 60 
o
C, 4 h, 90%;  (iii) 
Me3O
+
F4B
-
, CH2Cl2, rt, 90% 
 
The presence of a dimethyl group at that position can block possible deprotonation and 
subsequent loss of catalytic activity through aromatization of the isoquinolinium moiety 
(Scheme 2-5) as suggested by Bohé. Salt 27 is one of the most reactive iminium salts 
reported in Bohé’s group, epoxidizing trans-stilbene with 100% conversion in 1.5 hours 
when employing 5 mol% catalyst loading.23  
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Scheme 2-5 - Bohé's proposed mechanism for iminium salt aromatization
23
 
 
Our approach to synthesize the dihydroisoquinoline iminium salts involving 
functionalization at the nitrogen atom provides catalysts that are generally very reactive in 
the catalytic epoxidation of functionalized alkenes, and in some cases the catalysts can be 
used at just 0.1 mol% loading, suggesting that these catalysts do not suffer the degradative 
aromatization9 suggested by Bohé. 
 
2.1.4 Synthesis of Catalysts based on the Biphenyl-Azepinium Motif 
 
There are two routes available to access the biphenyl-based iminium salts by reacting the 
chiral primary amines with one of these biphenyl precursors; 2-[2-(bromomethyl) 
phenyl]benzene carbaldehyde 30 or 2,2’-bis(bromomethyl) biphenyl 31 – both are 
synthesized from 2,2’-biphenyldimethanol 28. Treating compound 28 with 24% HBr 
afforded dibenzoxepine 29 in 96% yield, which can be used directly for the next step 
without purification. Reaction of 29 with bromine in carbon tetrachloride CCl4 afforded the 
bromoaldehyde 30 in 98% yield. Cyclocondensation with primary amine 11 and 12 
produced the corresponding iminium salt catalysts 7 and 8, both as yellow solids in 68% 
and 66% yields respectively after recrystallization from ethanol (Scheme 2-6).7 
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Scheme 2-6 – Reagents and conditions: (i) 24% HBr (15 mL/g of 28), 100 
o
C, 40 min, 96%; (ii) Br2 (1.1 equiv), 
CCl4 (20 mL/g of 29), 0 
o
C – reflux, 99%; (iii) Primary amine 11 or 12 (1 equiv), 0 
o
C – reflux, overnight, NaBPh4 
(1.1 equiv), 5 min 
 
Another route for the preparation of the biphenyl-derived azepinium salts is carried out by 
treatment of 28 with HBr (48%), to afford 2,2’-bis(bromomethyl) biphenyl 31. Diol 28 
undergoes a double nucleophilic substitution of hydroxyl groups by bromide ions. The 
mixture was heated under reflux for 2 hours and compound 31 was recrystallized as 
colourless crystals from a mixture of ethyl acetate/light petroleum in excellent yield 
(Scheme 2-7).7 
 
 
Scheme 2-7 – Reagents and conditions: (i) 48% HBr (10 mL/g of 28), reflux, 2 h, 92% 
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Cyclocondensation of the (S,S)-acetonamines 11 and 12 with 2,2’-bis(bromomethyl) 
biphenyl 31 using CsCO3 as the base in acetonitrile proceeded smoothly, generating the 
corresponding compounds 32 and 33 in 97% and 84% yields, respectively. The oxidation of 
the biphenyl azepine compounds 32 and 33 was carried out by addition of NBS in 
dichloromethane and the solution was heated under reflux for 3 hours. This was followed 
by an anion exchange with sodium tetraphenylborate. After recrystallization from ethanol, 
iminium salts 7 and 8 were obtained in 57% and 25% yields respectively as yellow foams 
(Scheme 2-8). The proposed mechanism of the oxidation reaction can be seen below 
(Scheme 2-9). 
 
 
Scheme 2-8 – Reagents and conditions: (i) Cs2CO3 (2 equiv), primary amine 11 or 12 (1 equiv), MeCN, reflux, 
overnight; (ii) NBS (1.2 equiv), DCM, reflux, 3 h; (iii) NaBPh4 (1.1 equiv) in minimum amount of MeCN, EtOH, 
rt, 5 min 
 
 
The oxidation is believed to proceed through bromination of the nitrogen atom on the 
seven-membered ring forming the positively charged intermediate. The iminium species is 
then formed by abstraction of a proton and simultaneous expulsion of bromide in an E2 
mechanism (Scheme 2-9). 
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Scheme 2-9 - Mechanism for formation of biphenyl-derived iminium salt catalyst 
 
2.1.5 Synthesis of Catalysts based on the Binaphthyl-Azepinium Motif 
 
Binaphthyl-based systems have emerged as some of the best ligands in asymmetric 
synthesis. In metal catalysis, for example, 2,2’-bis(diarylphosphino)-1,1’-binaphthyl (Figure 
2.10) ligands exhibit extremely high chiral recognition ability in catalytic reactions.24 The 
binaphthyl skeleton itself is known to have superior chirality recognition and induction 
abilities.25  
 
 
Figure 2.10 - 2, 2'-bis(diarylphosphino)-1, 1'-binaphthyl ligand
24
 
 
1,1’-Binaphthyl compounds represent a special class of biaryl molecules. The important 
role played by C2-symmetric chiral auxiliaries has been shown to provide a high level of 
stereoselectivity in a wide range of asymmetric syntheses.26 For catalytic asymmetric 
CHAPTER 2 - RESULTS AND DISCUSSIONS 
 
 
 
 
80 
epoxidation reactions, the binaphthyl motifs have been widely used in designing both 
metal- and organo-catalysts. In 1999, Yamamoto et al. successfully prepared a new chiral 
hydroxamic acid 34, derived from 2,2’-binaphthol, serving as a monovalent ligand 
coordinated with a vanadium complex used for the asymmetric epoxidation of allylic 
alcohols giving ees of up to 94%.27 In 2000, a new series of porphyrins 35 that incorporate 
four identical chiral binaphthyl derivatives in the meso-positions was synthesized by 
Reginato et al. (Figure 2.11).28 
 
Figure 2.11 - Examples of metal-based catalyst with binaphthyl motif 
 
Examples of binaphthyl-based organocatalysts include the C2-symmetric cyclic chiral 
ketones (R)-37, derived from 1,1’-binaphthyl-2,2’-dicarboxylic acid (R)-36, which were 
prepared by Yang et al. (Figure 2.12).29–31 
 
Figure 2.12 - Yang's ketone catalyst
29,30
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Similarly, Aggarwal et al. designed iminium salts based on the (S)-(+)-binaphthyl motif. 
These binaphthalene-fused azepinium salt catalysts, achiral at the nitrogen substituent, 
afforded ees of 71% and 45% for the oxidation of 1-phenylcyclohexene and -
methylstilbene, respectively.32 
 
There are two different routes reported by Page’s group to access the binaphthyl 
azepinium salts. The required catalysts were readily prepared over two steps from 
bromoaldehyde 38 by cyclocondensation with primary amines, affording catalysts 9 and 10 
in good yields, 66% and 65%, respectively (Scheme 2-10).14 
 
 
Scheme 2-10 - Reagents and conditions: (i) Primary amine 11 or 12 (1 equiv), EtOH, 40 
o
C, overnight; (ii) 
NaBPH4 (1.1 equiv) in minimum amount of MeCN, 5 min 
 
The second route involves the formation of an azepine from (R)-2,2’-bis(bromomethyl)-
[1,1’]-binaphthalene 39, by substitution of the two bromides with a primary amine; 
oxidation to the iminium species and anion exchange yields the desired catalysts (Scheme 
2-11). Within this report, we have exclusively used the latter route, as isolation of 
compound 39 is far easier than that of bromoaldehyde 38. 
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Scheme 2-11 - Reagents and conditions: (i) Primary amine 11 or 12 (1.1 equiv), K2CO3 (3 equiv), MeCN, reflux, 
overnight; (ii) NBS (1.2equiv), DCM, reflux, 3 h; (iii) NaBPh4 in minimum amount of MeCN, EtOH, 5 min 
 
Compound 39 is not commercially available, but can be obtained from several steps in high 
yield (Scheme 2-12). The synthesis can be started from a commercially available 
enantiomerically pure (R)-BINOL 42. The bistriflate (R)-43 was prepared in 98% yield by 
treatment of (R)-BINOL 42 with an excess of trifluoromethanesulfonic anhydride (triflic 
anhydride), and 2,6-lutidine in the presence of a catalytic amount of 4-(dimethylamino) 
pyridine (DMAP) in dichloromethane at –30 oC (Scheme 2-12). The triflate moiety is one of 
the perfluoroalkane sulfonic acid derivatives, which are important reagents in modern 
synthetic as well as mechanistic organic chemistry. Due to their excellent leaving group 
properties, the triflate group has considerably extended the range of sulfonic ester 
reactivity and thereby added a new dimension to its chemistry.33 
 
 
Scheme 2-12 – Reagents and conditions: (i) Tf2O, 2, 6-lutidine, DMAP, DCM, –30 
o
C to rt, overnight, 98%; (ii) 
MeMgBr  (4 equiv), NiCl2(dppp)2 (0.07 equiv),  Et2O, –78 
o
C to rt, 16 h, 95%; (iii) NBS (2 equiv), AIBN (10 mol%), 
cyclohexane, reflux, 3 h, 51% 
 
Subsequent Kumada-type cross-coupling of 43 with methylmagnesium bromide and the 
nickel catalyst [NiCl2(dppp)2] in Et2O or THF afforded the dimethylated compound (R)-44, 
again in excellent yield (95%). Grignard reagents occupy a prominent position among 
CHAPTER 2 - RESULTS AND DISCUSSIONS 
 
 
 
 
83 
organometallics used in aromatic cross-coupling reactions with a relatively fast rate of 
oxidative addition to Ni(0).34 The conversion of compound (R)-44 into the 
bis(bromomethyl)binaphthalene (R)-39 was achieved using a free radical bromination 
which involved the use of NBS and azobis(isobutyronitrile) (AIBN) as the initiator in 
cyclohexane. The product was afforded as a crystalline solid in 51% yield. Previously, Zhang 
et al. reported the bromination of 44 using NBS and benzoyl peroxide in the carcinogenic 
carbon tetrachloride as the solvent in 69% yield.35 
 
(R)-bis(Bromomethyl)binaphthalene (R)-39 can be directly converted into the 
corresponding amines (R)-40 and 41 by heating under reflux with primary amines 11 and 12 
in the presence of K2CO3 in acetonitrile followed by the oxidation of the binaphthyl azepine 
compounds 40 and 41 by NBS. Addition of sodium tetraphenylborate provided the iminium 
tetraphenylborate salts 9 and 10, which are generally highly crystalline, in 73% and 59% 
yields, respectively, after recrystallization from ethanol (Scheme 2-11). The synthesis 
follows the procedure described above for the preparation of biphenyl-derived catalysts 7 
and 8 (Scheme 2-8).  
 
For this project, the (R)-binaphthalene enantiomer was specifically chosen because the (S)-
binaphthyl-derived catalysts prepared with the enantiomerically pure amine 11 are poor in 
terms of selectivity and reactivity.  
 
 
Figure 2.13 - (S)-Binaphthyl-derived catalysts by Page 
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2.2 Synthesis of Chromene Substrates 
 
The aim of the second part of this research is to synthesize chromene analogues with 
different substituents on the aromatic ring for the application of asymmetric epoxidation 
reactions (Figure 2.14).  
 
The use of various synthetic approaches is discussed in order to achieve the synthesis of 
the chromene substrates. Several different phenol-protecting groups – acetate, 
trifluoroacetate and benzoate – have been used to derivatise chromenols 47, 48 and 50 
and to study their reactivity under asymmetric epoxidation conditions using iminium salt 
catalysts. 
 
 
Figure 2.14 – The chromene substrates and their derivatives synthesized 
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2.2.1 6-Hydroxy-2, 5, 7, 8-tetramethyl-2-(4-methylpent-3-ene)chromene 47 
 
Chromane 61 is an analogue with a shorter isoprenoid chain than α-tocotrienol 60 (Figure 
2.15), a class of chemical compounds related to vitamin E, which is an interesting 
compound for its biological properties such as anti-oxidant.36  
 
Figure 2.15 – The structures of the vitamin E constituent, α-tocotrienol, 60 and its analogue, chromane 61 
 
The initial plan to synthesize 6-hydroxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-
ene)chromane 61 was based on an acid-catalysed condensation procedure reported by 
Gembus et al.37 followed by oxidation using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ). Trimethylhydroquinone (TMHQ) 62 was heated under reflux in xylene with linalool 
63 in the presence of camphorsulfonic acid ((±)-CSA) as the acid catalyst to obtain 
compound 61 (Scheme 2-13). This reaction, however, was unsuccessful.  
 
 
Scheme 2-13 – The initial plan for synthesis of 6-hydroxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-
ene)chromane 61 
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In 2006, Odinokov described the same reaction but using n-octane as the solvent.38 When 
we used n-octane as the solvent, a mixture of inseparable cyclic isomers in 5:1 ratio (61:64) 
was obtained in 95% yield (Scheme 2-14). This ratio was determined using 1H NMR 
spectroscopic analysis by integration of the areas of the signals corresponding to the 
protons from the methyl group on C2 of compound 61 and the cyclic isomer 64. 
 
 
Scheme 2-14 - Reagents and conditions: (i) 63 (2 equiv), (±)-CSA (0.1 equiv), n-octane, reflux overnight, 95%, 
5:1 ratio of compound 61 and 64 
 
Analysis of the 1H NMR of the mixture of 61 and 64 does not allow for easy identification of 
the structure of the major compound. The formation of cyclic isomers has also been 
reported by Ichikawa in 1968. Ichikawa synthesized the α-tocopherol analogue 61 by 
condensation of 62 and geraniol 67 in benzene in the presence of boron trifluoride 
(Scheme 2-15). He then reported that the two cyclic isomers 61 and 64 could be separated 
as their acetates. 
 
Scheme 2-15 - Reagents and conditions: (i) 67 (2 equiv), BF3 (10 mol%), benzene
39
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In our hands, acetate protection of the mixture of 61 and 64 yielded product 65 in 73% 
yield (Scheme 2-16). Compound 66 co-elutes with compound 65 and we were unable to 
separate compound 66 using column chromatography. 
 
 
Scheme 2-16 - Reagents and conditions: (i) Ac2O (25 equiv), pyridine (2 mL/g of starting material), rt, 73% 
yield of 65 
 
Ichikawa reported the isolation of 66. The 1H NMR spectroscopic analysis of 66 showed 
signals at δ 0.90 (singlet, 3 H, CH3C–), 1.00 (singlet, 3 H, CH3C–), 1.16 (singlet, 3 H, CH3CO–), 
2.35 – 2.60 (multiplet, 2 H, Ar–CH2–), 1.30 – 1.80 (multiplet, 6 H,–CH2–), 2.23 (singlet, 3 H, 
CH3COO–), 2.05 (singlet, 3 H, CH3–Ar) and 1.95 (singlet, 6 H, CH3–Ar), with no signal of the 
olefinic proton.39 The similarities between the 1H NMR spectra of 66 and the minor 
compound from the mixture of 61 and 64 allowed us to confirm the structure of compound 
64. Analysis of the 1H NMR spectrum of 65 indicates the presence of the core structure of 
chromanol 61, further confirming that 61 is the major compound in the inseparable 
mixture. We were then able to determine the ratio of 61:64 (5:1) in the inseparable 
mixture from the cyclization reaction. 
 
Odinokov reported the use of heptane which gave a 2:1 ratio of 61:64 while the reaction in 
aromatic solvents such as benzene and toluene gave nearly equimolar mixtures, and the 
reaction in dioxane did not proceed at all.40 
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Odinokov suggested that the ratio of the products is greatly influenced by the catalyst 
activity.41 Thus, several other mild acid catalysts were used to improve the isomer ratio but 
to no avail. The use of p-TsOH in our hands for this reaction was found to be less reactive, 
giving only 21% yield with the ratio of the isomers in accord with Odinokov’s report.38 The 
use of other acids, Amberlyst® 15 and silica gave no reaction at all. The collected results can 
be seen in Table 2-2. 
Table 2-2 - Acid-catalysed condensation of 62 and 63 
Acid Solvent Product 
(±)-CSA Xylene No reaction 
(±)-CSA n-octane Mixture of isomers 61 and 64, 5:1, 95% 
p-TsOH n-octane Mixture of isomers 61 and 64, 5:1, 21% 
Amberlyst® 15 Toluene No reaction 
Amberlyst® 15 Dichloromethane No reaction 
Silica Toluene No reaction 
Silica Dichloromethane No reaction 
 
In 2005, Odinokov reported the use of this approach to synthesize the vitamin K1 dihydro 
derivative (naphthotocopherol) 68 and an analogue 69. Compound 68 and its cyclic isomer 
69 were obtained as a mixture in a 3:7 ratio according to GLC (Scheme 2-17).42 
 
 
Scheme 2-17 - Reagents and conditions: (i) 63 (1.0 equiv), (±)-CSA (0.1 equiv), n-octane, reflux, 3 h, 3:7 ratio of 
68 and 69 by GLC
42
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Using the approach discussed above, propargyl alcohol 70 (3,7-dimethyl-6-octen-3-ol-1-
yne) would be the desired precursor to obtain the chromene substrate 47 directly (Scheme 
2-18).  
 
 
Scheme 2-18 - Synthesis of 47 using propargyl alcohol 70 
 
The precursor 70 was readily accessed by us through the addition of a Grignard reagent, 
ethynylmagnesium bromide 72, to commercially available 6-methylhept-5-en-2-one 71 
(Table 2-3). 
 
Table 2-3 – Reaction conditions for synthesis of 3,7-dimethyloct-6-en-3-ol-1-yne 70 
Entry Compound 71 Compound 72 Solvent Temp, oC Product 70 
1 1 equiv 1.5 equiv THF –78 oC – rt No reaction 
2 1 equiv 4.5 equiv THF 0 oC – rt 62% 
3 1 equiv 10.0 equiv THF 0 oC – rt 70% 
4 1 equiv 1.2 equiv THF/Et2O 
(1:1) 
rt 88% 
 
No reaction progress was observed when the reagent 71 was added at –78 oC. When the 
addition of 71 took place at 0 oC, 70 was obtained in 62% yield. Increasing the number of 
equivalents of 72 also led to an increase in the yield. Nevertheless, the best outcome was 
obtained when 1.2 equiv. of 72 were used at room temperature: ketone 71 was dissolved 
in a mixture of anhydrous Et2O/THF (1:1)
43 and this solution was added dropwise to a 
solution of the Grignard reagent 72 at room temperature under argon. The residue was 
purified by column chromatography on neutral alumina, giving the product 70 in 88% yield. 
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The product decomposed when silica was used for the separation (Scheme 2-19). Under 
these conditions, increasing the number of equivalents of 70 did not improve the yield. 
 
 
Scheme 2-19 – Reagents and comditions: (i) 72 (1.2 equiv), anhydrous Et2O/THF (1:1), rt, Ar, 3 h, 88% 
 
With propargyl alcohol 70 in our hands, we then attempted the synthesis of chromene 47 
under acid catalysis, by reacting with phenol 62 in the presence of a catalytic amount of (±)-
CSA and heating under reflux (Scheme 2-20). 
 
 
Scheme 2-20 - Reagents and conditions: (i) (±)-CSA, n-octane, reflux 
 
Unfortunately, the desired product was not isolated and the starting material was 
decomposed under these conditions. A base-catalysed reaction was also attempted using 
propargyl alcohol 70 and trimethylhydroquinone 62. According to a method by Godfrey 
(used to prepare compound 49),44 propargyl alcohol 70 was first converted into the 
corresponding trifluoroacetate analogue by addition of trifluoroacetic anhydride (TFAA) in 
an ice-brine bath in the presence of DBU. The solution was stirred at 0 oC for 30 min. The 
solution of phenol 62 in CH3CN in the presence of DBU and a catalytic amount of CuCl2.H2O 
was then added into the trifluoroacetyl solution. However this attempt also failed (Scheme 
2-21). 
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Scheme 2-21 - Reagents and conditions: (i) DBU (1.3 equiv), TFAA (1 equiv), 0 
o
C; (ii) 62, DBU (1.12 equiv), 
CuCl2.H2O (10 mol%), CH3CN, 0 
o
C 
 
Due to unsuccessful attempts to synthesize compound 47 using both acid- and base-
catalysed condensation procedures presented above, we turned our attention towards 
another method. We finally managed to obtain chromene 47 through reaction of 
trimethylhydroquinone 62 with citral 73 in the presence of phenylboronic acid by heating 
under reflux for 1.5 hours in toluene, affording 45% yield of chromene 47 (Scheme 2-
22).45,46 This method was reported previously by Jung et al. to synthesize (+)-decursinol 8147 
and is further discussed in Chapter 2.2.2. 
 
 
Scheme 2-22 – Reagents and conditions: (i) 73 (3 equiv), PhB(OH)2 (1.6 equiv), propionic acid (0.3 equiv), 
toluene, reflux, 1.5 h, 45% 
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2.2.2 6-Hydroxy-2,2,5,7,8-pentamethylchromene 48 
 
Zhou prepared chromane 75 (2,2,5,7,8-pentamethyl-6-hydroxychromane or PMC) using an 
acid-catalysed method (Scheme 2-23). Phenol 62 was coupled with 2-methyl-3-buten-2-ol 
74 using trifluoroacetic acid (TFA) as catalyst under inert atmosphere followed by 
cyclization to give PMC in 80% yield.48 An earlier report of this trifluoroacetic acid-catalysed 
reaction at room temperature by Ismail et al. described the isolation of 75 in 63% yield. 
Ismail also reported that the presence of water (up to 10% v/v) in the reaction was found 
to increase the reaction rate.49 
 
 
Scheme 2-23 - Reagents and conditions: (i) 2-methyl-3-buten-2-ol 74, TFA, N2, 80%
48
 
 
Our first attempt to synthesize compound 48 was modelled on Zhou’s approach. This 
procedure failed to yield 48 from related dimethyl propargyl alcohol 76 (Scheme 2-24). 
 
 
Scheme 2-24 - Reagents and conditions: (i) 2-methyl-3-butyn-2-ol 76, TFA, N2 
 
The failure of the acid-catalysed condensation of phenol 62 and propargyl alcohol 76 is 
probably due to Rupe/Meyer-Schuster rearrangement forming the corresponding α, β-
unsaturated carbonyl compounds. Protonation of the propargylic alcohol followed by the 
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removal of water as leaving group formed the carbocation intermediate (Scheme 2-25). 
This intermediate rearranges in two pathways: Rupe rearrangement or Meyer-Schuster 
rearrangement.50,51 The difference between these two reaction pathways occurs early on: 
initial β-elimination of the propargyl alcohol provides an enyne en route to the Rupe 
product (path a), whereas as 1, 3-hydroxyl shift and tautomerization in path b leads to the 
Meyer-Schuster product. This also explains our failure to synthesize compound 47 using 
propargyl alcohol 70 (Scheme 2-19).50 
 
 
Scheme 2-25 – Path a: Rupe rearrangement and; Path b: Meyer-Schuster rearrangement mechanism
50
 
 
The synthesis of compound 48 was achieved by the ring formation of 62 with 3-methyl-2-
butenal 77, using phenylboronic acid (2 equiv) with an excess of acetic acid in toluene 
afforded the desired chromene 48 in 61% yield (Scheme 2-26). The mixture was heated 
under reflux in toluene overnight under N2 atmosphere. The use of a Dean-Stark apparatus 
did not improve the yield. 
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Scheme 2-26 – Reagents and conditions: (i) 77 (1.5 equiv), PhB(OH)2 (2 equiv), acetic acid (excess), toluene, 
reflux, N2, 61% 
 
This method was outlined by Jung et al. to synthesize (+)-decursinol 81 from a commercially 
available starting material, umbelliferone 78.  Umbelliferone 78 was first reduced using 
H2/Pd-C at room temperature for 10 hours to afford compound 79 in 94% yield, which was 
then subjected to ring formation reaction of the chromanone 79 with aldehyde 77 in the 
presence of phenylboronic acid and propionic acid to afford compound 80 in 62% yield 
(Scheme 2-27).47 
 
 
Scheme 2-27 – Reagents and conditions: (i) Pd-C/H2, AcOH, rt, 10 h, 94%; (ii) PhB(OH)2 (1.5 equiv), 77 (1.5 
equiv), propionic acid (1.5 equiv), toluene, reflux, 36 h, 62%
47
 
 
Phenylboronic acid is a useful reagent to produce quinonemethide intermediates, such as 
85, catalysing a reaction between a phenol and an aldehyde.52 Nagata first reported this 
reaction in 1976; he later proposed that the mechanism proceeded through a [3,3]-
sigmatropic rearrangement pathway, and he was able to isolate benzodioxaborines, such 
as 84 (Scheme 2-28). Phenylboronic acid adduct 82 reacted with the required aldehyde to 
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form benzodioxaborine 84, which rearranged to produce quinonemethide intermediate 85. 
The substituted 2-phenyl-4H-1,3,2-benzodioxaborin 84 is a stable compound that can be 
stored indefinitely at room temperature. Intramolecular hetero electrocyclization of the 
exo-quinonemethide 85 with the –double bond gave the desired product 48 in a good 
yield (61%). 
 
 
Scheme 2-28 - Ring formation mechanism with phenylboronic acid via [3,3]-sigmatropic rearrangement 
pathway
53
 
 
The reaction is regioselective, attack occurring exclusively at the ortho position with 
regards to the phenolic hydroxyl.54 No reaction was observed without phenylboronic acid, 
or acetic acid. Besides Jung, this methodology has been successfully applied by Broadhurst 
and Hassan to the synthesis of anthracyclines (Figure 2.16).45 
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Figure 2.16 - Two types of anthracyclines synthesized by Broadhurst et al.
45
 
 
We attempted to use this method to synthesize compound 47, taking into account our 
previous experience of inseparable mixture of isomers in synthesizing 47 via acid-catalysed 
reaction. This was carried out by heating under reflux a mixture of the corresponding 
phenol, trimethylhydroquinone 62 (1 equiv), citral 73 (3 equiv), and PhB(OH)2 (1.6 equiv) in 
the presence of a catalytic amount of propionic acid (0.3 equiv) in toluene. The first 
attempt using PhB(OH)2 and an excess of acetic acid, following the method to synthesize 
48, failed. However, Chambers et al. reported the use of propionic acid (0.3 equiv) instead 
of acetic acid for the synthesis of compound 47 (Scheme 2-22). This one-pot reaction is 
very much preferable even though the yield is just 45% as no mixture of inseparable cyclic 
isomers is formed. The crude product was purified by column chromatography in 95/5: 
petroleum ether/ethyl acetate as eluent to obtain compound 47. 
 
2.2.3 6-Cyano-2, 2-dimethyl-2H-1-benzopyran 49 
 
Within the Page group, two methods have been used to access the chromene substrate 49. 
The first procedure to synthesize 2,2-dimethyl chromenes from electron-deficient phenols 
has been developed by North et al.,55 which is complementary to that of Crombie56 and 
Camps.57 This methodology involves a base-catalysed condensation of 4-cyanophenol 86 
with diethyl acetal 87 in p-xylene and affords 6-cyano-2,2-dimethylchromene 49 in 87% 
yield (Scheme 2-29). The second method proceeds through the thermal rearrangement of a 
suitable propargyl ether (Scheme 2-30). 
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Scheme 2-29 - Reagents and conditions: (i) 86 (2 equiv), p-xylene, 3-picoline (0.25 equiv), reflux, 24 h, 87% 
 
 
Scheme 2-30 - Thermal rearrangement of a propargyl ether 
 
The synthesis of chromene 49 using the first method begins with the preparation of the 
diethyl acetal 87 (Scheme 2-31). The synthesis of diethyl acetal 87 from ethanol, triethyl 
orthoformate 88, and 3-methyl-2-butenal 77 in the presence of p-toluenesulfonic acid was 
found unsuccessful due to polymerization of the aldehyde as reported by North et al. North 
then ultimately found that KHSO4 afforded the best yield of 87, up to 86% yield.
55 
 
 
Scheme 2-31 - Preparation of diethyl acetal 87. Reagents and conditions: (i) NH4NO3 (25 mol%), EtOH, rt, 24 h 
 
In 1986, Mori et al. reported the use of NH4NO3 as a solid acid catalyst to synthesize the 
α,β-unsaturated acetal 87 which was then used without further purification for asymmetric 
Simmons-Smith reactions.58 In our hands, the reaction was complete within 24 hours. 
Evaporation of the reaction solvent however had to be carried out carefully at low 
temperature (approx. room temperature) due to the boiling point of the acetal. According 
to NMR spectroscopic analysis, the brownish liquid obtained is a pure sample of acetal 87. 
The use of orthoesters, such as trimethyl- or triethyl orthoformate, with aldehydes or 
CHAPTER 2 - RESULTS AND DISCUSSIONS 
 
 
 
 
98 
ketones in the carbon-oxygen bond formation is a well-established reaction.59 The 
proposed mechanism of acetalization is shown below (Scheme 2-32). 
 
Scheme 2-32 - Acetalization mechanism
60
 
 
Acetal 87 was freshly prepared due to the instability of this compound at room 
temperature. This compound also tends to decompose when kept in the refrigerator for a 
period of time. Acetal 87 was subsequently heated under reflux with 4-cyanophenol 86 in 
p-xylene in the presence of 3-picoline as the base.  
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The suggested mechanism of the base-catalysed condensation of an α,β-unsaturated acetal 
and a phenol is illustrated below (Scheme 2-33).55,61 First, the phenol is deprotonated. 
North suggested that the phenol also acts as an acid catalyst to activate the acetal.55 The 
ethanolysis of the acetal produced the oxonium ion, which then attacked by phenolate to 
give the corresponding dienone 89. Rearomatization of 89 leads to 90, and subsequent 
elimination of ethanol allows formation of enone 91. Finally, electrocyclic ring closure 
provides chromene 49. 
 
 
Scheme 2-33 - Mechanism of the base-catalysed condensation of an acetal and a phenol to form a chromene 
 
The rearrangement/cyclization of propargyl ether 93 is another potential method 
developed by Harfenist and Thom to access chromenes such as 49 (Scheme 2-34),62 and has 
been recognised as one of the general methods for the synthesis of chromenes.63 The 
dimethylated propargyl alcohol 76 was first converted to the corresponding dimethylated 
propargyl chloride 92 using calcium chloride, cuprous chloride and a catalytic amount of 
copper powder and cold concentrated hydrochloric acid, according to a method by 
Boisselle.64  
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The o-alkylation of 4-cyanophenol 86 was achieved by heating the phenol and 3-chloro-3-
methyl-1-butyne 92 with potassium carbonate and potassium iodide in acetone: the 
propargyl ether 93 was obtained in excellent yield, as high as 99%. Thermal rearrangement 
of the ether 93 in high boiling point solvent (>150 oC) allowed cyclization of the ether in an 
almost quantitative yield.65 
 
 
Scheme 2-34 - Reagents and conditions: (i) CaCl2, CuCl2, Cu, cold conc. HCl, 0 
o
C, 5 hrs; (ii) 4-cyanophenol, 
K2CO3 (1.0 eq), KI (0.1 eq), N2, acetone, reflux; (iii) N,N-diethylaniline, N2, reflux. 
 
Previously, the thermal Claisen rearrangement had been performed by heating a solution 
of 93 in o-chlorobenzene,62 a mixture of dry DMF, N, N-diethylaniline66, and poly(ethylene 
glycol).67 The thermal rearrangement of simple propargyl ethers to produce chromenes was 
first reported by Iwai and Ide68 in 1963 and remains a convenient method for the 
preparation of 2,2-dimethylchromenes.69–73 Ethylene glycol was used by us as the solvent 
as its high miscibility with water facilitates the work-up; indeed, a simple extraction with 
diethyl ether and a water wash are sufficient to separate the ethylene glycol from the 
desired product. The chromene 49 was then recrystallized from the residue using light 
petroleum.  
 
Godfrey showed that the conversion of 76 to 93 could also be achieved by converting the 
propargyl alcohol into trifluoroacetate 94. The trifluoroacetate 94 is an effective leaving 
group for the alkylation in the presence of a copper catalyst (Scheme 2-35). Base-catalysed 
condensation of compound 94 was achieved in 86% yield using DBU as the base with the 
presence of a catalytic amount of copper chloride at 0 oC for five hours.74,75 
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Scheme 2-35 - Reagents and conditions: (i) (CF3CO)2O, DBU, CH3CN, 0
 o
C, %; (ii) 4-cyanophenol, DBU, CH3CN, 
Cu2Cl2 (0.1 mol%), 0 
o
C, 5 hr, 86%; (iii) reflux
74,75
 
 
The mechanism of the thermal cyclization of aryl propargyl ethers into chromenes was 
proposed by Zsindley and Schmid (Scheme 2-36)70 and involves an initial Claisen 
rearrangement of aryl propargyl ether 95 to give γ,δ-unsaturated allene carbonyl 
intermediate 96. Enolization of 96 gives intermediate 97 which then undergoes a [1,5]-
sigmatropic hydrogen shift to yield 98 followed by an electrocyclic reaction to give the 
related chromene 99.72 
 
 
Scheme 2-36 - Proposed mechanism of thermal cyclization of aryl propargyl ethers
70
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2.2.4 6-Hydroxy-2,5,7,8-tetramethylchromene-2-carboxylate 50 
 
 
Figure 2.17 - Structure of the chromene substrate 50 
 
The chromene substrate 50 was synthesized by heating the trimethylhydroquinone 62 and 
methyl methacrylate 100 in a formalin solution (37 wt%) at 180 oC in a pressure tube to 
afford a white solid, which was recrystallized from methanol giving 101, in up to 71% yield, 
followed by protection of the phenol group and dehydrogenation at C3 and C4 (Scheme 2-
37). 
 
 
Scheme 2-37 - Synthesis plan of chromene substrate 103 
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The Mitsubishi Corporation developed this method on an industrial scale. In most literature 
reports, compound 101 was readily synthesized from the commercially available Trolox® 
(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), 104 after a simple methyl 
esterification (Scheme 2-38).76–78 Compound 101 is a very useful intermediate for 
functionalization at both the ester functionality and the phenol group. 
 
 
Scheme 2-38 – p-TsOH (0.3 equiv), MeOH (20 mL/g of 104), CH2Cl2 (4 mL/g of 104), rt, 95%
77
 
 
For example, Atkinson et al. reported the preparation of photoaffinity analogues of α-
tocopherol 108. Starting from (S)-Trolox® 104, the carboxylic acid was first transformed 
into its methyl ester 101, followed by protection of the phenolic hydroxyl as the 
corresponding tert-butyldimethylsilyl ether 105. Selective reduction of the ester group into 
aldehyde 106 was carried out using diisobutylaluminium hydride (DIBAL). Then, the 
incorporation of the photolabile group to the side chain was accomplished using ω-
hydroxyalkyl phosphonium bromide 109. Treatment of 109 with a strong base produced 
the ylide, which was coupled to the aldehyde 106 in a Wittig reaction to form the alkenol 
107. The saturated side chain was then obtained by catalytic reduction using Pd/C. 
Compound 108 was obtained after several further steps (Scheme 2-39).76 
 
CHAPTER 2 - RESULTS AND DISCUSSIONS 
 
 
 
 
104 
 
Scheme 2-39 - Reagents and conditions: (i) TBDMSCl, imidazole, DMF, 85 
o
C, 97%; (ii) DIBAL, CH2Cl2, –60 
o
C, 
86%; (iii) 109, LiHMDS, THF, –60 
o
C, 81 – 89%
76
 
 
Naumann et al. studied the functionalization at the phenolic hydroxyl position.  Previously, 
this group reported that the presence of both a lipophilic and an acid moiety on the 
carbazole or the carprofen scaffold seemed to be essential for the modulatory effect on the 
γ-secretase enzyme, displaying activities as low as a micromolar range for the most active 
derivatives (Figure 2.18, compound 110 and 111).79 The γ-secretase enzyme has been 
demonstrated to reduce the production of amyloid-β42 peptides (Aβ42) and to increase the 
formation of shorter Aβ-peptides like Aβ38. The more hydrophobic Aβ42 species has a higher 
tendency to aggregate compared to Aβ38 which is more soluble. The aggregation-prone 
Aβ42 peptides are the central drivers of the pathological process in Alzheimer’s disease.
80–83 
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Figure 2.18 - Structures of carprofen, carbazole, and two selected γ-secretase modulators
79
 
 
Referring to these previous studies, Naumann et al. synthesized tocopherol derivatives by 
adding lipophilic chains to the chromane derivative 104 to study the impact of the acidic 
moiety’s location on the γ-secretase modulators’ (GSM) activity and to compare the 
influence of several lipophilic chains of various lengths including octyl- (112a), undecyl- 
(112b), tetradecyl- (112c), the terpene-related farnesyl- (112d), and phytyl- (112e) (Scheme 
2-40).79 The study revealed that all the synthesized chromane derivatives with an acidic 
moiety (112b – 112e) exhibited GSM activity, increased the generation of Aβ38 and reduced 
the generation of Aβ42, except for compound 112a, which contains only eight carbon atoms 
on the lipophilic chain, which is too short to provide stable anchoring in the membrane.79 
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Scheme 2-40 - Reagents and conditions: (i) K2CO3, MeI, DMF, rt; (ii) Cs2CO3, R1-X, DMF, 100 
o
C; (iii) KOH, 
dioxane/water (5:1), 75 
o
C 
 
As discussed above, the modification of the methyl ester or phenol in compound 101 gives 
rise to a number of biologically active compounds. However, to the best of our knowledge, 
there is no report on potential modifications at the C3-C4 position of 101, which would be 
interesting to explore.  
 
2.2.5 Protection of the Phenolic Hydroxyl Functional Group 
 
After we had successfully synthesized all the desired chromene substrates, chromenes 47, 
48, and 50 were subjected to phenolic hydroxyl group protection. Protection is necessary 
prior to the asymmetric epoxidation reaction. Oxidation attempts on compounds 47, 48, 
and 50 were unsuccessful perhaps due to the electron-donating properties of the hydroxyl 
group, which may stabilize the carbocation issued from the ring opening of the epoxide; 
this is discussed further below (Chapter 2.3). Several hydroxyl protecting groups had been 
chosen with electron-withdrawing abilities on the basis that this would increase the 
stability of the resulting epoxide. We successfully prepared the protected chromene 
compounds using several protecting groups, including the acetate, trifluoroacetate and 
benzoate groups. 
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2.2.5.1 Acetate Protection of the Phenolic Hydroxyl Group 
 
Acetate protection of the phenolic hydroxyl moiety proceeded smoothly, the chromene or 
chromane compound, pyridine and acetic anhydride, stirred at room temperature 
according to method by Ordinokov et al.40 affording yields as high as 86% yield (Table 2-4). 
Another method, reported by Patti et al.,84 gives up to 74% yield of the desired acetate, 
when triethylamine and acetic anhydride were used in t-butylmethyl ether as the solvent. 
Table 2-4 - Acetate protection of chromane/chromene 
Chromene/ 
Chromane 
Product Yield 
(%) 
 
Chemical shift of 
acetyl, δ (ppm) 
47 
 
86 2.33 
48 
 
82 2.32 
61 
 
73 2.32 
99 
 
59 2.25 
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The presence of the acetate group can be confirmed using 1H NMR spectroscopic analysis. 
The signal corresponding to the protons from the acetate group is observed as a singlet 
between 2.2 and 2.4 ppm. Analysis of the IR spectrum confirms the presence of carbonyl 
group of the acetate which gives a strong peak in the range of 1750 – 1760 cm-1. 
 
For chromane 61, we only protected this compound using acetate group as the phenolic 
hydroxyl protection of this compound was carried out in order to separate the cyclic 
mixture (Chapter 2.2.1). We did not protect this compound using other protecting groups. 
 
2.2.5.2 Trifluoroacetate Protection of the Phenolic Hydroxyl Group 
 
Trifluoroacetylation of phenolic hydroxyl group was carried out using trifluoroacetic 
anhydride (TFAA) in anhydrous THF as the solvent and pyridine as the base at 0 oC. The 
trifluoroacetate-protected compounds were obtained in 65 – 99% yields (Table 2-5). 
Unexpectedly, we obtained almost quantitative yield of 52 after 24 hours reaction. 
Table 2-5 - Trifluoroacetate protection of chromane/chromene 
Entry Chromene/ 
Chromane 
Product Yield 
(%) 
1 47 
 
99 
2 48 
 
84 
3 99 
 
65 
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As no additional signal is expected when the 1H NMR spectrum of the compounds is 
analysed, the attachment of trifluoroacetate group can be confirmed by analysing their 13C 
NMR spectrum: indeed, the presence of two quartet signals in the 110 – 120 ppm (1JC–F = 
284 – 287 Hz, CF3) and 150 – 160 ppm regions (
2JC–F = 40.0 – 45.0 Hz, C=O) proves it. 
Analysis of the IR spectrum confirms the presence of the trifluoroacetyl group which gives 
two strong and broad peaks between 1100 – 1200 cm-1.85 It was also determined that the 
compound contained a carbonyl group from the peak between 1790 – 1800 cm-1. The 
carbonyl stretching of the trifluoroacetate group is higher than the average ester carbonyl 
frequency (ca. 1740 cm-1). The force constant of the C=O bond is higher relative to the 
hydrogenated ester due to the presence of the highly electronegative fluorine atoms.86 
 
2.2.5.3 Benzoate Protection of the Phenolic Hydroxyl Group 
 
Benzoylation of the phenolic hydroxyl groups were successfully achieved by reacting the 
phenol with sodium hydride as the base and benzoyl chloride under anhydrous conditions.  
The addition of the phenol (dissolved in anhydrous THF) into a suspension of the base in 
THF under inert atmosphere gave the corresponding phenoxide ion. Hydrogen evolution 
immediately occurred and the colour of the solution changed as the phenol solution was 
slowly added. Benzoyl chloride was then added into the mixture and the benzoate 
protected product was obtained in good to excellent yield (Table 2-6). 
Table 2-6 - Benzoate protection chromane/chromene: NaH (1.1 equiv), benzoyl chloride (1.0 equiv), dry THF, 
N2 
Chromene/ 
Chromane 
Product Yield 
(%) 
Reaction time 
(hours) 
47 
 
75 Overnight 
CHAPTER 2 - RESULTS AND DISCUSSIONS 
 
 
 
 
110 
48 
 
84 0.5 
99 
 
50 Overnight 
 
 
Initial attempts to use pyridine as the base were disappointing as the benzoylation reaction 
was found to be very slow: the desired benzoate was obtained in 20% yield when the 
reaction was left overnight. Addition of a catalytic amount of DMAP did not improve the 
yield. 
 
2.2.5.4 Methyl Ether Protection of the Phenolic Hydroxyl Group 
 
Apart from protecting the phenolic hydroxyl using an electron withdrawing group, we also 
attempted an electron donating group protection, methyl ether protection, in this 
research. Methyl ether is one of the simplest protecting groups. This type of protection is 
normally avoided except when the hydroxyl needs to survive strongly basic or acidic 
conditions as the deprotection is difficult in which harsh conditions are required.87 But the 
removal is not as difficult with phenols.  
 
The introduction of the methyl group was carried out via Williamson Ether synthesis. The 
use of sodium hydride and methyl iodide under inert atmosphere, afforded the 
corresponding products in good yield (Table 2-7) after few hours of stirring at room 
temperature (Scheme 2-41). In contrast, when we used an approach by Pan,88 reaction of 
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chromene 48 with potassium carbonate as the base in acetone and stirred for 48 hours, 
disappointingly, we obtained only 11.6% yield of 117, as compared to 87% yield using 
sodium hydride as the base. 
 
Scheme 2-41 - Reagents and conditions: (i) NaH (1.1 equiv), anhydrous THF, MeI (1 equiv), rt 
Table 2-7 Methyl ether protection of the phenolic hydroxyl 
Chromene/ 
Chromane 
Product Yield 
(%) 
Reaction time 
(hours) 
48 
 
87 3 
99 
 
69 24 
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2.2.6 Synthesis of 3, 4-Dehydro Derivatives of Chromane 
 
It has been reported that chromane compounds can be dehydrogenated to the 
corresponding chromenes by 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (Scheme 2-
42).89  
 
Scheme 2-42 – Reagents and conditions: (i) DDQ, dry toluene, 105 
o
C – reflux, 24 h 
 
DDQ is a chemical reagent widely used in organic synthesis. It is a member of the large 
quinones family and is one of the most versatile reagents because it has high oxidant ability 
and relative stability compared to others. The dehydrogenation of hydroaromatic 
compounds by quinones was first reported in 1930 by Clar and John.90 However it failed to 
gain general acceptance until the more extensive investigations of Braude, Jackman, 
Linstead, and co-workers, 20 years later.91 The advantage of quinone hydrogenation as a 
method of selective abstraction of hydrogen from hydroaromatic compounds is the mild 
conditions used. 
 
The suggested mechanism for dehydrogenation involves a 2-step reaction mechanism: an 
initial rate-determining transfer of a hydride ion followed by a rapid proton transfer leading 
to the hydroquinone formation (Scheme 2-43).90,92 
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Scheme 2-43 - Suggested reaction mechanism for dehydrogenation of hydrocarbons using DDQ
90,92
 
 
Rosenau has reported that mixtures of different dimers were obtained when non-
protected chromanols were reacted with DDQ, whereas the reaction with appropriately O-
protected chromanols proceeded smoothly. Thus, suitable protection of the phenolic 
hydroxyl is essential before the actual dehydrogenation step, and deprotection can be 
done afterwards.89 Previously, the acetate protecting group was chosen due to simplicity 
and near-quantitative yields of both attachment and removal of protecting group.89 Thus, 
we decided to do the oxidation reaction using the acetate-protected chromane.  
 
Both working in an inert atmosphere and using carefully dried solvents were imperative to 
obtain good yields (about 70% after purification). Anhydrous reaction conditions are 
essential when using DDQ as this oxidant decomposes in the presence of water with the 
evolution of HCN.92 
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Table 2-8 - Oxidation using DDQ 
Entry Chromane Product Yield (%) 
1 65 
 
24 
2 113 
 
48 
3 115 
 
43 
 
As can be seen in Table 2-8, the yield of the oxidation reactions we obtained in our lab, is 
moderate, below 50% yield. Rosenau reported oxidation of 2,2,5,7,8-
pentamethylchromane 119, afforded the corresponding chromene 54 in 76% yield (Scheme 
2-44).89 The lower yield obtained with our chromanes could be explained by the difference 
between the steric hindrance caused by the side chains at the C2 position (methyl group vs. 
long alkyl chain or carboxylate group). There is no significant difference in the reaction yield 
observed when the acetate group is replaced with a benzoate group (Table 2-8, entry 2 and 
3). 
 
Scheme 2-44 - Reagents and conditions: (i) DDQ, toluene, reflux, 24 h, 76%
89
 
 
TLC analysis of the reaction mixture showed the product and the starting material have the 
same Rf, but the starting material can be distinguished from the product by charring the 
TLC plate with 4% H2SO4 in MeOH. The starting material and the product turn yellow and 
brown, respectively.76 
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An example of dehydrogenation of a chromene derivative was reported by Chauncey et al. 
in 1980; the chromane 120 was heated under reflux in anhydrous benzene for 48 hours to 
give the corresponding chromene 121 in 77% yield (Scheme 2-45).93 
 
Scheme 2-45 – Reagents and conditions: (i) DDQ, dry benzene, reflux, 48 h, 77%
93
 
 
A functionality that is capable of stabilizing the cation formed and initiate hydrogen 
transfer is needed, typically an aromatic moiety. Hydrocarbons lacking these functionalities 
are stable to the action of DDQ. In 1982, Ahluwalia reported that the presence of an 
electron-donating group on the aromatic ring can facilitate the oxidation reaction. 
Ahluwalia showed an example using chromanes 122a and 122b bearing a methoxy group 
on the aromatic ring, gave the corresponding chromenes 123a and 123b in 80 and 85% 
yields, respectively (Scheme 2-46).53 
 
Scheme 2-46 - Reagents and conditions: (i) DDQ, anhydrous benzene, reflux, 20 h
53
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2.3 Asymmetric Epoxidation of Chromene Substrates  
 
Epoxidation reactions are important transformations of alkenes, as epoxides are versatile 
intermediates in organic syntheses. In the final part of this research, we aimed to apply 
asymmetric epoxidation reactions, using our iminium salt catalysts 3, 4, 7 – 10, to the 
chromene substrates and their derivatives. Chromenes and 3,4-epoxychromane derivatives 
have attracted much attention because of their biological activities and importance as 
synthetic intermediates for biologically active compounds.41,94–100  
 
The chromene substrates and their derivatives we synthesized earlier are not natural 
compounds. However, asymmetric epoxidation of compound 49 followed by the treatment 
with pyrrolidin-2-one allows access to levcromakalim, a hypertensive agent, as discussed in 
Chapter 1.2.4 (Scheme 1-24, page 32).101 As for compound 47, 48, and 50, these 
compounds are analogues of the vitamin E constituent, tocotrienol, a very interesting 
compound with antioxidant property. Thus, application of asymmetric epoxidation 
reactions to these compounds can be used to study the antioxidant property of the 
modified analogues. 
 
2.3.1 Determination of Enantiomeric Excess 
 
In asymmetric synthesis, determination of the enantiomeric excess (ee) is important to 
evaluate the dominance of major enantiomer. In this research, there are two methods used 
in evaluating the enantiomeric excesses of the chiral epoxides i.e. using chiral HPLC or using 
1H NMR spectroscopy with addition of chiral shift reagent, Eu (hfc)3. 
 
2.3.1.1 By Chiral HPLC 
 
Chiral HPLC is one of the most common methods to determine the ee of a chiral 
compound. A racemic sample is first synthesized and the purified racemic product is then 
subjected to analysis to determine a suitable HPLC system. The solvent flow rate and the 
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solvent mixture (in this research we used HPLC grade hexane and isopropanol) can be 
adjusted to optimize the HPLC system to provide well-separated peaks of the enantiomers. 
When a system has been determined for the racemic mixture of one compound, the 
system can then be applied to enantioenriched samples. 
 
For example, an analytical method using HPLC was established with the racemic (±)-124 
using a Chiralpak column at flow rate of 0.5 mL/min; the enantiomers appeared at 36.2 – 
38.9 min and 40.6 – 44.2 min retention time. Racemic (±)-124 was afforded from the 
reaction of 49 with 2 equiv of m-CPBA in DCM at 0 oC (Scheme 2-47). The HPLC trace of the 
racemic (±)-124 can be seen in Figure 2.19 below, showing the presence of a mixture of 
enantiomers in 50:50 ratio in the sample by measuring the areas of the peaks: 
 
Scheme 2-47 - Preparation of the racemic epoxide 124 
 
 
Figure 2.19 - HPLC trace of the racemic epoxide 124 
 
Once the HPLC system for the racemic sample is predetermined, the analysis of 
enantiopure sample can be carried out. In the example below, reaction of 49 under non-
aqueous conditions in the presence of the iminium salt catalyst 7 (10 mol%), afforded (–)-
1S,2S-124 in ≥99% ee (Scheme 2-48). The enantiomeric excess of the enantiomerically 
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enriched epoxide can be calculated from the areas of peaks obtained from 
chromatographic data (Table 2-9).  
 
Scheme 2-48 - Asymmetric epoxidation of chromene 49 
 
 
Figure 2.20 - Enantioenrich sample of 124 
Table 2-9 - Peaks area and height 
UV Results     
Retention Time Area Area % Height Height % 
36.623 347322 0.33 11791 0.61 
40.790 104456189 99.67 1922846 99.39 
     
Totals     
 104803511 100.00 1934637 100.00 
 
From the example of the HPLC trace of the enantiopure compound 124 (Figure 2.20), the 
enantiomeric excess is ≥99% using the formula below: 
% ee =  
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2.3.1.2 By 1H NMR Spectroscopy with the Chiral Shift Reagent Eu (hfc)3 
 
In some cases, the enantiomeric excess for epoxide samples cannot be determined using 
chiral HPLC as the peaks corresponding to both enantiomer are not resolved; therefore 
alternative methods of determining enantiomeric excess are required. In this research, the 
other method used to determine the ee is using chiral shift reagent. The mixture of epoxide 
enantiomers forms a pair of diastereomeric complexes in the presence of the chiral shift 
reagent. The two resulting complexes exhibit a different set of signals using 1H NMR 
spectroscopy and integration of a proton signal corresponding to each complex allows ee to 
be determined. Currently several chiral shift reagents are commercially available, including 
the europium shift reagent Eu(hfc)3, Kagan’s amide shift reagent and Pirkle reagent. The 
best chiral shift reagent used for epoxide samples in our group is europium tris[3-
(heptafluoropropylhydroxymethylene)-(+)-camphorate], Eu(hfc)3 125 (Figure 2.21). 
 
 
Figure 2.21 - Europium tris[3-(heptafluoropropylhydroxymethylene)-(+)-camphorate]
102
 
 
One example of chiral epoxides that cannot be resolved using chiral HPLC is 1-
phenylcyclohexene oxide 127; hence the chiral shift reagent was used to determine the ee 
of the chiral epoxide 127. The method involved sequential addition of the chiral shift 
reagent Eu(hfc)3 into the analysed compound in a deuteriated solvent until the signals 
corresponding to each complex appeared. Enantioenriched epoxide 127 was prepared 
under aqueous conditions to test this method (Scheme 2-49). 
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Scheme 2-49 - Asymmetric epoxidation reaction on alkene 126 under aqueous conditions 
 
The signal corresponding to the protons at the 2-position of compound 127 is observed at 
3.08 ppm in deuterated chloroform (Figure 2.22). After addition of chiral shift reagent, the 
peak corresponding to the same proton in each diastereoisomeric complex can be seen at 
3.45 and 3.55 ppm, respectively (Figure 2.23) 
 
 
 Figure 2.22 - 
1
H NMR of enantioenrich sample of 1-phenylcyclohexene oxide 127 
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 Figure 2.23 - 
1
H NMR of enantioenriched sample of 1-phenylcyclohexene oxide 127 + Eu(hfc)3 125 
 
The ee can be calculated using the same formula as used for chiral HPLC. In the example 
above, the percentage of ee is 53%. 
 
2.3.2 Preparation of Racemic Epoxides 
 
Generally, racemic epoxidation of alkenes in our laboratory is carried out by reaction of the 
alkene with m-CPBA in DCM or chloroform reacting at 0 oC for few hours. After the reaction 
is complete, the organic layer is extracted a few times by using a saturated solution of 
NaHCO3 or 10% Na2CO3; otherwise some of the m-chlorobenzoic acid still remains in the 
organic layers. The crude epoxides can be further purified by column chromatography. The 
epoxide is not stable to acidic silica gel which leads to epoxide decomposition, thus 
addition of 2% TEA to the solvent is crucial. The solvents can then be easily removed using 
a water bath maintained at 40 – 50 oC. Higher temperatures should be avoided because the 
epoxide is very reactive and undergoes decomposition at higher temperature. 
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Racemic epoxides can also be prepared using DMDO as oxidant. This method is normally 
used for acidic-sensitive epoxides as this reagent is neutral. DMDO can be prepared using 
the procedure by Adam et al. in a large scale.103 It was prepared by us by the reaction of 
Oxone® in mixture of acetone/water with the presence of NaHCO3 (Scheme 2-50) in 3 L 
three-neck flask and DMDO was collected under a moderate vacuum (80 – 100 Torr) in 
receiving flask immersed in acetone/dry ice at –78 oC with vigorous stirring. The acetone 
solution of dimethyldioxirane was dried with K2CO3, filtered off and stored in the freezer (–
20 oC) over molecular sieve (4Å). Due to stability problems during transport and storage, it 
is still not possible to purchase this reagent from common suppliers of research and fine 
chemicals. 
 
Scheme 2-50 - Reagents and conditions: (i) H2O (254 mL), acetone (192 mL), NaHCO3 (58 g), 5 
o
C to 10 
o
C 
 
The concentration of DMDO was determined by iodometric titration. The acetone solution 
of DMDO was added to an Erlenmeyer flask containing water (20 mL), glacial acetic acid (1 
mL) and a freshly prepared solution of NaI, and was titrated using a 0.02 M aqueous 
solution of sodium thiosulfate (Na2S2O3). The concentration was then calculated using the 
following equation: 
Concentration of DMDO = 
                                  
                      
   
For a smaller scale, a simplified preparation of DMDO, the method reported by Taber can 
also be used.104 In this method, a mixture of distilled H2O (20 mL), acetone (30 mL) and 
NaHCO3 (24 g, 0.285 mol) was stirred at 0 
oC prior to addition of Oxone®. The slurry was 
then attached to a rotary evaporator with the bath at room temperature, which was then 
increased up to 40 oC after 15 min. DMDO was collected in the rotary evaporator splash 
trap, which was chilled in acetone/dry ice bath as the vacuum of 115 mmHg applied, giving 
average volume of 25 mL of the pale yellow acetone solution of DMDO. The solution was 
then dried over Na2SO4, filtered and transferred into a 50 mL round bottom flask (dried in 
the oven overnight) containing molecular sieve. The concentration of DMDO solution 
obtained is typically in the range of 60 – 65 mM. 
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The latter method of DMDO preparation is much more convenient as the concentration of 
DMDO is much higher than the former method, and no apparatus involving large glassware 
is required. Since the amount of DMDO obtained is on the average of 25 mL per batch, the 
reagent can be freshly prepared for the racemic epoxidation reaction. 
 
The choice of reaction temperature is critical in epoxidation reactions. Hence, an 
investigation was carried out to study the best reaction temperature for racemic 
epoxidation reactions using chromene 54 as the substrate mediated by DMDO as the 
oxidant (Scheme 2-51). The data collected in Table 2-10, shows that 20 min is the fastest 
reaction time for complete conversion of chromene 54 to the corresponding epoxide (±)-
128, observed for the reactions carried out at 0 oC and room temperature. At lower 
temperatures, longer reaction times were required for the reactions to reach to 
completion. Thus, 0 oC was chosen as the standard temperature for racemic epoxidation 
reactions using DMDO as the oxidant rather than room temperature to avoid possible 
decomposition of the epoxides at higher temperatures. 
 
Scheme 2-51 - Reagents and conditions: (i) DMDO (1.5 equiv), DCM, 100% conversion 
Table 2-10 - Racemic epoxidation at different temperature 
Temperature (oC) Reaction time (min) 
–45 240 
–20 80 
0 20 
Room temperature 20 
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Using these several approaches of preparation of the racemic epoxides, we started our 
investigation of the racemic epoxidation reactions on the chromenes 47 – 50. The 
chromene 49 is quite stable under mild acidic conditions as the racemic epoxidation using 
m-CPBA as the oxidant afforded the corresponding epoxide 124. Unfortunately, the 
racemic epoxidation reactions of compounds 47 and 48 were unsuccessful due to the 
decomposition of the starting material under all the reaction conditions mentioned above.  
 
In the case of acetyl-, trifluoroacetyl and benzoyl-protected 2,2,5,7,8-
pentamethylchromenes, 54, 55 and 56 respectively, unfortunately preparation of racemic 
3, 4-epoxychromane using m-CPBA was unsuccessful probably due to inherent instability of 
the epoxides in acidic solutions. Commercially available m-CPBA contains up to 15% m-
chlorobenzoic acid105 which may react with acid-sensitive epoxides to give hydroxyester as 
the major product. This is supported by the IR spectrum of the products from racemic 
epoxidation of the acetyl-protected chromene 54 and the benzoyl-protected chromene 56, 
showing that the products contain a hydroxyl group by the presence of broad peak at 3475 
cm-1 and 3450 cm-1 respectively resulting from the epoxide ring opening (Scheme 2-52). 
 
Scheme 2-52 – Possible ring-opening of the epoxide by m-chlorobenzoic acid 
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The use of pre-purified m-CPBA also disappointingly did not work for the racemic 
epoxidation of chromenes due to the presence of acidic m-chlorobenzoic acid as the by-
product of the reaction, even though the reactions were worked-up using Na2CO3 several 
times. The purification of m-CPBA was carried out by dissolving the commercial m-CPBA in 
ether followed by washing with a phosphate buffer solution (410 mL of 0.1 M NaOH, 250 
mL of 0.2 M KH2PO4 made up to 1 L, pH 7.5) several times as reported by Aggarwal,
106 
affording 72% yield of pure m-CPBA. However this has to be done carefully at room 
temperature as the peroxyacid is potentially explosive.  
 
Addition of 10% aqueous Na2CO3 solution in racemic epoxidation of the chromene using 
pre-purified m-CPBA was found to be successful for chromene 54. The base was added to 
neutralize the acidic by-product formed in the reaction. According to 1H NMR spectroscopic 
analysis, the signals corresponding to the H(3) and H(4) of the (±)-128 are observed as  
doublets at 3.47 and 4.13 ppm respectively. A conversion of 81% of alkene to epoxide was 
obtained after 6 hours reaction. 
Table 2-11 - Racemic epoxidation of protected 2,2,5,7,8-pentamethylchromene 
Chromene/ 
Oxidant 
m-
CPBA 
10%Na2CO3+  
m-CPBA 
DMDO 
 
No 
epoxide 
  
 
No 
epoxide 
No epoxide 
 
 
No 
epoxide 
No epoxide 
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The racemic epoxidation reactions using DMDO as the oxidant were found to be more 
convenient for the protected chromene substrates. All the protected chromene substrates, 
acetyl-, trifluoroacetyl- and benzoyl-protected chromenes 54, 55 and 56, were easily 
converted into their corresponding epoxy chromanes 128, 129 and 130 respectively at 0 oC 
(Table 2-11). 
 
The 6-trifluoroacetyl-3,4-epoxy-2,2,5,7,8-pentamethylchromane 129 is the most unstable 
epoxide compared to the related 6-acetyl- and 6-benzoyl-3,4-epoxy-2,2,5,7,8-
pentamethylchromanes 128 and 130. If compound 129 was stored in the refrigerator for 
some time, it would ring-open to form the corresponding diols 131 (Scheme 2-53). The 
instability of the trifluoroacetate-protected compounds is also observed on 6-
trifluoroacetyl-2,2,5,7,8-pentamethylchromene 55 and 6-trifluoroacetyl-2,5,7,8-
tetramethylchroman-2-carboxylate 114. These compounds decomposed when left on the 
open bench for few weeks. 
 
Scheme 2-53 - Ring-opening of epoxide 129 
 
As DMDO was found to be the most suitable oxidant, we decided to carry out the racemic 
epoxidation reactions under these conditions for the other chromenes. Racemic 
epoxidation of chromene 57 afforded the related epoxide 132 in 35% yield (Scheme 2-54). 
 
Scheme 2-54 - Reagents and conditions: (i) DMDO (1.5 equiv), CHCl3, 100% conversion 
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Interestingly, the racemic epoxidation of compound 51 using DMDO did not give the 
expected epoxide 133 (Scheme 2-55). Generally, cis-alkenes are more reactive towards the 
electrophilic DMDO107 due to the steric interactions compared to trans-alkenes (Figure 
2.24). However, this was not observed in the epoxidation of chromene 51. 
 
Figure 2.24 - Interaction of alkenes and DMDO 
 
According to the 1H NMR spectroscopic analysis, the disappearance of the triplet peak of 
the olefinic proton of the side chain at C3-C4 was observed suggesting that the epoxidation 
reaction by DMDO is much preferable on the double bond of the side chain to afford two 
pairs of diastereomers of compound 134 (Scheme 2-55). It is probably because the double 
bond in the pyran ring is much more hindered as compared to the double bond in the side 
chain. 
 
Scheme 2-55 - Reagents and conditions: (i) DMDO (1.5 equiv), CHCl3, 100% conversion 
 
This chemoselectivity observed for the epoxidation of the less electron-rich alkene over the 
more electron-rich alkene by DMDO is an attractive finding. In the oleochemistry industry, 
epoxidation of the unsaturated fatty acid is an important reaction. The oxygenated fatty 
acids are employed industrially as lubricants and as secondary plasticizers.108 
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2.3.3 General Reaction Conditions of Asymmetric Epoxidation 
 
There are two standard iminium salt epoxidation conditions being used in our laboratory – 
aqueous and non-aqueous conditions. Aqueous conditions employ the triple salt Oxone® (2 
KHSO5KHSO4K2SO4) as a stoichiometric oxidant, Na2CO3 or NaHCO3 as the base, and 
acetonitrile: water as the solvent mixture. The presence of water is crucial for the 
epoxidation reaction to proceed, as the Oxone® is not soluble in organic solvent. The major 
limitation to these systems is the restricted range of temperatures at which the 
epoxidation can be performed (0 oC to room temperature). The upper limit is determined 
by the stability of Oxone®, which decomposes relatively quickly in the basic medium at 
room temperature.109 The aqueous medium used determines the lower limit: the typical 
ratios of acetonitrile to water solvent used as solvent lie between 1:1 and 10:1, and the 
medium freezes at around –10 oC.110 Epoxidation reactions in aqueous conditions have to 
be carried out carefully. Any addition of oxidant has to be accompanied by addition of 
Na2CO3 as the presence of water can cause the epoxide to ring open. 
 
In the non-aqueous system for the asymmetric epoxidation reactions developed in our 
group, we use tetraphenylphosphonium monoperoxysulfate (TPPP), which is soluble in 
organic solvent, as oxidant.109,111 TPPP is prepared as a colourless solid by treating Oxone® 
with tetraphenylphosphonium chloride:109 
Ph4P
+ Cl– + Oxone® (2 KHSO5KHSO4K2SO4)  Ph4P
+ (HSO5)
– 
The use of TPPP eliminates the need of water as solvent and base. The presence of base 
under aqueous conditions is essential to neutralize the acidity of triple salt Oxone® and the 
absence of base in the reaction can improve the reaction as addition of base suppresses 
the epoxidation process. In organic solvent, typically chloroform,109 the reaction can be 
carried out at much lower temperature, down to –40 oC or lower. 
 
The reaction time was limited to 48 hours with addition of 2 equiv. of oxidant every 8 hours 
if there was still starting material observed by TLC. The time limit was set; as the epoxide 
decompose after a long period of time, as observed by TLC. 
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The most favourable conditions involved the cooling of all reagents – the oxidant, catalyst 
and substrate – separately in the reaction medium to the desired temperature. The oxidant 
was first dissolved in the reaction solvent and cooled down to the desired temperature. 
This was followed by dropwise addition of catalyst, in order to minimize the increase in 
reaction temperature. This mixture was stirred for some time prior to dropwise addition of 
the substrate to allow stabilization of the mixture.  
 
2.3.4 Catalysts Testing on Asymmetric Epoxidation 
 
Before investigating the asymmetric epoxidation reactions, all the iminium salt catalysts 3, 
4, 7 – 10 synthesized were tested on the commercially available unfunctionalized alkene, 1-
phenylcyclohexene 126 under aqueous conditions, and the ee values and yields were 
compared to the literature values (Scheme 2-56 and Table 2-12). 1-Phenylcyclohexene 126 
was chosen as the test substrate for the investigation as both percentage of conversion and 
ee (using chiral shift reagent) can be easily determined using 1H NMR spectroscopic 
analysis. Asymmetric epoxidation of this substrate has also been reported previously in our 
group using some of the catalysts, thus our results can be compared with our previous 
literature reports. 
 
Scheme 2-56 - Reagents and conditions: (i) Na2CO3 (4 equiv), Oxone® (2 equiv), iminium salt (5 mol%), 
MeCN/H2O (1:1), 0 
o
C, 24 h 
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Table 2-12 - 
a
Enantiomeric excesses were determined by 
1
H NMR spectroscopy in the presence of (+)-Eu(hfc)3; 
b
The absolute configuration of the major enantiomers were determined by comparison of optical rotations 
with those reported in the literature 
Iminium salt catalyst Conversion, 
(%) 
Ee, 
(%)a 
Configurationb 
In each case: Actual results/Literature value 
 
3 
 
100/5520 35/41 (–)-(1S, 2S)/(–)-(1S, 2S) 
 
4 
 
100/1008 26/39 (–)-(1S, 2S)/(–)-(1S, 2S) 
 
7 
 
100/1007 56/60 (–)-(1S, 2S)/(–)-(1S, 2S) 
 
8 
100/478 40/56 (–)-(1S, 2S)/(–)-(1S, 2S) 
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9 
 
100/699 71/91 (–)-(1S, 2S)/(–)-(1S, 2S) 
 
10 
 
100/7014 67/76 (–)-(1S, 2S)/(–)-(1S, 2S) 
 
 
The data collected in Table 2-12 show that the ee values are comparable to those 
previously reported although slightly lower for all the catalysts. The configuration of the 
product 1-phenylcyclohexene oxide 127 is identical in all cases. Full conversion of the 
alkene to the corresponding epoxide was attained by stirring the reaction overnight. As our 
results were in line with the previous reports, we proceeded with the investigation of the 
asymmetric epoxidation of chromenes. 
 
2.3.5 Asymmetric Epoxidation of Chromene by Iminium Salt Catalysts 
 
Our initial attempt at a catalytic asymmetric epoxidation reaction on the 6-hydroxy-
2,2,5,7,8-pentamethyl-3-chromene 48 using the synthesized iminium salts was 
unsuccessful. Under both aqueous and non-aqueous conditions, the starting material was 
decomposed (Scheme 2-57), as shown by the presence of a large number of products using 
TLC analysis. 
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Scheme 2-57 – Decomposition of the chromenol during asymmetric epoxidation of non-protected chromene  
 
Surprisingly, in contrast with this result,  epoxidation of 6-substituted 2,2-
dimethylchromenes bearing an electron donating group have been reported 
previously.88,112 In one of the latest reports, in 2012, Cheng demonstrated the asymmetric 
catalytic activity of Mn(III) complexes 131 towards the oxidation of the mono-substituted 
2,2-dimethylchromene, affording excellent ees between 80 – 95% (Scheme 2-58).112 
 
Scheme 2-58 - Reagents and conditions: (i) Mn(III) catalyst 135 (5 mol%), NaOCl (2 equiv), PyNO (15 mol%), 
ionic liquid (ʟ-1-ethyl-(1'hydroxy-2'-propanyl)imidazolium bromide)
112
 
 
The presence of the four electron-donating groups on the aromatic ring of the chromenes 
may have led to the decomposition of the starting material and/or possibly the 
corresponding product under oxidative conditions during the asymmetric epoxidation 
reactions. However there is no further evidence to prove this. Based on this, asymmetric 
epoxidation reactions were attempted with our iminium salt catalysts – both under 
aqueous and non-aqueous conditions – using 4-cyano-2,2-dimethylchromene 49, bearing 
an electron-withdrawing group at the 6-position of the chromene substrate (Scheme 2-59).  
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Scheme 2-59 - Reagents and conditions: (i) TPPP (4 equiv), CHCl3, 0 
o
C, 2 days 
 
Under non-aqueous conditions, excellent enantioselectivity was observed for catalysts 4, 7 
and 8 for the asymmetric epoxidation reactions of chromene 49, affording the 
corresponding epoxy-chromane 124 (Scheme 2-59). When the dihydroisoquinoline-derived 
catalyst 3 was used, however, decomposition of the starting material was observed. When 
the binaphthyl-derived catalysts 9 and 10 were used under non-aqueous conditions, no 
conversion to the epoxide was detected using 1H NMR spectroscopic analysis of the 
unpurified reaction mixtures. The highest ee was observed using iminium salt 7 as the 
catalyst, affording the epoxide in >99% ee. 
Table 2-13 - Asymmetric epoxidation of 49 under non-aqueous conditions
a 
Iminium salt 
catalyst 
Yield (%) ee (%)b Configurationc 
3 – – – 
4 59 97.0 (–)-1S, 2S 
7 20 99.3 (–)-1S, 2S 
8 20 96.6 (–)-1S, 2S 
9 – – – 
10 – – – 
a
Reagents and conditions: Iminium salt (10 mol%), TPPP (6 equiv), CHCl3, 0 
o
C, 1 day; 
b
Enantiomeric excesses 
were determined by chiral HPLC on Chiracel OD column; 
c
The absolute configuration of the major 
enantiomers were determined by comparison of optical rotations with those reported in the literature;  
 
The binaphthyl-derived catalysts 9 and 10 are much less reactive compared to the others. 
As can be seen in Table 2-13, under non-aqueous conditions, reaction with chromene 49 
shows no conversion occurred even after 48 hours of reaction. This reduced reactivity for 
these catalysts has been reported previously in our group.13 
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We were expecting that the reactions using binaphthyl-derived catalysts 9 and 10 under 
aqueous conditions would be more successful, as these catalysts were reported to be more 
reactive under aqueous conditions. The corresponding epoxide products were obtained 
from asymmetric epoxidation reactions mediated by 9 and 10, but unfortunately the 
epoxy-chromane 124 was unstable under aqueous conditions, fully converting to the 
corresponding diol 136, the product of the ring opening of the epoxide 124 (Scheme 2-60). 
Fortunately, we were able to determine the enantiomeric purity of the diol using chiral 
HPLC analysis. Following this result, we attempted the reaction using other catalysts, and 
evaluated the ee of the diol products using chiral HPLC analysis (Table 2-14). Reactions of 
chromene 49 under aqueous conditions afforded (+)-(3S,4R)-136. The data collected in 
Table 2-14 show that both biphenyl-derived catalysts 7 and 8 are the most reactive and 
selective, giving the best ees of 68% and 71%, respectively. The absolute configuration of 
the diol was determined by comparing the optical rotations to those in the literature as 
reported by Patel et al.113 
 
Scheme 2-60 - Reagents and conditions: (i) Na2CO3 (4 equiv), Oxone® (6 equiv), iminium salt catalyst (10 
mol%), MeCN/H2O (1:1), 0 
o
C, 24 h 
Table 2-14 – Formation of diol 136 under aqueous conditions
a 
Iminium salt 
catalyst 
Conversion (%) ee (%)b Configurationc 
3 65 60 (+)-(3S, 4R) 
4 44 57 (+)-(3S, 4R)                                                                                 
7 100 68 (+)-(3S, 4R) 
8 100 71 (+)-(3S, 4R) 
9 25 - - 
10 52 20 (+)-(3S, 4R) 
 a
Reagents and conditions: Iminium salt catalyst (10 mol%), Oxone® (6 equiv), Na2CO3 (4 equiv), MeCN/H2O 
(1:1), 0 
o
C, 24 h; 
b
Enantiomeric excesses were determined by chiral HPLC on Chiracel OD column; 
c
The 
absolute configuration of the major enantiomers were determined by comparison of optical rotations with 
those reported in the literature. 
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We next attempted to apply the non-aqueous reaction conditions to the 2,2,5,7,8-
pentamethylchromenol compounds 54, 55 and 56. Protection of the hydroxyl moiety at the 
6-position using acetate, trifluoroacetate and benzoate groups was targeted to improve the 
stability of the chromene by reducing the electron-donating effect of the free hydroxyl 
(Figure 2.25). 
 
Figure 2.25 - The protected derivatives of 2,2,5,7,8-pentamethylchromenol 48 
 
Investigation of the asymmetric epoxidation on acetyl protected chromene 54, using the 
most selective iminium catalyst in our hands, catalyst 7, showed that the acetyl-protected 
chromene is quite stable under the reaction conditions compared to the corresponding 
non-protected chromene 47 (Scheme 2-61). Under non-aqueous conditions, compound 128 
was obtained in 48% conversion and 20% yield. 
 
Scheme 2-61 - Asymmetric epoxidation reactions of acetyl-protected chromene 54. Reagents and conditions: 
(i) TPPP (4 equiv), CHCl3, 0 
o
C, 2 days 
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Unfortunately, we were unable to resolve the epoxy-chromane 128 enantiomers using 
chiral HPLC. Attempts to determine the ee using chiral shift reagent also failed. Thus, no ee 
values of the asymmetric epoxidation reaction on chromene 54 could be recorded. The 
same problem was also identified for 6-trifluoroacetate- and 6-benzoate-3,4-epoxy-
2,2,5,7,8-pentamethylchromanes, 55 and 56, respectively. Compound 55 was obtained in 
93% conversion and 62% yield while compound 56 was obtained in 63% conversion and 
33% yield. 
 
Asymmetric epoxidation reactions on chromene 57 were also unsuccessful. No reaction 
was observed when the chromene was subjected to epoxidation reactions under our 
standard non-aqueous conditions after 48 hours (Scheme 2-62). These results were 
expected as the alkene moiety is relatively electron-poor due to the presence of an 
electron withdrawing group, a carboxylate, at the α-position.  
 
Scheme 2-62 - Reagents and conditions: (i) TPPP (4 equiv), CHCl3, 0 
o
C, 2 days 
 
This low reactivity of the electron-poor alkenes in the asymmetric epoxidation mediated by 
these iminium salts has been observed previously in our group for reactions on both seselin 
137 and xanthyletin 138.114,115  
 
Figure 2.26 - Structures of seselin 137 and xanthyletin 138 
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2.4 Conclusion and Future Works 
 
Iminium salt catalysts 3, 4, 7 – 10 were successfully synthesized using a condensation 
reaction of the chiral primary amines 11 and 12 with the corresponding backbone moieties 
– 2-(2-bromoethyl)benzaldehyde 26, 2,2’-bis(bromomethyl) biphenyl 29, and (R)-2,2’-
bis(bromomethyl)[1, 1’]-binaphthalene 33. Several improvements to the previously 
reported procedures afforded better yield of the products, such as the use of (±)-CSA 
instead of HBr in the ketalization of diols 13 and 15. The deprotection of formate of 14 and 
17 was carried out in 98% hydrazine hydrate solution compared to 85% solution in previous 
method, giving 11 and 12 in better yields, 96% and 73% respectively. 
 
In the second part of the research, the desired chromenes were successfully synthesized 
using various approaches (Figure 2.27). 
 
Figure 2.27 - Various synthetic approaches for the synthesis of chromenes 47 – 50 
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Various approaches were used including; A: oxidation of chromanes using DDQ; B: acid-
catalysed condensation mediated by PhB(OH2); C: Claisen thermal rearrangement of 
propargyl ether; D: Williamson synthesis of ether; E: base-catalysed condensation of phenol 
and dialkyl acetal; F: pressure-induced condensation of phenol, formaldehyde and methyl 
methacrylate; G: acid-catalysed condensation of phenol and allylic alcohol to produce 
chromane. 
 
In the asymmetric epoxidation reactions of the chromene substrates mediated by iminium 
salts, we eventually found that the 6-cyano-3,4-epoxy-2,2-dimethylchromane 124 is 
unstable under aqueous conditions, forming the corresponding diols, 6-cyano-3,4-diol-2,2-
dimethylchromanes 136, giving as high as 71% ee of (+)-(3S, 4R)-136 as the major 
enantiomer using catalyst 8. Under non-aqueous conditions, we obtained as high as 99.3% 
ee of (S,S)-epoxide 124 using the biphenyl-catalyst 7. From these results we obtained, we 
concluded that the biphenyl-derived catalysts 7 and 8 are the most selective iminium salt 
for the asymmetric epoxidation reactions under our standard conditions. 
 
Future work should aim to achieve the separation of the epoxy chromanes bearing three 
methyl groups on the aromatic rings, followed by kinetic resolution studies. The effect of 
the protecting group at the 6-position on the asymmetric epoxidation of the chromene 
could also be further studied. Further investigation of the formation of diols from the 
chromene substrates under aqueous conditions by our iminium salts would also be 
interesting. 
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3 EXPERIMENTAL PROCEDURES 
3.1 General Experimental  
3.1.1 Physical Characterisation and Spectroscopic Techniques 
 
1H- and 13C-NMR spectra were recorded in Fourier Transform mode either on a Varian Unity 
Plus 400 machine operating at a nominal frequency of 400.13 and 100.62 MHz, on a Varian 
Gemini 300 spectrometer, at 300.05 and 75.45 MHz, on a 400 MHz Bruker Avance III 2 
channel nanobay NMR spectrometer, at 400.13 and 100.03 MHz, or on a Bruker Avance III 
500 MHz NMR spectrometer, at 500.21 and 125.05 MHz, using the specified deuterated 
solvent. All spectra were processed using MestR-C Nova software. The chemical shifts for 
both 1H- and 13C-NMR were recorded in ppm and were referenced to the residual solvent 
peak or TMS peak. Multiplicities in the NMR are described as: s = singlet, d = doublet, dd = 
doublet of doublets, ddd = doublet of doublet of doublets, t = triplet, td = triplet of 
doublets, q = quartet, sept. = septet, m = multiplet, br = broad, coupling constants, J values 
are reported in Hertz (Hz).  
 
Low resolution mass spectra were recorded using Shimadzu LCMS 2010EV operated under 
electrospray ionisation in positive (ES+) or negative (ES-) modes. Mass spectra were 
recorded by the ESPRC national mass spectrometry service at the University of Wales, 
Swansea, utilising electron-impact (EI), fast atom bombardment (FAB), electrospray (ES) 
and MALDI-TOF.  
 
Melting points were recorded using open capillary tubes on a Büchi B-545 melting point 
instrument and are uncorrected; melting points are quoted as a range, and were observed 
manually whilst those quoted as a specific value were recorded by the instrument and 
correspond to the temperature at which the sample reached 40% translucency in 
accordance with the British Pharmacopeia. 
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Infrared spectra were recorded as neat samples using a Perkin-Elmer Spectrum BX FT-IR. All 
IR data were manipulated using Spectrum v5.0.1 software. Optical rotation measurements 
were obtained using a Bellingham and Stanley ADP-440 polarimeter operating at the 
sodium (D) line emission of λ = 589 nm at the temperature specified. The solvents used for 
these measurements were of spectrophotometric grade. The solutions for these 
measurements were prepared in volumetric flasks for maximum accuracy of the volume of 
solvent used. 
 
3.1.2 Enantiomeric Excess Determination 
 
Enantiomeric excesses were determined either by Chiral HPLC, Chiral GC-FID or 1H NMR. 
Chiral HPLC traces were run on a Chiracel OD column eluting with HPLC grade Hexane/IPA. 
Data were recorded using a Hitachi Elite LaChrom instrument fitted with a L2400 UV 
detector (256 nm unless otherwise stated), L2300 column oven, L2200 autosampler, L2130 
pump, a chiracel OD-H 5m particle size column. The 1H-NMR spectra were run on a Bruker 
Avance III 500 MHz NMR spectrometer in the presence of europium (III) tris[3-(hepta-
fluoroprophylhydroxymethylene)-(+)camphorate], [(+)-Eu(hfc)3] as the chiral shift reagent 
and TMS as the internal standard. 
 
3.1.3 Chromatographic Techniques 
 
The reactions were monitored by thin-layer chromatography (TLC). Thin layer 
chromatography was carried out on Merck aluminium-backed plates coated with 0.2 mm 
Kieselgel 60 GF254 (40 mm x 80 mm, 0.20 mm thickness) and mixtures of ethyl acetate/light 
petroleum, dichloromethane/light petroleum as eluent.  After elution, the TLC plates were 
visualized under UV light followed by staining with phosphomolybdic acid (10% solution in 
EtOH), potassium permanganate (KMnO4), or vanillin stains and developed by heating. 
Flash chromatography was carried out using glass columns packed with Merck Kieselgel 45-
60 silica-gel with mixtures of ethyl acetate/light petroleum, dichloromethane/light 
petroleum as eluent.  
CHAPTER 3 – EXPERIMENTAL PROCEDURES 
 
 
147 
 
3.1.4 Reagent, Solvent and Apparatus Preparation 
 
Commercially available reagents were used as supplied, without any further purification, 
unless stated otherwise and stored according to the manufacturer’s recommendations. 
Optical purity of chiral starting material was also not checked prior usage. Light petroleum 
refers to the fraction of petroleum ether which boils between 40 oC and 60 oC and was 
obtained from manufacturer, labelled as petroleum ether 40/60. 
 
Diethyl ether (Et2O) and tetrahydrofuran (THF) were dried over the sodium/benzoquinone 
ketyl radical system and distilled; toluene was dried over sodium wire and distilled; 
dichloromethane and petroleum ether 40/60 was distilled over calcium hydride prior to 
use. The reactions requiring anhydrous conditions were carried out using glassware dried 
overnight at 150 oC and the apparatus was dried using a flame gun and a stream of Ar for 
procedures where the exclusion of water was necessary. Brine refers to a saturated 
aqueous solution of sodium chloride. 
 
3.2 Numbering Systems 
 
The assignments of the proton and carbon-13 resonances have been made according to 
numbering systems (Figure 3.1). Some of these systems used are standard chemical 
nomenclature while others were introduced arbitrarily by the present author. In the latter 
case, the introduced system was based on the structural resemblance of the compounds 
with others that possessed a formal system. 
 
Aromatic systems are numbered according to the standard protocol. Aromatic carbon 
atoms bearing a substituent are always quaternary (C quat. arom.). All aromatic carbon 
atoms which are attached to a hydrogen atom are termed C arom. (13C spectra) or CH 
arom. (1H spectra). The dihydroisoquinolinium nucleus is numbered according to a standard 
system but the carbon atoms of this moiety are termed isoq. except for those in the 
dimethylene part which are designated Ar-CH2 and CH2N in the assignment. The biphenyl 
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system is also numbered and carbon atoms of this moiety are termed biphenyl. The 
binaphthalene nucleus is numbered, with the carbon atoms termed binap (Figure 3.1). 
 
 
Figure 3.1 - Nomenclature of catalysts backbone moities 
 
N-protected amino acid derivatives are numbered with the carboxylic acid carbon first as in 
the example given in Figure 3.2. The protecting group will be referred to by its 
abbreviation. The 1,3-dioxane nucleus is numbered according to the standard protocol as 
are the 5-membered oxazolidines, with substituents off the ring being numbered in order. 
 
 
Figure 3.2 - Numbering system 
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3.3 Individual Experimental Procedures 
3.3.1 Synthesis of Iminium Salt Organocatalysts 
3.3.1.1 General Procedure for Formyl Protection of the Amino Group 
 
 
 
 
 
The amino diol (1.0 equiv) was dissolved in methanol (10 mL per gram of amino diol), and 
methyl formate (1.1 equiv) was added with sodium methoxide (0.1 equiv). The reaction 
mixture was stirred overnight at room temperature and the solvent removed under 
reduced pressure. The crude oil was dissolved in a solution of CSA (0.1 equiv) in acetone 
(50 mL per gram of amino diol) and 2, 2-dimethoxypropane (10.0 equiv). The reaction was 
stirred up to 4 hours and monitored by TLC. Solvents were removed under reduced 
pressure and the residue re-dissolved in ethyl acetate, which was washed with saturated 
sodium hydrogen carbonate (2 X 20 mL per gram of amino diol) and brine (2 X 20 mL per 
gram of amino diol). The organic layer was dried (MgSO4) and the solvents were removed 
under reduced pressure. 
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3.3.1.2 (4S,5S)-5-(Formylamino)-2,2-dimethyl-4-phenyl-1,3-dioxane1 
 
 
Prepared according to the general procedure from (1S,2S)-(+)-2-amino-1-phenylpropane-1, 
3-diol 13 (0.5 g, 2.99 mmol). The product 14 was isolated as yellowish oil (0.66 g, 95%). νmax 
(neat)/cm-1 3295, 2992, 1668, 1500, 1382, 1200, 1088, 844, 700; 1H-NMR (500 MHz, CDCl3): 
δ 1.56 (s, 3H, CH2OC(CH3)2), 1.60 (s, 3 H, OC(CH3)2), 3.91 (dd, J = 12, 2 Hz, 1H, CH2OC(CH3)2), 
4.28 (dd, J = 12, 2 Hz, 1H, CH2OC(CH3)2), 4.33 (dd, J = 8, 2 Hz, 1H, (CHO)NHCH), 5.23 (d, J = 2 
Hz, 1H, (CHO)NHCHCH-Ar), 6.14 (d, J = 8 Hz, 1H, (CHO)NHCH), 7.26 – 7.35 (m, 5H, Ar-CH), 
7.99 (s, 1H, (CHO)NHCH); 13C-NMR (125 MHz, CDCl3): δ 18.5 (CH2OC(CH3)2), 29.7 
(CH2OC(CH3)2), 45.5 ((CHO)NHCH), 64.6 ((CHO)NHCH2), 71.7 ((CHO)NHCHCH-Ar), 99.7 (C 
quat., CH2OC(CH3)2), 125.2 (2C, 2 X C, C arom.), 127.7 (C arom.), 128.3 (2C, 2 X C, C arom.), 
138.0 (C quat. arom.), 160.5 ((CHO)NHCH). 
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3.3.1.3 (4S,5S)-5-(Formylamino)-2,2-dimethyl-4-[4-(methylthio)phenyl]-1,3-
dioxane2–4 
 
 
Prepared according to the general procedure from (1S,2S)-(+)-2-amino-1-[4-
(methylthio)phenyl]-1,3-propanediol 15 (10.0 g, 46.88 mmol). The crude compound was 
isolated as yellowish oil and was purified by column chromatography eluting with 2:1 
(EtOAc/light petroleum) as yellow oil (11.426 g, 87%); []D = +0.9
o (c = 1.00, CHCl3), [Lit.
4 
[]D = +1.3
o (c = 1.27, CHCl3)]. νmax (neat)/cm
-1 3429, 3054, 2991, 1686, 1602, 1497, 1383, 
1265, 1199, 1085, 948. 1H-NMR (400 MHz, CDCl3): δ 1.55 (s, 3H, CCH3), 1.58 (s, 3H, CCH3), 
2.46 (s, 3H, S-CH3), 3.89 (d, J = 12 Hz, 1H, OCHHCHNH), 4.27 (d, J = 12 Hz, 1H, OCH2CHNH), 
4.28 (d, J = 8 Hz, 1H, OCHHCHNH), 5.18 (s, 1H, CHNHCOH), 6.16 (d, J = 8 Hz, 1H, Ar-CH), 7.17 
– 7.30 (m, 4H, 4 X CH arom.), 7.98 (s, 1, NHCOH); 13C-NMR (100 MHz, CDCl3): δ 14.2 (SCH3), 
18.5 (C quat., C(CH3)2), 29.7 (C(CH3)2), 45.3 (OCH2CHNH), 64.6 (OCH2CHNH), 71.4 (Ar-CH), 
99.7 (OC(CH3)O), 125.8 (2 X C arom.), 126.4 (2 X C arom.), 134.9 (C quat. arom., C-SCH3), 
137.8 (C quat. arom., OCH-C), 160.5 (NHCOH). 
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3.3.1.4 (4S,5S)-5-(Formylamino)-2,2-dimethyl-4-[4-(methylsulfonyl)phenyl]-1,3-
dioxane4,5 
 
 
(4S,5S)-5-(Formylamino)-2,2-dimethyl-4-[4-(methylthio)phenyl]-1,3-dioxane (11.43 g, 38.7 
mmol) 16 was dissolved in dichloromethane (100 mL), and the solution cooled to 0 oC. A 
solution of m-CPBA (20.7 g, 120 mmol) in chloroform (20 mL) was added dropwise over 10 
min. The reaction was stirred for 2 h, washed with saturated sodium hydrogen carbonate (2 
X 40 mL), and dried (MgSO4). The solvents were removed under reduced pressure to give 
colourless oil. Crystallization from chloroform/diethyl ether (1:3) gave the product as 
colourless crystalline solid (12.18 g, 98%); mp 126 – 127 oC [Lit.4 mp 146 – 147 oC]; []D = –
14.5o (c = 1.11, CHCl3), [Lit.
4 []D = –11.6
o (c = 1.21, CHCl3)]. νmax (neat)/cm
-1 3357, 2995, 
1671, 1515, 1383, 1300, 1239, 1202, 1149, 1086, 949. 1H-NMR (400 MHz, CDCl3): δ 1.59 (s, 
3H, CCH3), 1.61 (s, 3H, CCH3), 3.05 (s, 3H, SO2CH3), 3.88 (d, J = 12 Hz, 1H, OCHHCH), 4.33 (d, 
J = 12 Hz, 1H, OCHHCH), 4.43 (d, J = 10 Hz, 1H, CH2CHNH), 5.27 (s, 1H, CHNHCOH), 6.31 (d, J 
= 10 Hz, 1H, Ar-CH), 7.56 (d, J = 8 Hz, 2H, 2 X CH arom), 7.92 (d, J = 8 Hz, 2H, 2 X CH arom), 
7.96 (s, 1H, NHCOH); 13C-NMR (100 MHz, CDCl3): δ 18.5, 19.5, 44.5, 45.0, 46.6, 71.6, 100.1, 
126.5, 127.3, 139.7, 144.4, 160.3. 
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3.3.1.5 General Procedure for the Deprotection of Formamides with Hydrazine 
Hydrates 
 
 
The formate protected of acetonide was dissolved in aqueous hydrazine hydrate (98%) (20 
mL per gram of acetonide) and the solution was heated under reflux up to 3 hours. The 
solution was allowed to reach ambient temperature and extracted with ethyl acetate (3 X 
30 mL per gram of acetonide). The organic layers were washed with water (2 X 30 mL per 
gram of acetonide), brine (2 X 30 mL per gram of acetonide) and dried with MgSO4 and the 
solvent removed under reduced pressure. 
 
3.3.1.6 (4S, 5S)-5-Amino-2,2-dimethyl-4-phenyl-1,3-dioxane1,4 
 
 
Prepared according to the general procedure from (4S,5S)-5-(formylamino)- 2,2-dimethyl-
4-phenyl-1,3-dioxane 14 (0.667 g, 2.84 mmol). The title compound 11 was isolated as pale 
yellow oil without further purification (0.562 g, 96%); []D = +61.5
o (c = 2.15, ethanol), [Lit.4 
[]D = +45.5
o (c = 2.33, ethanol)]. νmax (neat)/cm
-1 3367, 2991, 1663, 1498, 1380, 1271, 
1239, 1160, 1198, 1130, 1088, 1052, 945, 845, 739, 700. 1H-NMR (400 MHz, CDCl3): δ 1.55 
(s, 3H, CCH3), 1.56 (s, 3H, CCH3), 2.79 (d, J = 4 Hz, 1H, OCH2CHNH2), 3.93 (dd, J = 12, 4 Hz, 
1H, OCHHCHNH), 4.31 (dd, J = 12, 4 Hz, 1H, OCHHCHNH), 5.12 (s, 1H, NH2CHCH(Ph)O), 7.28 
– 7.37 (m, 5H, 5 X Ar-H); 13C-NMR (100 MHz, CDCl3): δ 18.60 (CH3), 29.75 (CH3), 49.58 (NCH), 
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65.88 (CH2), 73.76 (Ar-CH), 99.22 (C quat.), 125.69 (2C, 2 X C arom.), 129.59 (2C, 2 X C 
arom.), 139.43 (C quat. arom.). 
 
3.3.1.7 (4S,5S)-5-Amino-4-[4-(methylsulfonyl)phenyl]-1,3-dioxane4,5 
 
 
Prepared according to the general procedure from (4S,5S)-5-(formylamino)-4-[4-
(methylsulfonyl)phenyl]-2,2-dimethyl-1,3-dioxane 17 (0.60 g, 1.92 mmol). The title 
compound was isolated as a colourless oil, and crystallized from diethyl ether/ethyl acetate 
(1:1) to obtain yellowish crystalline 12 (0.40 g, 73%); 121 – 123 oC [Lit.5 mp 120 – 122 oC]; 
[]D = +65.3
o (c = 1.05, CHCl3), [Lit.
5 []D = +50.0
o (c = 1.00, CHCl3)]. νmax (neat)/cm
-1 3055, 
2990, 1382, 1316, 1265, 1152, 1077, 957, 739. 1H-NMR (400 MHz, CDCl3): δ 1.53 (s, 6H, 
OCCH3), 2.83 (s, 1H, OCH2CHNH2), 3.03 (s, 3H, SO2CH3), 3.86 (d, J = 12 Hz, 1H, OCHHCHNH), 
4.30 (d, J = 12 Hz, 1H, OCHHCHNH), 5.15 (s, 1H, Ph-CH), 7.52 (d, J = 8 Hz, 2H, 2 X Ar-CH), 
7.92 (d, J = 8 Hz, 2H, 2 X Ar-CH); 13C-NMR (100 MHz, CDCl3): δ 18.6, 29.7, 44.6, 49.4, 66.3, 
73.4, 99.5, 126.8 (2C, 2 X C arom.), 127.5 (2C, 2 X C arom.), 139.5, 146.1. 
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3.3.1.8 General Procedure for the Synthesis of 2-(2-bromoethyl)benzaldehyde6 
 
 
Bromine (1.0 equiv) was added slowly over a period of 10 minutes to an ice-cooled solution 
of isochromane (1.0 equiv) in carbon tetrachloride (CCl4) with stirring. After the exothermic 
reaction subsided, the cooling bath was removed and dark brown solution heated under 
reflux until the reaction mixture became pale yellow, and liberation of HBr ceased (ca. 1.5 
hours). The solution was then allowed to reach ambient temperature and the solvent 
removed under reduced pressure. To the yellow oil obtained (1-bromoisochromane), 
aqueous hydrobromic acid (48%, 1.5 mL per gram of isochromane) was added and the 
reaction mixture heated under reflux. After 10 – 15 minutes the solution was allowed to 
cool and extracted with Et2O (4 X 1 mL per gram of isochromane). The organic extracts 
were washed with water (2 X 1 mL per gram of isochromane) and dilute aqueous Na2CO3, 
and dried over magnesium sulphate. The solvent removed under reduced pressure 
furnished crude 2-(2-bromoethyl)benzaldehyde 26 as a brownish liquid. νmax (film)/cm
-1 
3021, 2969, 2743, 1703, 1599, 1291. 1H-NMR (500 MHz, CDCl3): δ 3.36 – 3.64 (m, 4H, 
Ph(CH2)2Br, 7.34 (d, J = 8 Hz, 1H, CH arom., ortho to bromoethyl group), 7.49 (t, J = 8 Hz, 1H, 
CH arom., para to bromoethyl group), 7.56 (t, J = 8 Hz, 1H, CH arom., para to formyl group), 
7.83 (d, J = 8 Hz, 1H, CH arom., ortho to formyl group) 10.15 (s, 1H, CHO); 13C-NMR (125 
MHz, CDCl3): δ 32.8 (PhCH2), 36.3 (CH2Br), 127.7 (C arom.), 132.1 (C arom.), 133.7 (C arom.), 
133.9 (C quat. arom.), 134.5 (C arom.), 140.5 (C quat. arom.), 192.9 (1 C, CHO). Analytically 
pure samples may be obtained by distillation under reduced pressure at ca. 150 oC and 0.5 
bar; chromatography is not recommended. Both the crude and the distilled compound can 
be used in the synthesis of dihydroisoquinolinium salts. 
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3.3.1.9 General Procedure for the Synthesis of Dihydroisoquinolinium Salts from 
2-(2-bromoethyl)benzaldehyde and Primary Amines 
 
 
A solution of the primary amine in ethanol (10 mL per gram of amine) was added dropwise 
to 2-(2-bromoethyl)benzaldehyde 26 (1.2 equiv.; 1.8 equiv. If crude material was used), 
externally cooled using an ice bath. The reaction mixture was stirred for a few hours or 
overnight (depending on the amine used) while attaining ambient temperature. A solution 
of sodium tetraphenylborate (1.1 equiv.) in the minimum amount of acetonitrile was added 
in one portion, and after 5 minutes the organic solvents were evaporated under reduced 
pressure. Ethanol was added to the residue and the resulted solid collected by filtration 
and washed with additional ethanol and diethyl ether. 
 
3.3.1.10 (+)-N-[(4S,5S)-2,2-Dimethyl-4-phenyl-1,3-dioxan-5-yl]-3,4-
dihydroisoquinolinium tetraphenylborate3,5 
 
 
Prepared according to the general procedure from (4S,5S)-5-amino-2,2-dimethyl-4-phenyl-
1,3-dioxane 11 (0.12 g, 0.56 mmol) and 2-(2-bromoethyl)benzaldehyde 26, and purified by 
recrystallization from acetone/Et2O to give the product 3 as yellow solid, (0.21 g, 58%); mp 
162 – 165 oC [Lit.5 mp 169 – 170 oC]; [D] = +48.2
o (c = 2.64, CH3CN), [Lit.
5 []D = +38.6
o (c = 
2.70, CH3CN)]. νmax (neat)/cm
-1 3054, 2998, 1637, 1603, 1572, 1479, 1450, 1425, 1383, 
1342, 1315, 1285, 1265, 1238, 1225, 1202, 1163, 1114, 1083, 1069, 1031, 949, 842, 753, 
704, 666, 623, 612. 1H-NMR (500 MHz, CD3CN): δ 1.69 (s, 3H, OCCH3, C7 or C8), 1.71 (s, 3H, 
OCCH3, C7 or C8), 2.51 – 2.64 (m, 1H, Ar-CH2, isoq-4), 2.83 – 2.92 (m, 1H, Ar-CH2, isoq-4), 
3.40 – 3.50 (m, 1H, CH2N, isoq-3), 4.00 – 4.09 (m, 1H, CH2N, isoq-3), 4.21 (t, J = 3 Hz, 1H, 
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C5), 4.42 (dd, J = 14, 1 Hz, 1H, C6), 4.68 (dd, J = 14, 1 Hz, 1H, C6), 5.79 (d, J = 3 Hz, 1H, C4), 
6.88 (t, J = 8 Hz, 4H, CH arom., para in –BPh4), 7.03 (t, J = 8 Hz, 8H, meta in 
–BPh4), 7.33 – 
7.35 (m, 8H, CH arom., ortho in –BPh4), 7.35 – 7.46 (m, 6H, 6 X CH arom.), 7.53 (t, J = 7 Hz, 
1H, CH arom.), 7.78 (m, 2H, 2 X CH arom.), 7.87 (d, J = 7 Hz, 1H, CH arom.), 9.03 (s, 1H, 
N=CH); 13C-NMR (125 MHz, acetone-d6): 17.9 (CH3, C7 or C8), 24.5 (Ar-CH2, isoq-4), 28.7 
(CH3, C7 or C8), 51.6 (CH2N, isoq-3), 61.9 (CH2, C6), 65.8 (NCH, C5), 70.9 (ArCH, C4), 100.5 (C 
quat., C2), 121.4 (4C, 4 X C arom., para in –BPh4), 124.6 (C quat. arom.), 125.1 (2C, 2 X C 
arom., meta in –BPh4), 125.1 (2C, 2 X C arom., meta in 
–BPh4), 125.2 (2C, 2 X C arom., meta 
in –BPh4), 125.2 (2C, 2 X C arom., meta in 
–BPh4), 125.5 (2C, 2 X C arom.), 128.3 (C arom.), 
128.5 (C arom.), 128.5 (C arom.), 128.0 (4C, 4 X C arom., ortho in –BPh4), 134.4 (C arom.), 
136.2 (6C, 4 X C arom., ortho in –BPh4, 2 X C arom.), 136.7 (C quat. arom.), 137.0 (C quat. 
arom.), 138.6 (C arom.), 163.5 (C quat. arom.), 163.88 (C quat. arom.), 164.27 (C quat. 
arom.), 164.66 (C quat. arom.), 167.75 (HC=N). 
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3.3.1.11 (+)-N-[(4S,5S)-2,2-Dimethyl-4-phenyl-1,3-dioxan-5-yl]-3,4-
dihydroisoquinolinium tetraphenylborate2 
 
 
Prepared according to the general procedure from (4S,5S)-5-amino-6-(4-
methylsulfone)phenyl-2,2-dimethyl-1,3-dioxane 12 (0.40 g, 1.39 mmol) and 2-(2-
bromoethyl)benzaldehyde 26 (0.36 g, 1.67 mmol), and purified by crystallization from EtOH 
to give the product 4 as a yellow solid (0.80 g, 80%); mp 199 – 202 oC [Lit.2 mp 199 – 201 
oC]; []D = +195
o (c = 1.06, acetone), [Lit.2 []D = +126.7
o (c = 1.20, acetone)]. νmax (film)/cm
-1 
3419, 3278, 3055, 2999, 1719, 1636, 1603, 1572, 1479, 1426, 1384, 1315, 1266, 1202, 
1150, 1122, 1077, 1032, 956. 1H-NMR (500 MHz, acetonitrile-D3): δ 1.69 (s, 3H, OCCH3, C7 
or C8), 1.72 (s, 3H, OCCH3, C7 or C8), 2.62 (ddd, J = 18, 10, 7 Hz, 1H, Ar-CH2, isoq-4), 2.85 – 
2.90 (m, 1H, Ar-CH2, isoq-4), 3.03 (s, 3H, C16), 3.46 – 3.54 (m, 1H, CH2N, isoq-3), 3.99 – 4.08 
(m, 1H, CH2N, isoq-3), 4.25 (t, J = 3 Hz, 1H, C5), 4.42 (dd, J = 14, 1 Hz, 1H, C6), 4.68 (dd, J = 
14, 1 Hz, 1H, C6), 5.87 (d, J = 3 Hz, 1H, C4), 6.88 (t, J = 8 Hz, 4H, para in –BPh4), 7.03 (t, J = 8 
Hz, 8H, meta in –BPh4), 7.31 – 7.35 (m, 8H, ortho in 
–BPh4), 7.37 (d, J = 8 Hz, 1H, CH arom.), 
7.54 – 7.55 (m, 1H, CH arom.), 7.70 (d, J = 8 Hz, 2H, CH arom.), 7.96 (d, J = 8 Hz, 2H, CH 
arom.), 9.04 (s, 1H, C16); 13C-NMR (125 MHz, acetonitrile-D3): δ 18.5 (CH3, C7 or C8), 25.0 
(Ar-CH2, isoq-4), 29.1 (CH3, C7 or C8), 44.1 (SCH3, C16), 52.1 (CH2N, isoq-3), 62.3 (CH2, C6), 
65.5 (NCH2, C5), 71.0 (Ar-CH2, C4), 101.4 (C quat., C2), 122.4 (4C, 4 X C arom., para in 
–
BPh4), 124.8 (C quat. arom.), 126.2 (2C, 2 X C arom., meta in 
–BPh4), 126.2 (2C, 2 X C arom., 
meta in –BPh4), 126.2 (2C, 2 X C arom., meta in 
–BPh4), 126.2 (2C, 2 X C arom., meta in 
–
BPh4), 127.2 (C arom.), 128.6 (C arom.), 129.0 (2C, 2 X C arom.), 129.0 (C arom.), 129.3 (C 
arom.), 135.1 (C arom.), 136.2 (4C, 4 X C arom., ortho in –BPh4), 137.6 (C arom.), 139.5 (C 
arom.), 139.9 (C quat. arom.), 141.7 (C quat. arom.), 142.8 (C quat. arom.), 163.8 (C quat. 
arom.), 164.2 (C quat. arom.), 164.4 (C quat. arom.), 165.0 (C quat. arom.), 168.5 (HC=N). 
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3.3.1.12 5,7-Dihydrodibenzo[c,e]oxepine7 
 
 
A suspension of 2,2’-biphenyl dimethanol 28 (2.11 g, 9.75 mmol) in hydrobromic acid (30 
mL, 24%) was heated to 100 oC for 40 min. The cloudy solution was allowed to cool to room 
temperature and the aqueous phase extracted with Et2O (3 X 30 mL). The organic layers 
were washed with saturated aqueous NaHCO3 and brine (30 mL) and dried over MgSO4. 
The solvent was removed under reduced pressure to obtain a colourless solid of the title 
compound 29 (1.84 g, 96%); mp 66.6 – 68.8 oC [Lit.7 mp 56 – 58 oC]. νmax (neat)/cm
-1 2987, 
2305, 1421, 1377, 1265, 1198, 1156, 1075, 1044, 994, 944, 896, 739, 705, 621. 1H-NMR 
(500 MHz, CDCl3): δ 4.37 (s, 4H, 2 X OCH2), 7.40 – 7.45 (m, 4H, 4 X CH arom.), 7.49 – 7.52 
(m, 2H, CH arom.), 7.56 (m, 2H, CH arom.); 13C-NMR (125 MHz, CDCl3): δ 67.6 (2 C, 2 X 
OCH2), 127.5 (2C, 2 X C arom.), 128.3 (2 C, 2 X C arom.), 129.0 (2C, 2 X C arom.), 129.7 (2C, 2 
X C arom.), 135.2 (2C, 2 X C quat. arom.), 141.2 (2C, 2 X C quat. arom.). 
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3.3.1.13 2-[2-(Bromomethyl)phenyl]benzene carbaldehyde7 
 
 
To an ice-cooled solution of 5,7-dihydrodibenzo[c,e]oxepine 29 (1.8 g, 9.2 mmol, 1 equiv), 
in carbon tetrachloride (40 mL), in a round bottom flask equipped with a reflux condenser 
was added molecular bromine (1. 16 g, 10.1 mmol, 1.1 equiv) in carbon tetrachloride (CCl4) 
(6 mL), dropwise over 5 min (the reaction turned deep red). The cooling bath was removed 
and the reaction mixture heated under reflux until pale yellow and liberation of HBr ceased 
(ca 1 h.). The solvent was removed under reduced pressure, diluted with Et2O (100 mL), 
washed with saturated Na2CO3 (2 X 50 mL) and brine (50 mL) and dried over MgSO4. The 
solvents were removed under reduced pressure to yield brownish oil of 30 in excellent 
yield (2.50 g, 99%). νmax (neat)/cm
-1 3188, 1667, 1589, 1391, 1248, 1198, 774, 722, 630. 1H-
NMR (500 MHz, CDCl3): δ 4.25 (d, J = 10 Hz, 1H, Ar-CHHBr), 4.35 (d, J = 10 Hz, 1H, Ar-
CHHBr), 7.22 (dd, J = 8, 1 Hz, 1H, CH arom.), 7.41 (m, 3H, 3 X CH arom.), 7.58 (m, 1H, CH 
arom.), 7.67 (td, J = 8, 1 Hz, 1H, CH arom.), 8.07 (dd, J = 8 Hz, 1 Hz, 1H, CH arom.), 9.74 (d, J 
= 1 Hz, 1H, H-aldehyde); 13C-NMR (125 MHz, CDCl3): 31.4 (Ar-CH2Br), 127.7 (C arom.), 128.4 
(C arom.), 128.5 (C arom.), 129.05 (C arom.), 130.7 (C arom.), 130.7 (C arom.), 131.1 (C 
arom.), 133.6 (C arom.), 134.1 (C quat. arom.), 136.0 (C quat. arom.), 137.9 (C arom.), 143.3 
(C quat. arom.), 191.7 (CH aldehyde). 
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3.3.1.14 General Procedure for the Synthesis of Iminium Salt Catalyst from 2-[2-
(Bromoethyl)phenyl]benzene carbaldehyde and primary amines7 
 
 
A solution of the primary amine in ethanol (10 mL per gram of amine, 1 equiv), was added 
dropwise to a pre-cooled solution of 2-[2-(bromomethyl)phenyl]benzene carbaldehyde 30 
(1.1 equiv) in ethanol (10 mL per gram) at 0 oC. The reaction mixture was stirred overnight 
while attaining ambient temperature. Sodium tetraphenylborate (1.1 equiv), dissolved in 
the minimum amount of acetonitrile, was added in one portion and the reaction mixture 
stirred for 5 min. The solvents were removed under reduced pressure and ethanol was 
added to the residue, followed by water. The resulting solid was collected by filtration and 
washed with ethanol followed by Et2O. 
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3.3.1.15 Synthesis of 2,2’-Bis (bromomethyl)[1,1’]biphenyl from [1,1’]Biphenyl-2,2’-
diol8 
 
 
2,2’-Biphenyldimethanol 28 (1.14 g, 5.30 mmol) was dissolved in 48% HBr (10 mL per gram 
of 2,2’-biphenyldimethanol) and reflux for 2 hours. Dichloromethane (50 mL) was added to 
the solution, followed by water (50 mL). The solution was separated in a separating funnel. 
The product was in the bottom layer and washed several times with DCM. The organic 
phase was separated and dried (MgSO4). The solvent was removed under reduced pressure 
to yield the title compound 31 as a colourless solid, which was recrystallized from 1:1 
(EtOAc/light petroleum) (1.66 g, 92%); mp 89 – 92 oC [Lit.8 mp 91 – 93 oC]. νmax (neat)/cm
-1 
3059, 2995, 1476, 1444, 1265, 1221, 1007, 829, 808, 738, 704, 607, 537. 1H-NMR (400 MHz, 
CDCl3): δ 4.20 (d, J = 8 Hz,  2H, 2 x Ph-CHH), 4.35 (d, J = 12 Hz, 2H, 2 x Ph-CHH), 7.28 (d, J = 2 
Hz, 2H, 2 X CH arom., biphenyl-2,2’), 7.29 – 7.55 (m, 4H, 4 X CH arom.,  biphenyl-3,3’, 4,4’), 
7.57 (d, J = 2 Hz, 2H, 2 X CH arom., biphenyl-5,5’); 13C-NMR (100 MHz, CDCl3): δ 31.9 (2C, 2 X 
CH2Br), 128.3 (2C, 2 X C arom.), 128.7 (2C, 2 X C arom.), 130.2 (2C, 2 X C arom.), 130.7 (2C, 2 
X C arom.), 135.9 (2C, 2 X C quat. arom.), 139.4 (2C, 2 X C quat. arom.). 
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3.3.1.16 General procedure for the preparation of the biphenyl azepines 
 
 
Primary amine (1 equiv) dissolved in acetonitrile was added to a nitrogen purged stirred 
solution of 2,2’-Bis(bromomethyl)[1,1’]biphenyl 31 (1 equiv) and Cs2CO3 (2 equiv) in MeCN 
at room temperature under an atmosphere of N2. The solution mixture was heated under 
reflux overnight. The mixture was then cooled down to room temperature and the solvent 
was evaporated under reduced pressure and the residue re-dissolved in DCM. The resulting 
suspension was filtered into a separating funnel to remove excess Cs2CO3. The organic layer 
was washed several times with water and brine, and then dried (MgSO4). The solvent was 
removed under reduced pressure.  
 
3.3.1.17 (+)-6-[(4S,5S)-2,2-Dimethyl-4-phenyl-1,3-dioxan-5-yl]-6,7-dihydro-5H-
diezo[c,e]azepine9 
 
 
Prepared according to the general procedure for the preparation of biphenyl azepines from 
(4S,5S)-5-amino-4-phenyl-2,2-dimethyl-1,3-dioxane 11 (0.56 g, 2.71 mmol) and 2,2’-
bis(bromomethyl)[1,1’]-biphenyl 31 (0.92 g, 2.71 mmol) to give the title compound 32 as 
yellow foam (1.02 g, 97%). νmax (neat)/cm
-1 3054, 2987, 2684, 2305, 1721, 1688, 1449, 1441, 
1421, 1381, 1265, 1198, 1174, 1152, 1079, 896, 706. 1H-NMR (500 MHz, acetone-d6): δ 1.61 
(s, 6H, 2 X OCCH3), 2.99 (d, J = 3 Hz, 1H, NCHCH2O), 3.52 (d, J = 12 Hz, 1H, NCHCHHO), 3.70 
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(d, J = 12 Hz, 1H, NCHCHHO), 4.28 (d, J = 3 Hz, 2H, downfield portion of A system, 2 X 
ArCH2N), 4.40 (s, 2H, upfield portion of A system, 2 X ArCH2N), 5.23 (d, J = 3 Hz, 1H, 
NCHCHAr-O), 7.24 – 7.47 (m, 13H, 13 X CH arom.); 13C-NMR (125 MHz, acetone-d6): δ 19.2 
(C(CH3)2), 29.5 (C(CH3)2), 54.0 (NCHCH2O), 60.9 (NCHCH2O), 62.2 (ArCH2N), 67.6 (ArCH2N), 
74.7 (NCHCHAr-O), 99.1 (C quat., OC(CH3)O), 126.3 (C arom.), 126.8 (C arom.), 127.3 (C 
arom.), 127.5 (C arom.), 127.5 (C arom.), 127.72 (C arom.), 127.82 (C arom.), 128.29 (C 
arom.), 128.96 (C arom.), 129.38 (C arom.), 129.73 (C arom.), 135.16 (C quat. arom.), 
136.63 (quat. arom.), 140.19 (C quat. arom.), 140.96 (C quat. arom.), 141.22 (C quat. 
arom.). 
 
3.3.1.18 (+)-6-[(4S,5S)-2,2-Dimethyl-4-(4-(methylsulfonyl)phenyl)-1,3-dioxan-5-
yl]-6,7-dihydro-5H-diezo[c,e]azepine9 
 
 
Prepared according to the general procedure for the preparation of biphenyl azepines from 
(4S,5S)-5-amino-6-(4-methylsulfone)phenyl-2,2-dimethyl-1,3-dioxane 12 (2.75 g, 9.62 
mmol) and 2,2’-bis(bromomethyl)[1,1’]-biphenyl 31 (3.272 g, 9.62 mmol) to give the title 
compound 33 as yellow foam (3.75 g, 84%). νmax (neat)/cm
-1 3054, 2987, 1677, 1602, 1480, 
1440, 1315, 1265, 1200, 1151, 1076, 1012, 957, 896, 852. 1H-NMR (400 MHz, acetone-d6): δ 
1.58 (s, 3H, OCCH3), 1.60 (s, 3H, OCCH3), 3.04 (s, 1H, NCH), 3.05 (s, 3H, -SO2CH3), 3.45 (d, J = 
16 Hz, 2H, upfield portion of A system, 2 X ArCH2N), 3.68 (d, J = 16 Hz, 2H, downfield 
portion of A system, 2 X ArCH2N), 4.24 (m, 2H, NCHCH2O), 5.30 (s, 1H, NCHCH(Ph-
SO2CH3)O), 7.18 (dd, J = 8, 1 Hz, 2H, 2 X CH arom.), 7.28 – 7.42 (m, 6H, 6 X CH arom.), 7.65 
(d, J = 8 Hz, 2H, 2 X CH arom.), 7.92 (d, J = 8 Hz, 2H, 2 X CH arom.); 13C-NMR (100 MHz, 
acetone-d6): δ 19.1 (C(CH3)2), 29.3 (C(CH3)2), 44.6 (-SO2CH3), 530.9 (2 C, 2 X ArCH2N), 60.4 
(NCHCH2O), 61.6 (NCHCH2O), 74.2 (NCHCH(PhSO2CH3)), 99.3 (quat., OC(CH3)O), 126.7 (2C, 2 
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X C arom.), 127.1 (2C, 2 X C arom.), 127.5 (2C, 2 X C arom.), 127.7 (2C, 2 X C arom.), 127.9 
(2C, 2 X C arom.), 136.2 (2C, 2 X C quat. arom.), 138.6 (2 C, 2 X C quat. arom.), 140.9 (2 C, 2 
X C quat. arom.), 147.0 (2 C, 2 X C quat. arom.). 
 
3.3.1.19 General Procedure for the Synthesis of Biphenyl Iminium Salts 
 
 
N-Bromosuccinimide (1.2 equiv) was added to the resulting crude amine product in 
dichloromethane, and the mixture was heated under reflux for 3 h, after which time the 
reaction mixture was allowed to cool to room temperature. The solvent was removed 
under reduced pressure and the residue re-dissolved in ethanol. A solution of sodium 
tetraphenylborate (1.1 eq) in a minimum amount of acetonitrile was added in one portion. 
The resulting mixture was stirred for 5 min, after which the solvent was removed under 
reduced pressure.  The yellow residue was dissolved in dichloromethane (40 mL per gram 
of dibromide) and washed with water (2 X 30 mL per gram of dibromide) and brine 2 X 30 
mL per gram of dibromide), the organic phase was dried (MgSO4), and the solvents were 
removed under reduced pressure. The yellow solid was recrystallized from ethanol, washed 
with ethanol followed by hexanes, and dried at 90 oC. 
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3.3.1.20  (–)-2-[(4S,5S)-2,2-Dimethyl-4-phenyl-1,3-dioxan-5-yl]-5H-
dibenzo[c,e]azepinium tetraphenylborate5 
 
 
Prepared according to the general procedure for the synthesis of biphenyl iminium salts 
from (+)-6-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]-6,7-dihydro-5H-dibenzo[c,e] 
azepine 32 (1.02 g, 2.64 mmol) to give the title compound 7 as yellow powder (1.06 g, 
57%); m.p. 183.4 – 184.0 oC [Lit.5 mp 187 – 188 oC]; []D = –44.4
o (c = 1.25, CH3CN), [Lit.
5 
[]D = –44.0
o (c = 1.01, CH3CN)]. νmax (neat)/cm
-1 3054, 2987, 1634, 1479, 1386, 1265, 1203, 
1115, 896, 739, 705. 1H-NMR (400 MHz, acetone-d6): δ 1.81 (s, 3H, OC(CH3)2), 1.83 (s, 3H, 
OC(CH3)2), 4.37 (br, 1H, NCHCHHO), 4.49 (dd, J = 20, 4, 4 Hz, 1H, NCHCH2O), 4.82 – 4.92 (m, 
2H, NCHCHHO/1 X ArCHHN), 5.86 (br, 1H, ArCHHN), 6.03 (s, 1H, NCHCHAr-O), 6.79 (t, J = 4 
Hz, 4H, para in –BPh4), 6.93 (t, J = 8 Hz, 8H, 8 X CH arom., meta in 
–BPh4), 7.33 – 7.67 (m, 
13H, 5 X CH arom./8 X CH arom. ortho in –BPh4), 7.70 – 7.77 (m, 6H, 6 X CH arom.), 7.99 – 
8.05 (m, 2H, 2 X CH arom.), 9.05 (br, 1 H, N=CH); 13C-NMR (100 MHz, acetone-d6): Only the 
counter-ion 13C signals were observed.  
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3.3.1.21 (–)-2-[(4S,5S)-2,2-Dimethyl-4-(methylsufonyl)phenyl-1,3-dioxan-5-yl]-5H-
dibenzo[c,e]azepinium tetraphenylborate5 
 
 
Prepared according to the general procedure from (+)-6-[(4S, 5S)-2,2-Dimethyl-4-(4-
(methylsulfonyl)phenyl)-1,3-dioxan-5-yl]6,7-dihydro-5H-diezo[c,e]azepine 33 (3.44 g, 12.05 
mmol). The title compound 8 was isolated as a yellow crystalline solid (2.34 g, 25%); mp 
145 – 150 oC [Lit.5 mp 162 – 165 oC]; []D = –52.7
o (c = 1.07, acetone), [Lit.5 []D = –50.3
o (c = 
1.09, acetone)]; νmax (neat)/cm
-1 3052, 2997, 1635, 1600, 1580, 1554, 1480, 1426, 1404, 
1382, 1303, 1265, 1239, 1199, 1147, 1091, 1054, 1030, 973, 948, 871, 841, 827, 782, 739, 
711. 1H-NMR (400 MHz, acetone-d6): δ 1.81 (s, 3H, OC(CH3)2), 1.84 (s, 3H, OC(CH3)2), 3.02 (s, 
3H, -SO2CH3), 4.40 – 4.43 (br, 1H, Ar-CHHN, up-field portion of AB system), 4.51 (d, J = 12 
Hz, 1H, NCHCHHO, up-field portion of ABX system), 4.89 (d, J = 12 Hz, 1H, NCHCHHO, down-
field portion of ABX system), 5.62 (br, 1H, Ar-CHHN, down-field portion of AB system), 6.13 
(s, 1H, NCHCH2O), 6.79 (t, J = 4 Hz, 4H, 4 X CH arom., para in 
-BPh4), 6.93 (t, J = 4 Hz, 8H, 4 X 
CH arom., meta in -BPh4), 7.43 – 7.46 (m, 8H, 4 X CH arom., ortho in 
-BPh4), 7.67 – 7.70 (m, 
5H, 5 X CH arom), 7.80 – 7.82 (m, 5H, 5 X CH arom), 7.96 – 8.03 (m, 5H, 5 X CH arom), 9.23 
(s, 1H, N=CH); 13C-NMR (100 MHz, acetone-d6): Only the counter-ion 
13C signals were 
observed.  
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3.3.1.22  (R)-1, 1’-Binaphthalene-2, 2’-diol bis-(trifluoromethanesulfonate)10 
 
 
(R)-[1,1’]Binaphthalene-2,2’-diol 42 (3.00 g, 10.50 mmol, 2.5 equiv) was dissolved in 
dichloromethane (60 mL) and the solution cooled to -30 oC and stirred at this temperature 
for 5 min. before addition of 4-dimethylaminopyridine (0.51 g, 4.20 mmol, 1.0 equiv), 2, 6-
lutidine (3.70 mL, 31.40 mmol, 7.5 equiv) and triflic anhydride (5.30 mL, 31.40 mmol, 7.5 
equiv). The resulting dark brown reaction mixture was allowed to reach ambient 
temperature and stirred overnight. Silica gel was added to the solvent and left stirred for ½ 
h and the solvent was then removed under reduced pressure. The product mixture, 
adsorbed onto silica gel, was then transferred to a sintered glass funnel, and the material 
washed with hexane until the product had eluted. The solvent was removed under reduced 
pressure to give a colourless solid, which was crystallized from hexane to afford the 
product 43 as colourless crystals (5.62 g, 98%); mp 83 – 84 oC [Lit.4 mp 76 – 78 oC]; []D = –
150.9o (c = 1.01, CHCl3), [Lit.
4 []D = –147.7
o (c = 1.01, CHCl3)]. νmax (neat)/cm
-1 3062, 1509, 
1424, 1247, 1140, 1066, 963, 867. 1H-NMR (400 MHz, CDCl3): δ 7.17 – 7.19 (m, 2H, 2 x CH 
arom., binap-3,-3’), 7.39 – 7.43 (m, 2H, 2 x CH arom., binap-7,7’), 7.57 – 7.63 (m, 4H, 4 x CH 
arom., binap-8,-8’,-9,-9’), 8.01 (d, J = 10 Hz, 2H, 2 X CH arom., binap-4,-4’), 8.14 (d, J = 10 
Hz, 2H, 2 X CH arom., binap-6,-6’); 13C-NMR (100 MHz, CDCl3): δ 116.5 (2C, 2 X C quat., q, J = 
79.5 Hz, 2 X CF3), 119.3 (2C, 2 X C arom., binap-8,-8’), 123.4 (2C, 2 X C quat. arom., binap-1,-
1’), 126.8 (2C, 2 X C arom., binap-3,-3’), 128.0 (2C, 2 X C arom., binap-9,-9’), 128.3 (2C, 2 X C 
arom., binap-4,-4’), 132.0(2C, 2 X C arom., binap-6,-6’), 132.3 (2C, 2 X C quat., arom., binap-
5,-5’), 133.1 (2C, 2 X C quat. arom., binap-10,-10’), 145.4 (2C, 2 X C quat. arom., binap-2,-
2’). 
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3.3.1.23 (R)-2,2’-Dimethyl-1,1’-binaphthalene4 
 
 
(R)-1,1’-Binaphthalene-2,2’-diol bis(trifluoromethanesulfonate) 43 (3.4 g, 6.24 mmol, 1 
equiv) and [1,3-bis(diphenylphosphanyl)propane]nickel(II) chloride (0.24 g, 0.44 mmol, 0.07 
equiv) were dissolved in anhydrous diethyl ether (100 mL). The reaction was cooled to –78 
oC, and methylmagnesium bromide (3 M in Et2O, 8.34 mL, 25 mmol) added dropwise over 
30 min. The reaction was allowed to reach room temperature and stirred for 16 h. The 
resulting dark green reaction mixture was diluted with diethyl ether (100 mL) and filtered 
through a pad of Celite. The filtrate was washed with 2 M hydrochloric acid (20 mL), water 
(100 mL) and brine (100 mL). Removal of solvent under reduced pressure gave a reddish 
crude oil, which was purified by column chromatography, eluting with ethyl 
acetate/hexane (1:4), to give a colourless powder. Crystallization from methanol afforded 
the product 44 as a colourless crystalline solid (1.67 g, 95%); mp 68 – 72 oC [Lit.4 mp 74 – 78 
oC]; []D = –40.9
o (c = 1.19, CHCl3), [Lit.
4 []D = –40.0
o (c = 1.12, CHCl3)]; νmax (neat)/cm
-1 
3054, 2246, 1594, 1506, 1420, 1265, 1217, 1142, 958, 943, 836, 814, 739, 705. 1H-NMR 
(400 MHz, CDCl3): δ 2.13 (s, 6H, 2 X Ar-CH3) 7.05 (d, J = 8 Hz, 2H, 2 x CH arom., binap-3,-3’), 
7.29 (d, J = 8 Hz, 2H, 2 x CH arom., binap-7,7’), 7.38 – 7.47 (m, 2H, 2 x CH arom., binap-8,-
8’), 7.54 – 7.62 (m, 2H, 2 x CH arom., binap-9,-9’), 7.92 – 7.98 (m, 4H, 4 X CH arom.), 8.03 
(d, J = 8 Hz, 2H, 2 X CH arom., binap-4,-4’), 8.09 (d, J = 8 Hz, 2H, 2 X CH arom., binap-6,-6’); 
13C-NMR (100 MHz, CDCl3): δ 116.5 (2C, 2 X C quat., q, J = 79.5 Hz, 2 X CF3), 119.3 (2C, 2 X C 
arom., binap-8,-8’), 123.4 (2C, 2 X C quat. arom., binap-1,-1’), 126.8 (2C, 2 X C arom., binap-
3,-3’), 128.0 (2C, 2 X C arom., binap-9,-9’), 128.3 (2C, 2 X C arom., binap-4,-4’), 132.0 (2C, 2 
X C arom., binap-6,-6’), 132.3 (2C, 2 X C quat. arom., binap-5,-5’), 133.1 (2C, 2 X C quat. 
arom., binap-10,-10’), 145.4 (2C, 2 X C quat. arom., binap-2,-2’). 
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3.3.1.24 (R)-2,2’-Bis(bromomethyl)[1,1’]binaphthalene4 
 
 
(R)-2,2’-Dimethyl-1,1’-binaphthalene 44 (1.67 g, 5.9 mmol) was dissolved in cyclohexane 
(14 mL), and N-bromosuccinimide (2.10 g, 11.8 mmol) and azobis(isobutyronitrile) (0.10 g, 
0.59 mmol) were added with stirring. The mixture was heated under reflux for 3 h, after 
which time complete disappearance of the starting material was observed by TLC. After 
cooling to room temperature, ethyl acetate (5 mL) and water (30 mL) were added to 
dissolve excess NBS and to allow trituration. The resulting suspension was stirred for 1 h, 
after which time precipitation had ceased. The mixture was filtered to afford the product 
39 as a colourless solid (1.32 g, 51%); mp 180 – 183 oC [Lit.4 mp 180 – 183 oC]; []D = 
+169.9o (c = 1.00, benzene), [Lit.11 []D = +186.4 (c = 1.00, benzene)]. νmax (neat)/cm
-1 3049, 
2925, 1777, 1725, 1507, 1433, 1361, 1328, 1212, 1025, 969, 821, 754, 726, 686, 626. 1H-
NMR (400 MHz, CDCl3): δ 4.25 (s, 4H, 2 X CH2Br), 7.07 (d, J = 8 Hz, 2H, CH arom.), 7.27 – 
7.29 (m, 2H, CH arom.), 7.47 – 7.49 (m, 2H, CH arom.), 7.75 (d, J = 8 Hz, 2H, CH arom.), 7.92 
(d, J = 8 Hz, 2H, CH arom.), 8.02 (d, J = 8 Hz, 2H, CH arom.); 13C-NMR (100 MHz, CDCl3): δ 
32.6 (2C, 2C, 2 X CH2Br), 126.8 (2C, 2 X C arom., binap-5,-5’), 126.8 (2C, 2 X C arom., binap-
6,-6’), 126.8 (2C, 2 X C arom., binap-7,-7’), 127.8 (2C, 2 X C arom., binap-3 or 4, -3’ or 4’), 
128.0 (2C, 2 X C arom., binap-8,-8’), 129.4 (2C, 2 X C arom., -3 or 4, -3’ or 4’), 132.5 (2C, 2 X 
C quat. arom., binap-5,5’), 133.3 (2C, 2 X C quat. arom., binap-10,-10’), 134.1 (2C, 2 X C 
quat. arom., binap-2,-2’), 134.2 (2C, 2 X C quat. arom., binap-1,-1’). 
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3.3.1.25 General Procedure for the Synthesis of Iminium Salt Catalyst from (R)-2,2’-
Bis(bromomethyl)[1,1’]binaphthalene and primary amines12 
 
 
The primary amine (1.1 equiv) was added to a nitrogen-purged stirred solution of (R)-2,2’-
bis(bromomethyl)[1,1’]binaphthalene 39 and potassium carbonate (3 equiv) in acetonitrile 
(10 mL per gram of dibromide) at room temperature. The reaction mixture was heated 
under reflux overnight or until disappearance of starting material was observed by TLC. The 
mixture was diluted with dichloromethane (40 mL per gram of dibromide) and washed with 
water (2 X 30 mL per gram of dibromide) and brine (2 X 30 mL per gram of dibromide). The 
organic phase was separated and dried (MgSO4). N-Bromosuccinimide (1.2 equiv) was 
added to the resulting crude amine product in dichloromethane, and the mixture was 
heated under reflux for 3 h, after which time the reaction mixture was allowed to cool to 
room temperature. The solvent was removed under reduced pressure and the residue re-
dissolved in ethanol. A solution of sodium tetraphenylborate (1.1 equiv) in a minimum 
amount of acetonitrile was added in one portion. The resulting mixture was stirred for 
5min, after which the solvent was removed under reduced pressure.  The yellow residue 
was dissolved in dichloromethane (40 mL per gram of dibromide) and washed with water 
(2 X 30 mL per gram of dibromide) and brine (2 X 30 mL per gram of dibromide), the 
organic phase was dried (MgSO4), and the solvents were removed under reduced pressure. 
The yellow solid was recrystallized from ethanol, washed with ethanol, followed by 
hexanes, and dried at 90 oC. 
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3.3.1.26 (R)-[(4S,5S)-2, 2-dimethyl-4-phenyl-1,3-dioxan-5-yl]-3H-4-azepinium-
cyclohepta[2,1-a;3,4-a’]dinaphthalene tetraphenylborate10 
 
 
Prepared according to the general procedure from (+)-(4S,5S)-2,2-dimethyl-4-phenyl-1,3-
dioxane-5-amine 11 (0.084 g, 0.41 mmol). The title compound 9 was isolated as bright 
yellow powder (0.24 g, 73%); mp 128.7 – 130.3 oC [Lit.4 mp 111 – 113 oC]; []D = –118.9
o (c 
= 1.09, acetone), [Lit.4 []D = –98.5
o (c = 1.04, acetone)]. νmax (neat)/cm
-1 3054, 2987, 1612, 
1422, 1385, 1265, 1203, 1163, 1110, 896, 816, 738, 705. 1H-NMR (400 MHz, CDCl3): δ 1.81 
(s, 3H, C(CH3)), 1.87 (s, 3H, C(CH3)), 4.42 (d, J = 16 Hz, 1H, ArCHHN, upfield portion of AB 
system), 4.53 (d, J = 12, 1H, NCH-CHH-O, upfield portion of ABX system), 4.74 (s, 1H, 
NCHCH2O), 4.82 (d, J = 12 Hz, 1H, NCH-CHH-O, downfield portion of ABX system), 5.96 – 
5.97 (m, 2H, 1 X ArCHHN, downfield portion of AB system/1 X NCH-CHAr-O), 6.77 (t, J = 8 
Hz, 4H, 4 X CH arom., para in -BPh4), 6.92(t, J = 8 Hz, 8H, 8 X CH arom., meta in 
-BPh4), 6.97 – 
7.07 (m, 4H, 4 X CH arom.), 7.27 – 7.29 (m, 2H, 2 X CH arom.), 7.34 – 7.37 (m, 11H, 8 X CH 
arom., ortho in -BPh4/3 X CH arom.), 7.46 – 7.47 (m, 2H, 2 X CH arom.), 7.59 (t, J = 8 Hz, 1H, 
CH arom.), 7.77 – 7.81 (m, 1H, CH arom.), 7.88 (d, J = 12 Hz, 1H, CH arom.), 8.11 (d, J = 8 Hz, 
1H, CH arom.), 8.17 – 8.25 (m, 3H, CH arom.), 9.11 (s, 1H, N=CH); 13C-NMR (100 MHz, 
CDCl3): δ 18.9 (CH3, C16 or C17), 29.7 (CH3, C16 or C17), 57.0 (Ar-CH2N), 61.9 (CH2, C14), 
68.1 (NCH, C13), 72.6 (Ar-CH, C18), 101.7 (C quat., C2), 120.5 (C quat. arom., binap.), 122.3 
(4C, 4 X C arom., para in BPh4), 124.3 (C arom., C22), 126.0 (8C, 8 X C arom., ortho in BPh4), 
126.2 (C quat. arom., binap.), 126.9 (C quat. arom., binap.), 127.8 (C arom., binap.), 128.0 
(C arom., binap.), 128.2 (2C, 2 X C arom., C20, C24), 128.7 (2C, 2 X C arom., C21, C23), 128.9 
(2C, 2 X C arom., binap), 129.5 (2C, 2 X C arom., binap), 129.6 (C arom., binap), 129.7 (C 
arom., binap), 130.2 (C arom., binap), 130.3 (C arom., binap), 131.3 (C arom., binap), 132.2 
(C arom., binap), 132.6 (C quat. arom., binap.), 132.9 (C arom., binap), 134.9 (C quat. arom., 
binap.), 136.3 (C quat. arom., binap.), 136.6 (C quat. arom., binap.), 137.2 (8 X C arom., 
meta in BPh4), 142.4 (C quat. arom., C19), 164.7 (4 X C quat.), 170.9 (HC=N). 
CHAPTER 3 – EXPERIMENTAL PROCEDURES 
 
 
173 
 
3.3.1.27 (R)-[(4S,5S)-2,2-dimethyl-4-(methylsulfonyl)phenyl-1,3-dioxan-5-yl]-3H-4-
azepinium-cyclohepta[2,1-a;3,4-a’]dinaphthalene tetraphenylborate4 
 
 
 
Prepared according to the general procedure from (4S,5S)-5-Amino-4-[4-
(methylsulfonyl)phenyl]-1,3-dioxane 12 (0.29 g, 1.016 mmol) to obtain 10 as a yellow 
powder (0.52 g, 59%). mp 161 – 163 oC [Lit.4 mp 159 – 163 oC]; []D = –238.9
o (c = 0.85, 
acetone), [Lit.4 []D = –283.7
o (c = 0.86, acetone)]. 1H-NMR (400 MHz, acetone-d6): δ 1.87, 
1.93, 3.00, 4.45 (d, J = 15 Hz, 1H), 4.57 (d, J = 15 Hz, 1H), 4.94 (dd, J = 15 Hz, 5 Hz, 1H), 5.12 
(s, 1H, NCH, H13), 6.21 (d, J = 15 Hz, 1H, Ar-CHHN, H11), 6.25 (d, J = 5 Hz, 1H, Ar-CH, H18), 
6.79 (t, J = 15 Hz, 4H, 4 X CH arom., para in BPh4), 6.94 (t, J = 15 Hz, 8H, 8 X CH arom., ortho  
in BPh4), 7.29 (ddd, J = 11, 6, 3 Hz, 1H, CH arom., binap.), 7.36 (m, 8H, 8 X CH arom., meta  
in BPh4), 7.49 (m, 3H, 3 X CH arom., binap.), 7.59 (dd, J = 8, 7, 1 Hz, 1H, CH arom., binap.), 
7.82 – 7.84 (m, 5H, 5 X CH arom.), 8.00 (d, J = 8 Hz, 1H, CH arom., binap.), 8.13 (d, J = 8 Hz, 
1H, CH arom.), 8.21 (d, J = 8 Hz, 1H, CH arom.), 8.24 (d, J = 9 Hz, 1H, CH arom.), 9.39 (s, 1H, 
HC=N); 13C-NMR (100MHz, acetone-d6): δ 18.2 (CH3, C16 or C17), 29.1 (CH3, C16 or C17), 
43.4, (CH3, SO2CH3, C25), 56.4 (CH2, ArCH2N, C11), 61.1 (CH3, NCHCH2O, C14), 66.9 (CH, NCH, 
C13), 71.5 (CH, ArCH, C18), 101.1 (C quat., C15), 121.5 (4C, 4 X C arom., para in BPh4), 125.0 
(C arom., binap), 125.1 (C arom., binap), 125.2 (C arom., binap), 125.3 (8C, 8 X C arom., 
ortho in BPh4), 126.0 (C quat., arom.), 126.5 (2C, 2 X C arom.), 126.8 (C arom., binap), 127.1 
(C arom., binap), 127.3 (C arom., binap), 127.9 (2C, 2 X C arom., binap), 128.8 (C arom., 
binap), 128.9 (C arom., binap), 129.4 (C arom., binap), 129.6 (C arom., binap), 130.6 (C 
arom., binap), 131.2 (C quat., arom.), 131.4, 131.7 (C arom., binap), 131.7, 133.9, 135.5, 
135.8, 136.2 (8C, 8 X C arom., meta in BPh4), 141.4, 142.2, 164.0 (4C, 4 X C quat., arom., q, J 
= 49 Hz, 4 C-B ipso in BPh4), 170.6 (HC=N). 
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3.3.2 Synthesis of Chromene Substrate 
3.3.2.1 3,7-Dimethyloct-6-en-1-yl-3-ol13 
 
 
A solution of 6-methyl-5-heptene-2-one 71 (1 mL, 6.8 mmol) in a mixture of anhydrous 
THF/Et2O (1:1) (4 mL) was added dropwise in 30 minutes, at room temperature, to a 
solution of ethynylmagnesium bromide (16 mL, 8.16 mmol, 0.5M in THF) in anhydrous 
diethyl ether (16 mL), under Ar. The reaction was stirred at room temperature for 3 hours. 
After the reaction had come to completion, the reaction was quenched with water and the 
mixture was extracted with Et2O. The combined organic layers were washed with brine and 
dried over MgSO4. The solvent was evaporated under vacuo. The solution was purified with 
neutral alumina using ethyl acetate/light petroleum (1:9) as the eluent. Product 70 was 
isolated as yellow oil (0.95 g, 88%). νmax (film)/cm
-1 3405 (OH), 3307 (acetylenic C – H 
stretch), 2927, 1725 (C=C), 1449, 1375, 1262 (C – OH),  627 (acetylenic C – H bend);  1H-
NMR (400 MHz, CDCl3): δ 1.49 (s, 3H, CH3COH), 1.65 (s, 3H, CHCH3), 1.69 (s, 3H, CHCH3), 
2.09 – 2.20 (m, 2H, CH2CH2CH or CH2CH2CH), 2.21 – 2.32 (m, 2H, CH2CH2CH or CH2CH2CH), 
2.45 (s, 1H, CH alkyne), 5.16 (m, 1H, CH alkene); 13C-NMR (100 MHz, CDCl3): δ 18.1 (C8 or 
C9), 24.0 (C8 or C9), 28.1 (C5), 30.2 (C10), 43.5 (C4), 68.7 (C quat., C3), 71.9 (acetylenic C), 
87.9 (C quat., C2), 124.0 (C6), 133.1 (C quat., C7). 
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3.3.2.2 6-Hydroxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chroman14 – 
Method I 
 
 
Linalool 63 (7.09 mL, 39.42 mmol, 2 equiv) was added dropwise to a boiling suspension of 
trimethylhydroquinone 62 (3.0 g, 19.71 mmol, 1 equiv) and (±)-CSA (0.1 equiv) in n-octane 
at 98 oC. The reaction mixture was kept at reflux and stirred overnight. After the reaction 
has come to completion, it was cooled down to room temperature, and poured into 50 mL 
saturated NaHCO3 solution. The product was extracted with EtOAc, and then washed with 
brine and the organic layer was dried (MgSO4). The solvent was removed under vacuo 
which was then purified by column chromatography, eluting with ethyl acetate/light 
petroleum (1:9), to give a mixture of the title compound 61 and its cyclic isomer 64 (5.39 g, 
95%). 1H-NMR (400 MHz, CDCl3): δ 1.24 (s, 3H, OCCH3), 1.50 – 1.68 (m, 2H, C
1’H2 or C
2’H2), 
1.60 (3 H, s, C3’H=C4(CH3)2), 1.67 (s, 3 H, C
3’H=C4(CH3)2), 1.70 – 1.84 (m, 2H, C
1’H2 or C
2’H2), 
2.11 (s, 6H, 2 X Ar-CH3), 2.16 (s, 3H, Ar-CH3), 2.60 (t, J = 8 Hz, 2H, Ar-CH2CH2 or Ar-CH2CH2), 
4.18 (s, 1H, Ar-OH), 5.12 (t,  J =  6 Hz, 1H, C3’H=C4(CH 3)2). 
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3.3.2.3 6-Hydroxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chroman15 – 
Method II 
 
 
A mixture of trimethylhydroquinone 62 (1 equiv), phenylboronic acid (1.6 equiv), citral 73 
(3 equiv) and propionic acid (0.3 equiv) in toluene was heated under reflux for 1.5 hours, 
with azeotropic removal of water using a Dean-Stark trap. The reaction mixture was 
concentrated and the resulting oil was chromatographed (95/5): light petroleum/ethyl 
acetate) to give the title compound 47 as brownish oil, 45%. νmax (film)/cm
-1 3434, 2969, 
2924, 1644, 1454, 1417, 1376, 1303, 1263, 1214, 1156, 1117, 1083, 1060, 923. 1H-NMR 
(400 MHz, CDCl3): δ 1.38 (s, 3H, OCCH3, C8), 1.61 (s, 3H, CH2CH=C(CH3)2, C1 or C2), 1.69 (s, 
3H, CH2CH=C(CH3)2, C1 or C2), 1.62 – 1.75 (m, 2H, CH2CH2CH=C(CH3)2, C5), 2.16 (s, 3H, Ar-
CH3, C17, C18 or C19), 2.19 (s, 3H, Ar-CH3, C17, C18 or C19), 2.21 (s, 3H, Ar-CH3, C17, C18 or 
C19), 2.10 – 2.20 (m, 2H, CH2CH2CH=C(CH3)2, C6), 4.21 (s, 1H, Ar-OH), 5.14 (t, J = 5 Hz, 1H, 
CH2CH=C(CH3)2, C4), 5.64 (d, J = 10 Hz, 1H, CH=CH-Ar, C9), 6.57 (d, J = 10 Hz, 1H, CH=CH-Ar, 
C10); 13C-NMR (100 MHz, CDCl3): δ 10.9 (Ar-CH3), 11.6 (Ar-CH3), 12.4 (Ar-CH3), 17.6 (C1/C2, 
OC(CH3)2), 22.8 (C5/C6, C(CH3)2CH=CH), 25.3 (C1/C2, OC(CH3)2), 25.7 (C8, OC(CH3)), 40.4 
(C5/C6, C(CH3)2CH=CH), 76.6 (C7, OC(CH3)2), 116.1 (C quat. arom.), 117.7 (C quat. arom.), 
120.2 (C9/C10), 122.3 (C quat. arom.), 123.0 (C quat. arom.), 124.4 (C4), 129.8 (C9/C10), 
131.5 (C quat., C3), 144.7 (C quat. arom.), 145.3 (C quat. arom.). 
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3.3.2.4 Methyl 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-
carboxylate16 
 
 
In a pressure tube equipped with a stirrer, trimethylhydroquinone 62 (1.55 g, 10.2 mmol), 
an aqueous formalin solution (37 wt%, 1.66 g), and methyl methacrylate 100 (4.95 g, 52.65 
mmol) were placed. The mixture was allowed to reach 180 oC and stirred for 3 hours, while 
the reactor was tightly closed. After completion of reaction, the reaction mixture was 
cooled down to room temperature, and methanol was added to the mixture, whereby 
crystals were precipitated. The crystals of the desired compound 101 were collected 
through filtration, and dried in the oven at 60 oC overnight (1.91 g, 71%); mp 157 – 160 oC 
[Lit. mp 134.5 – 136 oC]. νmax (film)/cm
-1 3530, 2989, 2928, 1739, 1454, 1428, 1375, 1335, 
1277, 1264, 1243, 1226, 1192, 1173, 1140, 1113, 1061, 1030, 967, 945. 1H-NMR (500 MHz, 
CDCl3): δ 1.59 (s, 3H, C11), 1.86 (m, 1H, C3), 2.05 (s, 3H, Ar-CH3, C15, C16 or C17), 2.14 (s, 
3H, Ar-CH3, C15, C16 or C17), 2.18 (s, 3H, Ar-CH3, C15, C16 or C17), 2.42 (m, 1H, C3), 2.50 
(m, 1H, C4), 2.64 (m, 1H, C4), 3.67 (s, 3H, C14); 13C-NMR (126 MHz, CDCl3): δ 11.3 (C15, C16 
or C17),  11.8 (C15, C16 or C17), 12.2 (C15, C16 or C17), 21.0 (C4), 25.4 (C11), 30.6 (C3), 
52.3 (C14), 77.1 (C2), 116.9 (C5), 118.5 (C6), 121.3 (C8), 122.6 (C9), 145.3 (C7), 145.5 (C10), 
174.5 (C12); m/z 265.437, C15H20O4H [M + H]
+ requires 265.1434. 
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3.3.2.5 1,1-Diethoxy-3-methyl-2-butene17 
 
 
Triethyl orthoformate 88 (1 equiv) and 3-methyl-2-butenal 77 (1 equiv) were added into a 
round bottom flask containing EtOH at room temperature. The mixture was stirred 5 min. 
prior to addition of NH4NO3 (25 mol%). The reaction mixture was left stirred for 24 hours. 
Saturated aqueous solution of NaHCO3 was added to the reaction followed by brine. The 
mixture was the extracted by using Et2O several times to give the title compound 87 as a 
brownish liquid. No further purification was required. νmax (film)/cm
-1 2975, 2930, 2914, 
2879, 1682, 1447, 1377, 1358, 1348, 1206, 1142, 1115, 1083, 1053, 1017, 991. 1H-NMR 
(500 MHz, CDCl3): δ 1.23 (m, 6H, C7 & C9), 1.72 (d, J = 1 Hz, 3H, C1 or C3), 1.75 (d, J = 1 Hz, 
3H, C1 or C3), 3.42 – 3.58 (m, 2H C6 or C8), 3.60 – 3.63 (m, 2H C6 or C8), 5.14 (d, J = 7 Hz, 
1H, C5), 5.30 (d, J = 7 Hz, 1H, C4); 13C-NMR (125 MHz, CDCl3): δ 15.5 (2C, C7 & C9), 18.4 (C6 
or C8), 25.6 (C6 or C8), 60.4 (2C, C1 & C3), 98.6 (C5), 125.1 (C4), 137.6 (C2). 
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3.3.2.6 6-Cyano-2,2- dimethylchromene – Method A17 
 
 
A reaction flask equipped with a distilling head was sequentially charged with the acetal 
compound 87 (1.74 g, 11.0 mmol), p-xylene (20 mL/g of phenol), 4-hydroxybenzonitrile 86 
(2.65 g, 22.0 mmol) and 3-picoline (0.27 mL, 2.75 mmol). The reaction mixture was heated 
under reflux for 24 h, after which the reaction mixture was cooled to ambient temperature. 
The clear, golden reaction mixture was diluted with EtOAc and washed with 1 N HCl. The 
acidic, aqueous washes were back extracted with EtOAc. The combined organic phases 
were washed with 1 N NaOH, brine and dried (MgSO4). The solvent was then evaporated 
under vacuo to give the title compound 49 as a bright yellow crystal. The yellow crystal was 
then recrystallized from light petroleum to give a yellowish powder (1.78 g, 87%); mp 47 – 
48 oC [Lit.17 mp 47 oC]. νmax (film)/cm
-1 3054, 2985, 2226, 1605, 1487, 1421, 1369, 1265, 
1212, 1148, 1128, 1107, 961, 896, 828, 739, 705. 1H-NMR (400 MHz, CDCl3): δ 1.45 (s, 6H, 
OC(CH3)2), 5.70 (d, J = 12 Hz, 1H, C(CH3)2CHCH), 6.28 (d, J = 12 Hz, 1H, C(CH3)2CHCH), 6.78 
(d, J = 8 Hz, 1H, CH arom.), 7.24 (d, J = 4 Hz, 1H, CH arom.), 7.37 (dd, J = 8 Hz, 4 Hz, 1H, CH 
arom.); 13C-NMR (100 MHz, CDCl3): δ 28.4 (2C, 2 X C(CH3)2), 77.9 (C(CH3)2, C quat.), 103.8 (C 
quat. arom.), 117.2 (C arom.), 119.3 (C quat., arom.), 120.6 (C(CH3)2CH=CH), 121.7 (C quat. 
arom.), 130.1 (C arom.), 132.2 (C(CH3)2CH=CH), 133.3 (C arom.), 156.8 (C≡N). 
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3.3.2.7 3-Chloro-3-methyl-1-butyne18 
 
 
A 1-L, three-necked flask provided with a magnetic stirrer, thermometer, and dropping 
funnel was charged with 56 g (0.5 mol) of CaCl2, 40 g of CuCl2, 400 mg of Cu bronze powder, 
and 430 mL (5 mol) of cold concentrated HCl. The mixture was flushed with argon gas 
several times and cooled in ice bath with stirring. 2-Methyl-3-butyn-2-ol 76 (1 mol) was 
added over 30 min. Stirring was continued for 1 h at 0 – 5 oC. The upper organic layer was 
separated and washed immediately with three 100 mL portions of cold concentrated HCl, 
with two 100 mL portions of water, then dried over K2CO3. The chloride was used without 
further purification. νmax (film)/cm
-1 2983, 2927, 1739, 1666, 1616, 1447, 1370, 1111, 938, 
836, 604; 1H-NMR (500 MHz, CDCl3): δ 1.87 (s, 6H, HC≡CC(CH3)2-Cl), 2.62 (s, 1H, 
HC≡CC(CH3)2-Cl); 
13C-NMR (125 MHz, CDCl3): δ 34.6 (2C, 2 X HC≡CC(CH3)2-Cl), 56.9 (C quat., 
HC≡CC(CH3)2-Cl), 71.9 (acetylenic C, HC≡CC(CH3)2-Cl), 86.5 (quat. C, HC≡CC(CH3)2-Cl). 
 
3.3.2.8 3-(3-Cyanophenoxy)-3-methylbut-1-yne19 
 
 
4-Cyanophenol 86 (0.5 g, 4.2 mmol), anhydrous K2CO3 (0.58 g, 4.2 mmol, 1.0 equiv), KI (0.07 
g, 0.42 mmol, 0.1 equiv), were stirred in acetone (25mL per gram of phenol) under N2. 
Addition of 3-chloro-3-methyl-1-butyne 92 (1.3 g, 8.8 mmol, 2.1 equiv) was followed by 
refluxing for 18 h to obtain the title compound 93 as light yellow oil (0.77 g, 99%) without 
further purification. νmax (film)/cm
-1 3292, 3103, 3078, 3048, 2991, 2939, 2226, 2112, 1602, 
1572, 1504, 1464, 1452, 1420, 1384, 1366, 1254, 1227, 1172, 1137, 956, 911, 839, 736, 
696, 671, 651. 1H-NMR (500 MHz, CDCl3): δ 1.70 (s, 6H, OC(CH3)2), 2.65 (s, 1H, alkyne), 7.28 
(d, J = 9 Hz, 2H, CH arom.), 7.57 (d, J = 9 Hz, 2H, CH arom.); 13C-NMR (125 MHz, CDCl3): δ 
29.5 (2C, 2 X CH3), 72.7 (OC(CH3), C quat.), 75.3 (-CCH), 84.7 (1 C, -CCH), 105.1 (C quat. 
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arom.), 119.1 (Ar-CN), 120.0 (2C, 2 X C arom.), 133.4 (2C, 2 X C arom.), 159.4 (C quat. 
arom.). 
 
3.3.2.9 6-Cyano-2, 2- dimethylchromene19 
 
 
A solution of the phenyl propargyl ether 93 in ethylene glycol (5 mL/g of the propargyl 
ether) was heated to 210 – 215 oC under a nitrogen atmosphere. After 24 hours of stirring 
at the reaction temperature, H2O was added to the crude and extracted with Et2O. The title 
compound 49 was crystallized using light petroleum. 
 
3.3.2.10 6-Hydroxy-2, 2, 5, 7, 8-pentamethyl-3-chromene20 
 
 
Trimethylhydroquinone 62 (0.535 g, 3.29 mmol) and phenylboronic acid (0.80 g, 6.57 
mmol) were each dissolved in 10 mL of toluene and were placed in flame dried flask 
equipped with a Dean-Stark apparatus. AcOH (in excess) was then added into the mixture 
at room temperature and stirred for 5 min. before addition of 3-methyl-2-butenal 77 (0.48 
mL, 4.70 mmol) was added in one portion and the clear colourless solution was wrapped in 
aluminium foil and heated to reflux under an atmosphere of N2 until starting material was 
judged to have disappeared by TLC. The solvents were removed and the resulting residue 
was re-dissolved with Et2O (50 mL) and water. The ethereal layer was separated and 
washed with saturated NaHCO3 (2 X 30 mL) and brine (50 mL). The organic layer was dried 
over MgSO4 and solvents were removed under reduced pressure to yield orange oil. The 
crude was purified by column chromatography eluting with light petroleum/EtOAc (9:1) to 
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isolate the product 48 as an orange oil (0.44 g, 61%). νmax (film)/cm
-1 3435, 2971, 2916, 
1634, 1270, 1214, 1136, 1086, 1063. 1H-NMR (400 MHz, CDCl3): δ 1.38 (s, 6H, OC(CH3)2), 
2.12 (s, 3H, ArCH3), 2.16 (s, 3H, ArCH3), 2.18 (s, 3H, ArCH3), 4.20 (s, 1H, phenol), 5.64 (d, J = 
10 Hz, 1H, C(CH3)2CHCH), 6.51 (d, J = 10 Hz, 1H, C(CH3)2CHCH); 
13C-NMR (100 MHz, CDCl3): δ 
10.9 (ArCH3), 11.6 (ArCH3), 12.4 (ArCH3), 27.3 (2C, 2 X CH3), 74.4 (OC(CH3), C quat.), 116.1 (C 
quat. arom.), 117.9 (C quat. arom.), 112.0 (OC(CH3)2CH=CH-), 122.5 (C quat. arom.), 122.6 
(C quat. arom.), 130.6 (OC(CH3)2CH=CH-), 144.6 (C quat. arom.), 145.4 (C quat. arom.). 
 
3.3.2.11 General Procedure of Acetate Protection of the Phenolic Hydroxyl 
 
 
A solution of chroman compound (1.0 equiv) in Ac2O (25 equiv) and pyridine (2 mL per 100 
mg of chroman compound) was kept and left stirred at room temperature until the 
reaction had come to completion according to TLC. The mixture was then poured into 20 
mL of ice water and extracted with EtOAc. The extract was washed with 3 M HCl, a 
saturated solution of NaHCO3, and H2O which then finally dried with MgSO4. The solvent 
was removed under reduced pressure. 
 
3.3.2.12 6-Acetoxy-2,5,7,8-tetramethylchroman-2-(4-methyl-3-pentene)21 
 
 
Prepared according to the general procedure of acetyl protection of phenolic hydroxyl 
group of chromanols from 6-hydroxy-2,5,7,8-tetramethylchroman-2-(4-methyl-3-pentene) 
61 (1.61 g, 5.59 mmol). The crude material was purified by column chromatography, 
typically eluting with ethyl acetate/light petroleum (1:99), to give the product 65 as a 
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yellow oil (1.34 g, 73%). νmax (film)/cm
-1 2977, 2929, 2863, 1758, 1676, 1577, 1455, 1416, 
1368, 1332, 1208, 1166, 1109, 1079, 1011, 918, 897, 850. 1H-NMR (400 MHz, CDCl3): δ 1.25 
(s, 3H, C8), 1.59 (m, 2H), 1.60 (s, 3H, C1 or C2), 1.68 (s, 3H, C1 or C2), 1.80 (qd, J = 14, 7 Hz, 
2H), 1.98 (s, 3H, C17, C20 or C21), 2.02 (s, 3H, C17, C20 or C21), 2.09 (s, 3H, C17, C20 or 
C21), 2.12 (m, 2H), 2.33 (s, 3H, C19), 2.60 (t, J = 7 Hz, 2H), 5.12 (t, J = 7 Hz, 1H, C4); 13C-NMR 
(126  MHz, CDCl3): δ 11.9 (C17, C20 or C21), 12.2 (C17, C20 or C21), 13.0 (C17, C20 or C21), 
17.6 (C1 or C2), 20.6 (C10 or C18), 20.6 (C10 or C18), 22.3 (1 C, C5), 25.7 (C1, C1 or C2), 31.0 
(C9), 38.1 (C6), 74.8 (C7), 117.4 (C quat. arom., C11), 123.1 (C quat. arom.), 124.5 (C4), 
125.0 (C quat. arom.), 126.7 (C quat. arom.), 131.5 (C quat. arom.), 140.6 (C quat. arom., 
C13), 149.4 (C quat. arom., C16), 169.8 (C quat. arom., C17); m/z 348.2534, C21H30O3NH4 [M 
+ NH4]
+ requires 348.2533. 
 
3.3.2.13 Methyl 6-acetoxy-2,5,7,8-tetramethylchroman-2-carboxylate 
 
 
Prepared according to the general procedure of acetyl protection of phenolic hydroxyl 
group of chromanols from methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate 
101 (0.811 g, 3.07 mmol). The yellow crude was purified by column chromatography, 
typically eluting with ethyl acetate/light petroleum (1:9), to give the product 113 as a white 
solid (0.67 g, 59%); m.p. 94 – 96 oC. 1H-NMR (400 MHz, CDCl3): δ 1.60 (s, 3H, OCCH3), 1.81 – 
1.94 (m, 1H, CHHCH2Ar), 1.94 (s, 3H, ArCH3), 2.03 (s, 3H, ArCH3), 2.16 (s, 3H, ArCH3), 2.32 (s, 
3H, Ph-OCOCH3), 2.38 – 2.44 (m, 1H, CHHCH2Ar), 2.48 – 2.66 (m, 2H, CH2CH2Ar), 3.68 (s, 3H, 
COOCH3); 
13C-NMR (100  MHz, CDCl3): δ 11.9 (Ar-CH3), 12.1 (Ar-CH3), 13.0 (Ar-CH3), 20.5 (Ar-
OCOCH3), 20.8 (C3 or C4), 25.5 (C11), 30.2 (C3 or C4), 30.4 (C2), 52.4 (C13), 77.3 (C quat. 
arom., C10), 117.1 (C quat. arom.), 123.1 (C quat. arom.), 124.9 (C quat. arom.), 127.1 (C 
quat. arom.), 141.3 (C quat. arom.), 169.6 (C12), 174.2 (C15); m/z 324.1803, C17H22O5 NH4 
[M + NH4]
+ requires 324.1805. 
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3.3.2.14 6-Acetoxy-2,2,5,7,8-pentamethylchromene20 
 
 
Prepared according to the general procedure of acetyl protection of phenolic hydroxyl 
group of chromanols from 6-hydroxy-2,2,5,7,8-pentamethyl-3-chromene 48 (0.55 g). The 
brown oil crude was purified by column chromatography eluting 1:9 (ethyl acetate/light 
petroleum) to obtain the title compound 54 as a white powder (0.53 g, 82%); m.p. 63 – 65 
oC. νmax (film)/cm
-1 3054, 2981, 2928, 1752, 1645, 1605, 1462, 1421, 1370, 1265, 1209, 
1135, 1080, 1062, 739, 705. 1H-NMR (400 MHz, CDCl3): δ 1.40 (s, 6H, OC(CH3)2), 2.02 (s, 3H, 
Ar-CH3), 2.05 (s, 3H, Ar-CH3), 2.10 (s, 3H, Ar-CH3), 2.32 (s, 3H, Ar-OCOCH3), 5.63 (d, J = 12 Hz, 
1H, CH=CH-Ar), 6.47 (d, J = 12 Hz, 1H, CH=CH-Ar); 13C-NMR (100 MHz, CDCl3): δ 11.6 (Ar-
CH3), 11.6 (Ar-CH3), 13.2 (Ar-CH3), 20.5 (Ar-OCOCH3), 27.7 (2C, 2 X CH3), 75.0 (C2), 117.9 (C 
quat. arom.), 119.6 (CH=CH-Ar), 122.4 (C quat. arom.), 122.8 (C quat. arom.), 129.0 (C quat. 
arom.), 130.3 (CH=CH-Ar), 141.4 (C quat. arom.), 148.4 (C quat. arom.), 169.5 (C14); m/z 
261.1486, C16H20O3H [M + H]
+ requires 261.1485. 
 
3.3.2.15 6-Acetoxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chromene15 
 
 
Prepared according to the general procedure of acetyl protection of phenolic hydroxyl 
group of chromanols from 6-hydroxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chromene 
47 (3.0 g, 1 eq) to give title compound 51 as an orange oil (2.97 g, 86%). νmax (film)/cm
-1 
3051, 2968, 2924, 1758, 1647, 1618, 1605, 1451, 1368, 1316, 1261, 1204, 1113, 1078, 
1062, 1008, 930, 913, 896, 849, 773, 742,675, 659, 613. 1H-NMR (400 MHz, CDCl3): δ 1.28 
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(s, 3H, OC(CH3)), 1.51 (s, 3H, CH2CH=C(CH3)2), 1.59 (s, 3H, -CH2CH=C(CH3)2, H1 or H2), 1.55 – 
1.61 (m, 2H, -CH2CH2CH=C(CH3)2, H6), 1.93 (s, 3H, Ar-CH3), 1.97 (s, 3H, Ar-CH3), 2.03 (s, 3H, 
Ar-CH3), 1.98 – 2.10 (m, 2H, -CH2CH2CH=C(CH3)2, H5), 2.25 (s, 3H, Ar-O-CO(CH3), H19), 5.03 
(t, J = 7 Hz, 1H, -CH2CH=C(CH3)2, H4), 5.51 (d, J = 10 Hz, 1H, H9 or H10), 6.42 (d, J = 10 Hz, 
1H, H9 or H10); 13C-NMR (100 MHz, CDCl3): δ 11.6, 11.6, 13.2, 17.6, 20.5, 22.8, 25.7, 40.9, 
117.6, 120.0, 122.4, 122.6, 124.3 (2C, 2 X C quat. arom.), 129.0, 129.4, 131.6, 133.1, 141.3, 
148.5, 169.5; m/z 346.2379, C21H28O3NH4 [M + NH4 ]
+ requires 346.2377. 
 
3.3.2.16 General Procedure of Trifluoroacetate Protection of the Phenolic Hydroxyl 
 
 
Chromenol was dissolved in pyridine (2 equiv) and dry THF (30 mL per gram of chromenol) 
as the solvent under Ar. The mixture was cooled down in brine-ice bath (-3 oC – 0 oC). After 
5 minutes of stirring, trifluoroacetic anhydride (TFAA, 1.2 equiv) was added dropwise over 
10 min. at reaction temperature. The reaction progress was checked by TLC plate. After the 
reaction had come to completion, the reaction was quenched with Et2O/DCM (2:1), and 
washed with 1% aqueous HCl. The organic layers were washed with saturated NaHCO3 and 
brine. The solvent is then dried (MgSO4) and reduced under pressure.  
 
3.3.2.17 6- Trifluorocetoxy -2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chromene 
 
 
Prepared according to the general procedure of trifluoroacetate protection of phenols from 
6-hydroxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chromene 47 (0.10 g, 0.18 mmol) to 
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obtain the title compound 52 as brownish oil (0.07 g, 97%). νmax (film)/cm
-1 2970, 2928, 
2858, 1798, 1677, 1608, 1455, 1413, 1377, 1355, 1224, 1169, 1138, 875, 831. 1H-NMR (500 
MHz, CDCl3): δ 1.37 (s, 3H, CH3, C1 or C2), 1.58 (s, 3H, CH3, C1 or C2), 1.65 – 1.75 (m, 2H, 
CH2), 1.66 (s, 3H, CH3, C1 or C2), 2.03 (s, 3H, Ar-CH3, C17, C20 or C21), 2.04 (s, 3H, Ar-CH3, 
C17, C20 or C21), 2.12 (s, 3H, Ar-CH3, C17, C20 or C21), 1.99 – 2.25 (m, 2H, CH2), 5.10 (ddd, J 
= 7, 6, 1 Hz, 1H, C4), 5.64 (d, J = 10 Hz, C9), 6.50 (d, J = 10 Hz, C9); 13C-NMR (125 MHz, 
CDCl3): δ 11.2 (Ar-CH3, C17 or C18), 11.6 (Ar-CH3, C17 or C20), 12.8 (Ar-CH3, C21), 17.6, 22.7, 
25.7, 25.9, 40.9, 77.7, 114.9 (q, 1JC–F  = 284 Hz, CF3), 116.1, 118.0, 119.5, 121.8, 123.3, 124.1, 
128.3, 130.1, 140.0, 149.4, 155.7 (q, 2JC–F = 42 Hz, C=O); m/z 382.1799, C21H25F3O3H [M + H]
+ 
requires 382.1796.  
 
3.3.2.18 6-Trifluorocetoxy-2,2,5,7,8-pentamethylchromene 
 
 
Prepared according to the general procedure of trifluoroacetate protection of phenols from 
6-hydroxy-2,2,5,7,8-pentamethylchromene 48 (1.66 g, 7.6 mmol) and purified by column 
chromatography using 1:99 (EtOAc/light petroleum) eluent to obtain the title compound 55 
as a light yellow solid (2.02 g, 84%); m.p. 62 oC. νmax (film)/cm
-1 3054, 2986, 2685, 2521, 
2410, 2305, 1795, 1606, 1551, 1421, 1358, 1265, 1224, 1175, 1143, 1131, 1105, 896, 876, 
743, 705. 1H-NMR (500 MHz, CDCl3): δ 1.41 (s, 6H, OC(CH3)2), 2.03 (s, 3H, Ar-CH3), 2.06 (s, 
3H, Ar-CH3), 2.12 (s, 3H, Ar-CH3), 5.67 (d, J = 10 Hz, 1H, CH=CHAr), 6.47 (d, J = 10 Hz, 1H, 
CH=CHAr); 13C-NMR (125 MHz, CDCl3): δ 11.2 (Ar-CH3), 11.6 (Ar-CH3), 12.8 (Ar-CH3), 27.7 
(2C, 2 X OC(CH3)2), 75.3 (C quat., OC(CH3)2), 113.8 (q, 
1JC–F  = 285Hz, CF3), 118.3 (C quat. 
arom.), 119.1 (CH=CHAr), 121.8 (C quat. arom.), 123.6 (C quat. arom.), 128.2 (C quat. 
arom.), 130.9 (CH=CHAr), 140.2 (C quat. arom.), 149.3 (C quat. arom.), 155.5 (q, 2JC–F = 46 
Hz, C=O); m/z 315.1201, C16H17F3O3H [M + H]
+ requires 315.1203. 
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3.3.2.19 Methyl 6-trifluoroacetoxy-2,5,7,8-tetramethylchroman-2-carboxylate 
 
 
Prepared according to the general procedure of trifluoroacetate protection of phenols from 
methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate 101 (1.99 g, 7.52 mmol), 
TFAA (1.27 mL, 9.02 mmol) and pyridine (1.22 mL, 15.04 mmol). The reaction completed in 
30 min and the solid obtained was recrystalized from MeOH to give the title compound 114 
as a white powder (1.99 g, 73%); m.p. 124.0 – 125.5 oC. νmax (film)/cm
-1 3000, 2957, 2938, 
1797, 1755, 1741, 1456, 1416, 1357, 1292, 1244, 1223, 1170, 1134, 1112, 875, 770. 1H-
NMR (500 MHz, CDCl3): δ 1.63 (s, 3H, C11), 1.87 (m, 1H, C3), 1.96 (s, 3H, C14, C17 or C18), 
2.04 (s, 3H, C14, C17 or C18), 2.18 (s, 3H, C14, C17 or C18), 2.48 (m, 2H, C3 and C4), 2.65 
(m, 1H, C4), 3.69 (s, 3H, C13); 13C-NMR (126 MHz, CDCl3): δ 11.8, 11.9, 12.6, 20.8, 25.4, 
30.1, 52.5, 77.5, 113.8, 114.9 (q, 1JC–F  = 286 Hz, CF3), 116.0, 117.6, 123.8, 124.4, 126.4, 
140.0, 150.2, 156.0 (q, 2JC–F = 42 Hz, C=O), 173.9; m/z 361.1249, C17H19F3O5H [M + H]
+ 
requires 361.1247. 
 
3.3.2.20 General Procedure of Benzoate Protection of the Phenolic Hydroxyl 
 
 
A solution of the phenol in anhydrous THF was added dropwise over 30 min to a 
suspension of NaH (1.1 equiv) in the same solvent, under stirring and under N2. An 
exothermic reaction with hydrogen evolution immediately occurred and the colour 
changed observed. After 10 min, a solution of benzoyl chloride (1.0 equiv) was added 
dropwise over 10 min. After the reaction has come to completion, mixture of Et2O/H2O 
(1:1) was slowly added into the reaction. The aqueous layer was separated and extracted 
again with Et2O. The combined organic layers were washed with 5% aqueous NaOH and 
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then with H2O and brine. The solvent was dried (Na2SO4), and evaporated under reduced 
pressure. 
 
3.3.2.21 6-Benzoyloxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chromene 
 
 
Prepared according to the general procedure for benzoate protection of phenols from 6-
hydroxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chromene 47 (0.10 g, 0.18 mmol), NaH 
(0.005 g, 0.19 mmol) and benzoyl chloride (0.02 mL, 0.18 mmol). The reaction was 
complete after overnight. The crude was purified by column chromatography eluting with 
ethyl acetate/light petroleum (10:90) to afford the title compound 53 as yellow oil (0.05 g, 
75%). νmax (film)/cm
-1 3061, 2968, 2925, 2857, 1774, 1737, 1644, 1603, 1585, 1451, 1413, 
1377, 1267, 1245, 1205, 1177, 1025, 1002, 922, 870. 1H-NMR (500 MHz, CDCl3): δ 1.16 (CH3, 
C8), 1.51 (CH3, C1 or C2), 1.61 (CH3, C1 or C2), 1.98 (Ar-CH3, C17, C25 or C26), 2.00 (Ar-CH3, 
C17, C25 or C26), 2.06 (Ar-CH3, C17, C25 or C26), 5.00 – 5.10 (m, 1H, C4), 5.53 (d, J = 10 Hz, 
1H, C10), 6.45 (d, J = 10 Hz, 1H, C9), 7.43 – 7.51 (m, 2H, CH arom.), 7.58 – 7.63 (m, 1H, CH 
arom.), 8.17 (dd, 2H, CH arom.); 13C-NMR (125 MHz, CDCl3): δ 11.7, 11.7, 13.3, 17.6, 22.8, 
25.7, 29.8, 40.8, 117.8, 120.1, 122.7, 124.3, 128.6, 129.0, 129.3, 129.5, 129.5, 130.2, 131.5, 
131.6, 133.5, 135.4, 141.4 (C quat. arom.), 148.6 (C quat. arom.), 165.0 (C=O, C18). No 
quaternary C of C2 is observed. m/z 408.2535, C26H30O3NH4 [M + NH4]
+ requires 408.2533. 
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3.3.2.22 6-Benzoyloxy-2,2,5,7,8-pentamethylchromene 
 
 
Prepared according to the general procedure for benzoate protection of phenols from 6-
hydroxy-2,2,5,7,8-pentamethylchromene 48 (1.35 g, 6.20 mmol), NaH (0.16 g, 6.82 mmol) 
and benzoyl chloride (0.72 mL, 6.2 mmol). The reaction completed in 30 min. The crude 
material was purified by column chromatography eluting with ethyl acetate/light 
petroleum (5:95). The residue was recrystallized from MeOH to provide the title compound 
56 as a yellow solid (1.68 g, 84%): m.p. 108 – 110 oC; νmax (film)/cm
-1 3067, 2975, 2926, 
1735, 1643, 1603, 1451, 1416, 1377, 1277, 1250, 1216, 1176, 1138, 1092, 1066, 1024, 905, 
773, 712. 1H-NMR (500 MHz, CDCl3): δ 1.42 (s, 6H, C11 & C12), 2.06 (s, 3H, C13, C15 or C16), 
2.09 (s, 3H, C13, C15 or C16), 2.14 (s, 3H, C13, C15 or C16), 5.65 (d, J = 10 Hz, 1H, C3), 6.50 
(d, J = 10 Hz, 1H, C4), 7.53 (m, 2H, CH arom.), 7.65 (m, 1H, CH arom.), 8.25 (m, 2H, CH 
arom.); 13C-NMR (125 MHz, CDCl3): δ 11.7 (C13, C14 or C15), 11.7 (C13, C14 or C15), 27.7 
(C13, C14 or C15), 75.0 (quat. C, C2), 118.0 (C quat. arom., C17), 119.7 (C3), 122.7 (C quat. 
arom., C9), 123.0 (C quat. arom., C5), 128.6 (2C, 2 X C arom., C18 & C22), 129.3 (C quat. 
arom., C6 or C8), 129.5 (C quat. arom., C6 or C8), 130.2 (2C, 2 X C arom., C19 & C21), 130.4 
(C4), 133.5 (C arom., C20), 141.6 (C quat. arom., C7), 148.5 (C quat. arom., C10), 165.0 
(C=O, C16); m/z 323.1644, C21H22O3H [M + H]
+ requires 323.1642. No quaternary C of C2 is 
observed. 
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3.3.2.23 Methyl 6-benzoyloxy-2,5,7,8-tetramethyl-3-chroman-2-carboxylate 
 
 
Prepared according to the general procedure for benzoate protection of phenols from 
methyl 6-hydroxy-2,5,7,8-tetramethyl-3-chroman-2-carboxylate 101 (1.503 g, 5.69 mmol), 
NaH (0.15 g, 6.25 mmol) and benzoyl chloride (0.66 mL, 5.69 mmol). The reaction was left 
stirred overnight. The crude was then purified by column chromatography eluting with 
ethyl acetate/light petroleum (10:90). White solid obtained was recrystallized from ethanol 
to give the title compound 115 as a white power (1.05 g, 50%): m.p. 130 – 132 oC; νmax 
(film)/cm-1 3071, 2996, 2953, 2934, 1733, 1644, 1601, 1584, 1451, 1414, 1374, 1334, 1239, 
1195, 1176, 1134, 1105, 1094, 1071, 1024, 978, 943, 802, 712; 1H-NMR (500 MHz, CDCl3): δ 
1.63 (s, 3H, C11), 1.89 (m, 1H, C3), 1.98 (s, 3H, C14, C15, C16), 2.46 (m, 2H, C3 & C4), 2.67 
(m, 1H, C4), 3.69 (s, 3H, C13), 7.53 (m, 2H, CH arom.), 7.65 (m, 1H, CH arom.), 8.25 (m, 1H, 
CH arom.); 13C-NMR (125 MHz, CDCl3): δ 11.9 (C14, C15 or C16), 12.2 (C14, C15 or C16), 13.1 
(C14, C15 or C16), 20.9 (C4), 25.5 (C11), 30.3 (C3), 52.4 (C13), 117.2 (C2), 123.17 (C quat. 
arom., C5), 125.2 (C quat. arom., C8), 127.4 (C quat. arom., C7), 128.6 (2C, 2 X C arom., C20 
& C22), 129.6 (C quat. arom., C9), 130.2, 133.5 (C arom., C21), 165.1 (C=O, C12), 174.3 (Ar-
C=O, C17); m/z 386.1963, C22H24O5NH4 [M + NH4]
+ requires 386.1962. No quaternary C of C2 
is observed. 
 
3.3.2.24 General Procedure of Methyl Ether Protection of the Phenolic Hydroxyl 
 
 
NaH (1.1 equiv) was dissolved in anhydrous THF (10 mL/g of phenol) and transferred into a 
flame-dried flask, flushed with N2. The phenol was dissolved in anhydrous THF was then 
added into the solution dropwise over 20 min. The reaction was stirred for 20 min prior to 
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addition of MeI (1 equiv). The solution was stirred at room temperature until complete 
disappearance of the starting material was observed on TLC plate. After the reaction had 
come to completion, it was treated with Et2O/H2O (20 mL/g of phenol, 1:1). The organic 
layer was washed with water and brine. The solvent was then reduced under pressure. 
 
3.3.2.25 6-Methoxy-2,2,5,7,8-pentamethylchromene22 
 
 
Prepared according to the general procedure of methyl protection of the phenolic hydroxyl 
using NaH (0.018 g, 0.76 mmol), 6-hydroxy-2,2,5,7,8-pentamethylchromene 48 (0.151 g, 
0.69 mmol) and MeI (0.043 mL, 0.69 mmol). The brownish crude oil was purified by column 
chromatography eluting with ethyl acetate/light petroleum (5:95) to give the title 
compound 117 as a yellowish oil (0.14 g, 87.2%). νmax (film)/cm
-1 3047, 2975, 2932, 1641, 
1597, 1461, 1406,1387, 1359, 1270, 1217, 1174, 1137, 1089, 1064, 1046, 1004, 943, 903, 
831.  1H-NMR (500 MHz, CDCl3): δ 1.39 (s, 6H, C11 & C12), 2.09 (s, 3H, C13, C15 or C16), 
2.18 (s, 3H, C13, C15 or C16), 2.21 (s, 3H, C13, C15 or C16), 3.62 (s, 3H, C14), 5.61 (d, J = 10 
Hz, 1H, C3 or C4), 6.49 (d, J = 10 Hz, 1H, C3 or C4); 13C-NMR (125 MHz, CDCl3): δ 11.6 (Ar-
CH3, C13, C15 or C16), 11.2 (Ar-CH3, C13, C15 or C16), 12.8 (Ar-CH3, C13, C15 or C16), 27.6 
(2C, 2 X CH3, C11 and C12), 60.4 (Ar-O-CH3, C14), 74.7 (OC(CH3)2, C2), 118.0 (C quat. arom.), 
120.0 (-CH=CH-Ar, C3), 122.8 (C quat. arom.), 123.2 (C quat. arom.), 130.1 (-CH=CH-Ar, C4), 
146.8 (C quat. arom.), 150.3 (C quat. arom.). 1 sp2 C not located.22 
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3.3.2.26 Methyl 6-methoxy-2,5,7,8-tetramethylchromene-2-carboxylate23 
 
 
Prepared according to the general procedure of methyl ether protection of the phenolic 
hydroxyl using NaH (0.03 g, 1.26 mmol), methyl 6-hydroxy-2,5,7,8-tetramethyl-3,4-
dihydrochromen-2-carboxylate 101 (0.303 g, 1.15 mmol) and MeI (0.07 mL, 1.15 mmol). 
The brownish crude oil was purified by column chromatography eluting with ethyl 
acetate/light petroleum (20:80) to give the title compound 118 as a yellowish oil (0.22 g, 
69%). νmax (film)/cm
-1 2985, 2935, 1754, 1736, 1457, 1404, 1375, 1293, 1255, 1199, 1173, 
1142, 1090, 1066, 1011, 915. 1H-NMR (500 MHz, CDCl3): δ 1.60 (s, 3H, C11), 1.75 – 1.86 (m, 
1H, C3), 2.10 (s, 3H, C14, C15 or C16), 2.16 (s, 3H, C14, C15 or C16), 2.19 (s, 3H, C14, C15 or 
C16), 2.37 – 2.42 (m, 1H, C3), 2.44 – 2.48 (m, 1H, C4), 2.56 – 2.65 (m, 1H, C4), 3.61 (s, 3H, 
C13), 3.68 (s, 3H, C17); 13C-NMR (125 MHz, CDCl3): δ 11.8 (Ar-CH3, C14 or C15), 12.6 (Ar-
CH3, C16), 20.9 (CH3, C11), 25.5 (CH2, C3), 30.5 (CH2, C3), 52.4 (-OCH3, C14), 60.4 (-OCH3, 
C16), 77.2 (C quat., C2), 117.2 (C quat. arom.), 122.9 (C quat. arom.), 125.7 (C quat. arom.), 
128.1 (C quat. arom.), 147.7 (C quat. arom.), 150.1 (C quat. arom.), 174.4 (CO2Me). 
 
3.3.2.27 General Procedure for Dehydrogenation of the Phenol-Protected Chroman 
with DDQ 
 
 
 
 
The solution of the respective chromane in anhydrous toluene (6 mL) was heated at 105 oC 
for 30 min. A solution of 2,3-dichloro-4,5-dicyanohydroquinone (DDQ) in anhydrous 
toluene was added dropwise over 30 min, and this mixture refluxed overnight. The solution 
was cooled down to room temperature and filtered, and the solvent was evaporated under 
reduced pressure. The residue was dissolved in diethyl ether, washed with 5% NaHCO3 
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solution and water, and brine. The solvent was dried over Na2SO4, and the solvent was 
evaporated under reduced pressure. The residue was purified by flash chromatography in 
silica gel. TLC showed the product nearly at the same position as the starting material, but 
on spraying with 4% H2SO4 in methanol and heating the starting material turned yellow and 
the product brown, and became thus distinguishable.  
 
3.3.2.28 6-Acetoxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene)chromene15 
 
 
Prepared according to the general procedure of dehydrogenation of the acetyl-protected 
chroman from 6-acetoxy-2,5,7,8-tetramethyl-2-(4-methylpent-3-ene) chromane 65 (0.17 g, 
0.5 mmol) to give the title compound 51 as an orange oil (0.04 g, 24%). 
 
3.3.2.29 Methyl 6-acetoxy-2,5,7,8-tetramethylchromene-2-carboxylate 
 
 
Prepared according to the general procedure of dehydrogenation of the acetyl-protected 
chroman from methyl 6-acetoxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylate 
113 (0.4 g, 1.31 mmol). The reddish crude was purified by column chromatography, 
typically eluting with ethyl acetate/light petroleum (10:90), and recrystallized from MeOH 
and dried at 60 oC to give the title compound 57 as a white solid (0.19 g, 48%); m.p. 114.5 – 
116.0 oC; νmax (film)/cm
-1 3011, 2992, 2956, 2941, 1751, 1644, 1612, 1453, 1369, 1261, 
1202, 1117, 1085, 1064, 750. 1H-NMR (500 MHz, CDCl3): δ 1.69 (s, 3H, CCH3), 2.04 (s, 3H, 
ArCH3), 2.04 (s, 3H, ArCH3), 2.19 (s, 3H, OCOCH3), 2.33 (s, 3H, ArCH3), 3.70 (s, 3H, COOCH3), 
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5.78 (d, J = 10 Hz, 1H, CCH=CH), 6.68 (d, J = 10 Hz, 1H, CH=CHAr); 13C-NMR (125 MHz, 
CDCl3): δ 11.5 (Ar-CH3), 11.7 (Ar-CH3), 13.3 (Ar-CH3), 20.5 (C16), 25.6 (C11), 52.5 (C13), 77.2 
(C quat., C2, or C quat. arom., C10), 77.5 (C2 or C10), 117.0 (C quat. arom.), 121.9 (Ar-
CH=CH), 122.9 (C quat. arom.), 123.1 (C quat. arom.), 124.5 (Ar-CH=CH), 130.0 (C quat. 
arom.), 142.1 (C quat. arom.), 169.4 (C12), 173.1 (C15); m/z 322.1650, C17H20O5NH4 [M + 
NH4]
+ requires 322.1649. 
 
3.3.2.30 Methyl 6-benzoyloxy-2,5,7,8-tetramethylchromene-2-carboxylate 
 
 
Prepared according to the general procedure of dehydrogenation of the chroman from 
methyl 6-benzoate-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-carboxylate 115 (0.51 g, 
1.38 mmol). The reddish crude was purified by column chromatography to give the title 
compound 59 as a colourless oil (0.22 g, 42.7%). 1H-NMR (500 MHz, CDCl3): δ 1.71 (s, 3H, 
C11), 2.08 (s, 3H, C14, C15 or C16), 2.08 (s, 3H, C14, C15 or C16), 2.23 (s, 3H, C14, C15 or 
C16), 3.72 (s, 3H, C13), 5.79 (d, J = 10 Hz, 1H, C3), 6.64 (d, J = 10 Hz, 1H, C4), 7.52 (td, J = 8, 
4 Hz, 2H, CH arom.), 7.65 (m, 1H, CH arom.), 8.23 (dd, J = 10, 8 Hz, 2H, CH arom.); 13C-NMR 
(125 MHz, CDCl3): δ 11.7 (2C, 2 X Ar-CH3), 13.4 (Ar-CH3), 52.5 (CO2-CH3, C13), 77.6 (C quat., 
C2), 117.2 (C arom.), 121.8 (C quat. arom.), 122.1 (C quat. arom.), 123.2 (C arom.), 124.5 (C 
quat. arom.), 128.7 (Ar-CH=CH, C4), 128.9 (C quat. arom.), 129.4 (C arom.), 130.2 (Ar-
CH=CH, C3), 133.6 (2C, 2 X C arom.), 142.2 (C quat. arom.), 148.3 (C quat. arom.), 148.6 (C 
quat. arom.), 164.9 (CO2-Ar, C19), 173.1 (CO2-CH3, C12); m/z 367.1542, C22H22O5H [M + H]
+ 
requires 367.1540. 
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3.3.3 Catalytic Asymmetric Epoxidation Reaction 
3.3.3.1 General Procedure for the Preparation of Racemic Epoxides Using m-CPBA 
 
The alkene was dissolved in CH2Cl2 (10 mL/g) and the solution cooled using an ice bath. A 
solution of m-CPBA (2 equiv) in CH2Cl2 (10 mL/g, pre-dried over MgSO4) was added. The 
reaction was allowed to reach ambient temperature and stirred until complete 
consumption of the substrate was observed by TLC. Saturated aqueous NaHCO3 (10 mL/g) 
was added and the layers were separated. The organic layer was washed with saturated 
aqueous NaOH (1.0 M, 10 ml/g) and dried (MgSO4). The solvents were removed under 
reduced pressure and the residue purified by column chromatography, typically eluting 
with ethyl acetate/light petroleum (1:99), to give the pure epoxide. 
 
3.3.3.2 Purification of m-CPBA 
 
 
10.0 g of commercial m-CPBA was dissolved in 100mL Et2O and washed with 3 X 50mL 
buffer solution (410 mL of 0.1 M NaOH, 250 mL of 0.2M KH2PO4 made up to 1 L, pH 7.5). 
The ether layer was dried over MgSO4 and carefully evaporated under reduced pressure to 
give ca. 7.0 g pure m-CPBA. 
 
3.3.3.3 General Procedure for the Preparation of Racemic Epoxides Using m-CPBA 
and 10% aqueous Na2CO3 
 
m-CPBA (4 equiv) was dissolved in a mixture of DCM (40 mL/g of alkene) and 10% aqueous 
solution of Na2CO3 (40 mL/g of alkene) at 0 
oC. The alkene was then added into the solution 
in one portion. The reaction progress is observed by TLC. After the reaction has come to 
completion, the mixture is washed using 10% aqueous solution of Na2CO3 and brine. The 
organic layer was dried (Na2SO4) and reduced under pressure. 
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3.3.3.4 Preparation of Dimethyldioxirane (DMDO) on a Large Scale24 
 
 
A 2-L, three-necked, round-bottom flask containing a mixture of water, acetone, and 
NaHCO3, was equipped with a large magnetic stirring bar and connected via a U-tube to a 
vacuum distilling adapter and a receiver, which was cooled at –78 oC. The mixture of water, 
acetone and NaHCO3 was cooled to 5 – 10 
oC. While cooling and stirring vigorously, Oxone® 
was added in 5 portions in 30 min intervals. The reaction was left stirred for 15 min then a 
moderate vacuum was applied. The DMDO/acetone solution was distilled and collected in 
the cooled (–78 oC) receiver. The DMDO solution was dried over anhydrous K2CO3 and 
filtered into a pre-cooled 1 L round bottom flask. The solution was flushed with Ar, 
stoppered with glass stopper and stored in the freezer (–20 oC) over molecular sieves (4 Å). 
(DMDO is slowly decomposed by K2CO3 therefore storage on K2CO3 should be avoided).  
 
3.3.3.5 Preparation of Dimethyldioxirane (DMDO) on a Small Scale25 
 
Distilled H2O (20 mL), acetone (30 mL), and NaHCO3 (24 g, 0.285 mol) were combined in a 
1-L round bottom flask and chilled in an ice/water bath with magnetic stirring for 20 min. 
After 20 min, stirring is halted and Oxone® (25 g, 0.164 mol) was added in a single portion. 
The flask was loosely covered and the slurry was stirred vigorously for 15 min while still 
submerged in the ice bath. After 15 min, the stir bar was removed from the reaction flask 
and rinsed with a small portion of distilled water.  
 
The flask containing the reaction slurry was then attached to a rotary evaporator with the 
bath at room temperature. The rotary evaporator splash trap (250 mL) was chilled in a dry 
ice/acetone bath and a vacuum of 155 mmHg was applied via a benchtop diaphragm pump 
and an accompanying in-line vacuum regulator. During this process, the flask was rotated 
vigorously (210 rpm) to prevent bumping of the slurry into the bump trap. After 15 min, the 
bath temperature was raised to 40 oC over the course of 10 min. When the bath reached 40 
CHAPTER 3 – EXPERIMENTAL PROCEDURES 
 
 
197 
 
oC, the distillation was halted immediately by releasing the vacuum and raising the flask 
from the heated water bath. 
 
The pale yellow solution of DMDO was decanted from the rotary evaporator splash trap 
directly into a graduated cylinder to measure the total volume of the solution (an average 
of 25 mL) and the solution was dried over Na2SO4. The Na2SO4 was removed by filtration 
and rinsed with 10 mL acetone. 
 
3.3.3.6 Determination of the Concentration of DMDO  
 
The concentration of DMDO was determined by iodometric titration as follows: 25 mL of 
0.02 M aqueous solution of sodium thiosulfate (496 mg Na2S2O3.5H2O in 100 mL H2O) was 
placed in 25 mL graduated burette. A 100 mL Erlenmeyer flask was charged with water (20 
mL), glacial acetic acid (1 mL), a freshly prepared solution of sodium iodide (10 mL)(10 g NaI 
in 50 mL H2O) and then the solution DMDO (2 mL) was added. The solution was titrated 
rapidly with 0.02 M sodium thiosulfate until the disappearance of the yellow iodine colour. 
The concentration was calculated according to the following equation: 
Concentration of DMDO = 
                                  
                      
 
 
3.3.3.7 General Procedure for the Preparation of Racemic Epoxides Using DMDO 
 
To a solution of an alkene in CHCl3 (2 mL per 0.1 g alkene) which was cooled to 0 
oC, the 
DMDO solution in acetone (0.03 M, 1.5 equiv) was gradually added. After 5 min of stirring, 
the reaction progress was checked by TLC. After the reaction had come to completion, the 
solvent was dried under reduced pressure at room temperature. The crude material was 
purified by column chromatography. 
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3.3.3.8 General Procedure for the Catalytic Asymmetric Epoxidation of Alkenes 
Mediated by Iminium Salts using Oxone under Aqueous Conditions5 
 
Oxone® (2 equiv with respect to alkene) was added with stirring to an iced-cooled solution 
of sodium carbonate (4 equiv) in water (12 mL per 1.50 g of Na2CO3), and the resulting 
foaming solution was stirred for 5-10 minutes, until most of the effervescence subsided. A 
solution of the iminium salt (10 mol% with respect to alkene) in CH3CN (6 mL per 1.50 g of 
Na2CO3), was added, followed by a solution of the alkene substrate in CH3CN (6 mL per 1.50 
g of Na2CO3). The suspension was stirred with ice-bath cooling until the substrate was 
completely consumed according to TLC. The reaction mixture was then diluted with ice-
cooled diethyl ether (20 mL per 100 mg substrate) and the same volume of water was 
added immediately. The aqueous phase was washed four times with diethyl ether and the 
combined organic solutions was then washed with brine and dried (MgSO4). Filtration and 
removal of solvents gave a yellow or light brown residue, which was purified by column 
chromatography, typically using ethyl acetate/light petroleum (1:99) to provide pure 
epoxide. 
 
3.3.3.9 Tetraphenylphosphonium monoperoxysulfate (TPPP) 
 
 
Tetraphenylphosphonium chloride (15.0 g, 40 mmol) was dissolved in DCM (200 mL) and 
cooled in ice-water bath in a round bottomed flask equipped with a stirrer bar. Oxone® 
(15.0 g, 48 mmol) which was dissolved in deionised water (300 mL) at 0oC, was added to 
the solution of tetraphenylphosphonium chloride over a period of 5 min. The resulting 
biphasic mixture was stirred vigorously for 1 h in the ice-water bath, after which time the 
organic layer was separated off and solvents were removed under reduced pressure at 
room temperature. The crude white solid was transferred to a sintered glass funnel and 
washed with deionised water (3 X 80 mL). The solid was re-dissolved in DCM (150 mL) and 
dried over MgSO4, hexane was added to this solution until a solid precipitate just started to 
form, and the flask was then placed in the freezer overnight, producing a white crystalline 
solid with 94% purity in peroxide. 1H-NMR (400 MHz, CDCl3): δ 7.63 – 7.67 (m, 8H, 8 CH X 
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arom.), 7.76 – 7.80 (m, 8H, 8 X CH arom.), 7.88 – 7.92 (m, 4H, 4 X CH arom.), 9.34 (s, 1H, 
OH). The oxygen content was measured by comparing the integrals of the aromatic signals 
with the hydroxyl proton.  
 
3.3.3.10 General Procedure for Catalytic Asymmetric Epoxidation of Simple 
Alkenes Mediated by Iminium Salts using Tetraphenylphosphonium 
Monoperoxysulfate (TPPP) 
 
Tetraphenylphosphonium monoperoxysulfate (2 equiv with respect to alkene) was 
dissolved in the desired solvent (2 mL per 0.1 g oxidant) and the solution cooled to the 
required temperature. To this was added the iminium salt as a solution (0.5 mL per 0.1 g 
oxidant). This iminium salt solution was cooled to the same temperature as the solution 
containing the oxidant and added dropwise to it over 15-20 min; the temperature of the 
reaction vessel was monitored to minimise increase in the temperature during the 
addition. A solution of the alkene in the reaction solvent (0.5 mL per 0.1 g oxidant) was 
added dropwise. The mixture was stirred at the reaction temperature until the alkene was 
completely consumed according to TLC. Et2O (pre-cooled to the reaction temperature) (20 
mL per 0.1 g oxidant) was added to induce precipitation of the remaining oxidant and the 
mixture filtered through Celite. The solvents were removed, Et2O (40 mL) was added to the 
residue and the solution was passed through a short pad of silica gel to remove catalyst 
residues. The solvents were removed to give the epoxide. If the reaction did not reach to 
completion then the epoxide could be separated from the alkene by column 
chromatography, eluting with ethyl acetate/light petroleum 1:99. 
 
3.3.3.11 1-Phenylcyclohexene Oxide26 
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The title compound 127 was isolated as a colourless oil after purification by column 
chromatography eluting with EtOAc/light petroleum (1:99). νmax (film)/cm
-1 3063, 3028, 
2937, 2858, 1603, 1495, 1446, 1360, 1298, 1249, 1177, 1079, 1031, 993, 975, 913, 853, 
823, 775, 749, 698; 1H-NMR (500 MHz, CDCl3): δ 1.32 (m, 1H), 1.47 (m, 1H), 1.59 (m, 2H), 
1.98 (m, 2H), 2.12 (m, 1H), 2.28 (m, 1H), 3.08 (d, J = 3 Hz, 1H), 7.26 (m, 1H, CH arom.), 7.35 
(m, 4H, CH arom.); 13C-NMR (125 MHz, CDCl3): δ 19.8, 20.1, 24.7, 28.2, 60.1, 61.8, 125.3, 
127.1, 128.2, 142.8. 
 
3.3.3.12 6-Acetoxy-3,4-epoxy-2,2,5,7,8-pentamethylchromene 
  
 
The title compound 128 was isolated as a yellow oil after purification by column 
chromatography eluting with EtOAc/light petroleum (5:95) + 2% TEA. νmax (film)/cm
-1 2978, 
2932, 1761, 1616, 1582, 1459, 1367, 1330, 1269, 1204, 1166, 1103, 1081, 1048, 1010, 947, 
918, 900, 880, 844, 785, 735, 697, 681, 611; 1H-NMR (400 MHz, CDCl3): δ 1.26 (s, 3H, 
OC(CH3)2), 1.61(s, 3H, OC(CH3)2), 2.08 (s, 3H, Ar-CH3), 2.10 (s, 3H, Ar-CH3), 2.24 (s, 3 H, Ar-
CH3), 2.37 (s, 3 H, Ar-OCOCH3), 3.47 (d, J = 5 Hz, epoxide), 4.13 (d, J = 5 Hz, epoxide); 
13C-
NMR (125 MHz, CDCl3): δ 11.5 (Ar-CH3, C14 or C17), 11.7 (Ar-CH3, C14 or C17), 13.3 (Ar-CH3, 
C18), 20.5 (CH3, C11 or C12), 22.9 (CH3-CO2-Ar, C15), 25.7 (CH3, C11 or C12), 48.2 (C-
epoxide), 62.2 (C-epoxide), 72.2 (C quat., C2), 115.7 (C quat. arom.),124.5 (C quat. arom.), 
126.7 (C quat. arom.), 130.5 (C quat. arom.), 141.8 (C quat. arom.), 148.0 (C quat. arom.), 
169.4 (C=O, C14) ; m/z 277.1435, C16H20O4H [M + H]
+ requires 277.1434. 
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3.3.3.13 6-Trifluorocetoxy-3,4-epoxy-2,2,5,7,8-pentamethylchromene 
 
 
The title compound 129 was isolated as foam after purification by column chromatography 
eluting with EtOAc/light petroleum (10:90) + 2% TEA. νmax (film)/cm
-1 2989, 2937, 1798, 
1464, 1420, 1358, 1276, 1228, 1173, 1139, 1104, 1042, 918, 877. 1H-NMR (500 MHz, CDCl3): 
δ 1.24 (s, 3H, OC(CH3)2), 1.60 (s, 3H, OC(CH3)2), 2.04 (s, 3H, Ar-CH3), 2.09 (s, 3H, Ar-CH3), 
2.22 (s, 3H, Ar-CH3), 3.48 (d, J = 5 Hz, 1H, epoxide), 4.10 (d, J = 5 Hz, 1H, epoxide); 
13C-NMR 
(125 MHz, CDCl3): δ 11.1 (Ar-CH3, C13 or C16), 11.6 (Ar-CH3, C13 or C16), 12.9 (Ar-CH3, C17), 
22.8 (CH3, C11 or C12), 25.6 (CH3, C11 or C12), 47.8 (C-epoxide, C4), 62.2 (C-epoxide, C3), 
72.6 (C quat., C2), 114.9 (q, 1JC–F  = 284 Hz, CF3, C15), 116.3 (C quat. arom.), 125.3 (C quat. 
arom.), 126.1 (C quat. arom.), 129.8 (C quat. arom.), 140.4 (C quat. arom.), 149.1 (C quat. 
arom.); m/z 331.1152, C16H17F3O4H [M + H]
+ requires 331.1152. 
 
3.3.3.14 6-Cyano-3,4-epoxy-2,2-dimethylchromene2 
 
 
The title compound 124 was isolated as a white solid after purification by column 
chromatography eluting with EtOAc/light petroleum (5:95) + 2% TEA. νmax (film)/cm
-1 3055, 
2987, 2305, 2228, 1616, 1580, 1494, 1466, 1421, 1385, 1369, 1344, 1265, 1236, 1207, 
1162, 1133, 1100, 1040, 958, 935, 920, 896, 868, 828, 816, 737, 705. 1H-NMR (500 MHz, 
CDCl3): δ 1.30 (s, 3H, OC(CH3)2), 1.60 (s, 3H, OC(CH3)2), 3.54 (d, J = 4 Hz, 1H, C(CH3)-
2CH(O)CH-Ar), 3.91 (d, J = 4 Hz, 1H, C(CH3)2CH(O)CH-Ar), 6.87 (d, J = 9 Hz, 1H, CH arom.), 
7.53 (dd, J = 9 Hz, 2 Hz, 1H, CH arom.), 7.65 (d, J = 2 Hz, 1H, CH arom.); 13C-NMR (125 MHz, 
CDCl3): δ 23.0 (CH3, C11 or C12), 25.5 (CH3, C11 or C12), 49.9 (C-epoxide, C3), 62.3 (C-
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epoxide, C4), 74.7 (C quat., C2), 104.3 (C quat. arom.), 118.8 (C quat. arom.), 119.1 (C 
arom.), 121.1 (C quat. arom.), 133.8 (C arom.), 134.4 (C arom.), 156.5 (-C≡N). 
 
3.3.3.15 Methyl 6-acetoxy-3,4-epoxy-2,5,7,8-tetramethylchromene-2-carboxylate 
 
 
Prepared according to the general procedure for the preparation of racemic epoxide using 
DMDO from methyl 6-acetoxy -2,5,7,8-tetramethylchromene-2-carboxylate 57 (0.051 g, 
0.17 mmol). The title compound 132 was isolated as a yellow oil after purification by 
column chromatography eluting with EtOAc/light petroleum (20:80) + 2% TEA (0.02 g, 
35%). νmax (film)/cm
-1 2960, 2918, 2851, 1756, 1620, 1583, 1453, 1370, 1292, 1245, 1201, 
1136, 1113, 1087, 1050, 1009, 895. 1H-NMR (500 MHz, CDCl3): δ 1.80 (s, 3H, C11), 2.04 (s, 
3H, C14, C17 or C18), 2.17 (s, 3H, C14, C17 or C18), 2.19 (s, 3H, C14, C17 or C18), 2.33 (s, 
3H, C16), 3.70 (s, 3H, C13), 3.97 (br, 1H, C3), 4.14 (d, J = 4 Hz, 1H, C4); 13C-NMR (125 MHz, 
CDCl3): δ 11.4, 11.5, 13.3, 20.5, 23.0, 52.7, 52.9, 60.0, 115.3, 124.7, 126.8, 130.9, 142.4, 
147.1, 169.2, 171.3, 171.9; m/z 321.1334, C17H20O6H [M + H]
+ requires 321.1333. 
 
3.3.3.16 6-Benzoyloxy-3,4-epoxy-2,2,5,7,8-pentamethylchromene 
 
 
The title compound 130 was isolated as a yellowish oil after purification by column 
chromatography eluting with EtOAc/light petroleum (5:95) + 2% TEA. νmax (film)/cm
-1 2974, 
2931, 1733, 1601, 1581, 1452, 1416, 1382, 1315, 1265, 1247, 1231, 1177, 1149, 1094, 
1058, 1025, 913. 1H-NMR (500 MHz, CDCl3): δ 1.26 (s, 3H, C11 or C12), 1.60 (s, 3H, C11 or 
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C12), 2.06 (s, 3H, Ar-CH3, C13, C15 or C16), 2.10 (s, 3H, Ar-CH3, C13, C15 or C16), 2.25 (s, 3H, 
Ar-CH3, C13, C15 or C16), 3.48 (d, J = 5 Hz, 1H, C3 or C4), 4.14 (d, J = 5 Hz, 1H, C3 or C4), 
7.53 (t, J = 7 Hz, 2H, 2 X CH arom.), 7.66 (t, J = 7 Hz, 1H, CH arom.), 8.25 (d, J = 7 Hz, 2H, 2 X 
CH arom.); 13C-NMR (125 MHz, CDCl3): δ 11.6 (Ar-CH3, C13 or C15), 11.7 (Ar-CH3, C13 or 
C15), 13.4 (Ar-CH3, C14), 22.9 (CH3, C11 or C12), 25.7 (CH3, C11 or C12), 48.3 (C-epoxide, 
C4), 62.2 (C-epoxide, C3), 72.3 (C quat., C2), 115.8 (C quat. arom.), 124.6 (C arom.), 127.0 (C 
arom.), 128.7 (2C, 2 X C arom.), 129.3 (C quat. arom.), 130.2 (2C, 2 X C arom.), 130.7 (C 
quat. arom.), 133.7 (C quat. arom.), 148.1 (C quat. arom.), 165.0 (C=O, C17); m/z 339.1593, 
C21H22O4H [M + H]
+ requires 339.1591. 
 
3.3.3.17 6-Trifluoroacetoxy-3,4-diol-2,2,5,7,8-pentamethylchromene 
 
 
Isolated as a brownish oil after purification by column chromatography eluting with 
EtOAc/light petroleum (5:95) + 2% TEA. νmax (film)/cm
-1 3388, 2981, 2926, 2851, 1797, 1462, 
1360, 1230, 1174, 1139, 1109, 876. 1H-NMR (500 MHz, CDCl3): δ 1.33 (s, 3H, C11 or C12), 
1.49 (s, 3H, C11 or C12), 2.09 (s, 3H, C13, C16 or C17), 2.16 (s, 3H, C13, C16 or C17), 2.24 (s, 
3H, C13, C16 or C17), 3.76 (d, J =  6 Hz, 1H, C3 or C4), 4.69 (d, J =  6 Hz, 1H, C3 or C4); m/z 
339.1633, C16H19 F3O5H [M + H]
+ requires 339.1631. 
 
3.3.3.18 6-Cyano-3,4-dihydroxy-2,2-dimethyl-6-cyanochromene27 
 
 
The chiral diol was obtained by asymmetric epoxidation reaction of the chromene 49 under 
aqueous conditions. Isolated as a brownish solid after purification by column 
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chromatography eluting with EtOAc/light petroleum (50:50) + 2% TEA. Drying the product 
at 60 oC under reduced pressure, afforded the title compound 136 as a yellow solid. m.p. 
147 – 149 oC; νmax (film)/cm
-1 3397, 2984, 2919, 2851, 2229, 1611, 1580, 1489, 1372, 1311, 
1273, 1195, 1147, 1126, 1072, 1037, 1000, 952, 921, 836. 1H-NMR (500 MHz, CDCl3): δ 1.25 
(s, 3H, C11 or C12), 1.52 (s, 3H, C11 or C12), 3.62 (d, J = 9 Hz, 1H, C3), 4.59 (d, J = 9 Hz, 1H, 
C4), 6.85 (d, J = 9 Hz, 1H, C9), 7.46 (ddd, J = 9, 2, 1 Hz, 1H, C8), 7.81 (dd, J = 2, 1 Hz, 1H, C6); 
13C-NMR (125 MHz, CDCl3): δ 19.3 (CH3, C11 or C12), 26.6 (CH3, C11 or C12), 68.6 (CH2-OH, 
C3), 75.8 (CH2-OH, C4), 79.8 (C quat., C2), 104.0 (C quat. arom.), 118.0 (C arom.), 119.2 (C 
quat. arom.), 124.4 (C quat. arom.), 132.4 (C arom.), 133.3 (C arom.), 156.0 (Ar-C≡N). 
 
3.3.3.19 General Procedure for the Formation of Racemic Diols28 
 
 
The racemic epoxide was dissolved in acetone (50 mL/g of epoxide) and stirred at room 
temperature for 5 min. Aqueous sulfuric acid (1 M, 5.5 equiv) was added to the solution, 
and the mixture was stirred for 1 hour at room temperature. After the reaction had 
reached completion, the reaction mixture was neutralized to pH 7 using sodium hydrogen 
carbonate. Dichloromethane (150 mL/g of epoxide) was added to the reaction mixture and 
the organic phase was separated. The aqueous layer was extracted with dichloromethane 
(2 X 150 mL/g of epoxide), and the organic layers were combined and dried (Na2SO4). The 
solvents were removed under reduced pressure, and the crude was purified by column 
chromatography. 
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1H NMR of 6-Cyano-3,4-epoxy-2,2-dimethylchromene 49 
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HPLC trace of racemic epoxidation of 6-cyano-2,2-dimethylchromene 
 
Data File: C:\EZChrom Elite\Enterprise\Projects\AMy\NAB036second run.dat  
Method: C:\EZChrom Elite\Enterprise\Projects\yohan\Method\99.1 0.5ml 90min.met  
Acquired: 04/04/2013 14:21:05  
Printed: 05/04/2013 10:49:24  
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UV Results     
Retention Time Area Area % Height Height % 
37.430 101873260 49.58 2120052 54.22 
41.977 103601872 50.42 1790157 45.78 
     
Totals     
 205475132 100.00 3910209 100.00 
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Asymmetric epoxidation of 6-cyano-2,2-dimethylchromene under non-aqueous 
conditions 
 
 
 
Data File: C:\EZChrom Elite\Enterprise\Projects\AMy\NAB034-conc5.dat  
Method: C:\EZChrom Elite\Enterprise\Projects\yohan\Method\99.1 0.5ml 90min.met  
Acquired: 04/04/2013 19:00:38  
Printed: 05/04/2013 10:58:53  
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UV Results     
Retention Time Area Area % Height Height % 
36.623 347322 0.33 11791 0.61 
40.790 104456189 99.67 1922846 99.39 
     
Totals     
 104803511 100.00 1934637 100.00 
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Area % Report 
 
Data File: C:\EZChrom Elite\Enterprise\Projects\AMy\NAB082B-22~26run.dat  
Method: C:\EZChrom Elite\Enterprise\Projects\AMy\99.1 1.0mL 90min.met  
Acquired: 01/11/2013 16:58:59  
Printed: 01/11/2013 20:17:45  
Minutes
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UV Results     
Retention Time Area Area % Height Height % 
22.677 8392677 1.70 137278 2.27 
25.583 483867773 98.30 5897355 97.73 
     
Totals     
 492260450 100.00 6034633 100.00 
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Formation of 6-Cyano-3,4-dihydroy-2,2-dimethylchromene 
 
 
 
Data File: C:\EZChrom Elite\Enterprise\Projects\AMy\NAB099Crun2.dat  
Method: C:\EZChrom Elite\Enterprise\Projects\AMy\99.1 1.0mL 140min DIOL.met  
Acquired: 01/03/2014 04:28:59  
Printed: 01/03/2014 08:07:41  
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UV Results     
Retention Time Area Area % Height Height % 
123.603 462058207 85.65 1167354 87.78 
146.573 77404027 14.35 162440 12.22 
     
Totals     
 539462234 100.00 1329794 100.00 
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1H NMR Comparison for Oxidation reaction using DDQ 
 
 
 
 
 
